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ABSTRACT 
CARDIOVASCULAR DISEASE RISK AND MENOPAUSE: EFFECTS OF 
CARDIORESPIRATORY FITNESS, EXERCISE, AND FOLLICLE 
STIMULATING HORMONE SEPTEMBER	2018	CORINNA	F.	SERVIENTE,	B.S.,	ITHACA	COLLEGE	M.S.,	UNIVERSITY	OF	MASSACHUSETTS	AMHERST	Ph.D.,	UNIVERSITY	OF	MASSACHUSETTS	AMHERST	Directed	by:	Professor	Sarah	Witkowski	
 
 
Menopause is associated with adverse changes in cardiovascular disease risk 
factors. A reduction in estrogens is most commonly associated with changing 
cardiovascular disease risk; however, recent observations suggest that the increase in 
follicle stimulating hormone that accompanies menopause may also influence risk, 
potentially through its influence on lipid levels. The changes in cardiovascular disease 
risk factors may adversely affect endothelial cell function, a pre-clinical marker for 
cardiovascular disease. Whether cardiorespiratory fitness is protective of endothelial 
health in this population, thereby mitigating the changes in risk that accompany 
menopause, is unclear. This dissertation evaluated differences in endothelial health and 
endothelial responses to acute exercise in women in various menopausal stages and with 
different levels of cardiorespiratory fitness. Endothelial health was assessed using flow-
mediated dilation and endothelial microparticles (EMPs). The project also evaluated 
whether follicle stimulating hormone (FSH) levels were related to lipid levels in a large 
  vi 
cohort of postmenopausal women. We found that: 1) endothelial function declines with 
menopause, independent of cardiorespiratory fitness, 2) EMPs are reduced with acute, 
moderate intensity exercise in midlife women, despite differences in menopausal status 
and cardiorespiratory fitness, 3) High FSH is related to dyslipidemia in postmenopausal 
women. Together, these data suggest that menopause and cardiorespiratory fitness 
differentially impact factors related to cardiovascular disease risk. 
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CHAPTER 1 
INTRODUCTION 
 
Cardiovascular disease (CVD) risk increases with menopause, with adverse 
changes in traditional CVD risk factors, such as blood pressure and lipids, beginning 
during the transitional (i.e. perimenopausal) years and continuing into postmenopause 
(108, 109). These changes have been largely attributed to the reduction in estrogens that 
accompany menopause; however, recent evidence suggests that follicle stimulating 
hormone (FSH) may independently affect CVD risk (44), potentially through its 
influence on lipid metabolism (25). The effects of FSH on lipid metabolism have largely 
been uninvestigated, making FSH a novel target that may influence CVD risk with 
menopause. The changes in risk, either through the effects of estrogen, FSH, or both, may 
adversely affect endothelial cell function, a preclinical marker of CVD (123). 
Endothelial cells line blood vessels throughout the vasculature and are involved in 
smooth muscle migration and proliferation, thrombolytic activity, inflammation, 
vasodilation, and vasoconstriction. Normal endothelial cell function is associated with a 
favorable balance of vasodilatory compared to vasoconstrictive factors, whereas in a 
dysfunctional state, this balance favors vasoconstrictive factors (36). Endothelial 
dysfunction is largely associated with a reduction in nitric oxide bioavailability, which 
can be assessed through flow-mediated dilation (FMD) (182). Changes in endothelial 
health are also associated with increased endothelial cell activation and apoptosis, which 
can be assessed through circulating endothelial microparticles (EMPs: CD62E+ and 
CD31+/42b-, respectively) (208). Endothelial microparticles levels and FMD change with 
disease and each have been proposed as novel biomarkers for CVD (2, 14). 
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Endothelial dysfunction may worsen with menopause. When comparing pre- to 
post-menopausal women there is consistently lower endothelial function in 
postmenopausal women (70, 71, 104, 123, 139). A cross-sectional study showed a 
progressive decline in FMD from pre- to peri- to post-menopause, independent of age 
(123); however, other work has shown that there is no difference in FMD between peri- 
and post-menopausal women (158). Endothelial microparticle levels may also differ with 
menopause, but to date, only one study has assessed EMPs in women at different 
menopausal stages (158). Therefore, to what extent and at what point during menopause 
endothelial dysfunction occurs is unclear. 
High cardiorespiratory fitness is generally associated with high levels of 
endothelial function; however, this benefit may be lost with menopause (139, 151). When 
comparing sedentary to active postmenopausal women there was no difference in FMD 
between groups (151). Further, the beneficial improvements in endothelial function with 
exercise training appear to be mediated, in part, by the effects of estrogen, as endothelial 
dysfunction may not improve with exercise training in postmenopausal women in the 
absence of estrogen therapy (124). Despite some evidence that there may be a resistance 
to the benefits of exercise training on endothelial function with menopause, there are 
conflicting results in the literature and most studies have only evaluated postmenopausal 
women. Therefore, future work needs to address if this resistance occurs and at what 
point it begins. 
Exposure to an acute exercise stress may help to elucidate differences in 
endothelial function that may not be apparent at rest. For example, when comparing 
sedentary to active men, there was no difference in FMD at baseline, but following an 
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acute bout of exercise, sedentary men had worse endothelial function, reflecting the 
difference in CVD risk between the two groups (68). This has also been shown in 
smokers compared to non-smokers (54), in lean compared to obese premenopausal 
women (43), and recently in peri- compared to post-menopausal women (158). This 
paradigm has been largely unused in the menopause literature and may help to further 
characterize differences in endothelial function, and therefore CVD risk, that might not 
be apparent in the absence of the acute hemodynamic stress of exercise. 
This dissertation aimed to address many of the gaps in the literature discussed 
above. This project evaluated differences in endothelial health, via FMD and EMPs, in 
pre-, peri-, and late post-menopausal women before and after an acute bout of exercise. 
Peri- and post-menopausal women were stratified by cardiorespiratory fitness to assess 
whether there is an endothelial resistance to the benefits of chronic exercise with 
menopause. Finally, the relationship between FSH and lipid levels was assessed in a 
cohort of postmenopausal women from the Kuopio Ischaemic Heart Disease Risk Factor 
Study. These questions were addressed through the following aims and hypotheses:  
 
Aim 1: To determine the effects of menopause and cardiorespiratory fitness on markers 
of endothelial health. 
 
Aim 1a: To determine whether there are differences in endothelial health, assessed via 
flow-mediated dilation and CD31+/42b- and CD62E+ endothelial microparticles, in 
women in progressive menopausal stages. 
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Hypothesis 1a: There will be a progressive decline in FMD and an increase in 
CD31+/42b- and CD62E+ EMPs in women in progressive menopausal stages. 
 
Aim 1b: To determine whether cardiorespiratory fitness affects differences in endothelial  
health in women in progressive menopausal stages. 
Hypothesis 1b: Perimenopausal women with higher cardiorespiratory fitness will have 
higher FMD and lower CD31+/42b- and CD62E+ EMPs compared to their low-fit 
counterparts, while FMD and CD31+/42b- and CD62E+ EMPs values will not differ in 
high vs. low-fit late postmenopausal women (Figure 1.1).  
 
Aim 2:  To determine the effects of menopause and cardiorespiratory fitness on 
endothelial responses to acute exercise.  
Aim 2a: To determine whether there are differences in endothelial responses, assessed 
via flow-mediated dilation and CD31+/42b- and CD62E+ endothelial microparticles, to 
acute exercise in women in progressive menopausal stages. 
Hypothesis 2a: In response to acute exercise, the change in FMD will progressively 
decrease and the change in CD31+/42b- and CD62E+ EMPs will progressively increase in 
premenopausal, perimenopausal, and late postmenopausal women, respectively. 
 
Aim 2b: To determine whether cardiorespiratory fitness affects differences in endothelial 
responses to acute exercise in women in progressive menopausal stages. 
Hypothesis 2b: Compared to their low-fit counterparts, high-fit perimenopausal and late 
postmenopausal women will have an increase in FMD and a decrease in CD31+/42b- and 
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CD62E+ EMPs in response to acute exercise. FMD responses will progressively decrease 
and CD31+/42b- and CD62E+ EMPs levels will progressively increase in high-fit 
premenopausal, and high- vs. low-fit perimenopausal, and late postmenopausal women 
respectively (Figure 1.2). 
 
 
Aim 3: To evaluate the relationship between FSH and lipid levels in women in a large 
cohort of postmenopausal women. 
Hypothesis 3: FSH levels will be positively related to total cholesterol, low-density 
lipoprotein cholesterol and triglycerides and negatively related to high-density lipoprotein 
cholesterol.  
Figures 
 
Figure 1.1. Proposed Hypotheses for Endothelial Changes with Menopause. 
PRE: premenopausal; PERI: perimenopausal; POST: postmenopausal; EMP: endothelial 
microparticles; FMD: flow mediated dilation. 
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Figure 1.2. Proposed Hypotheses for Endothelial Responses to Acute Exercise.  
Pre: premenopausal; PERI: perimenopausal; POST: postmenopausal; EMP: endothelial 
microparticles; FMD: flow mediated dilation. 
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CHAPTER 2 
LITERATURE REVIEW 
Introduction 
Menopause, which is associated with the cessation of ovarian function, is an 
inevitable transition that women experience as they age. This transition is generally 
associated with changes in sex hormone levels, which adversely affects cardiovascular 
disease risk. Increases in cardiovascular disease (CVD) risk factors, such as blood 
pressure and low-density lipoprotein cholesterol occur around the final menstrual period 
(108). While reductions in estrogens have been the primary focus of research related to 
increasing CVD risk with menopause, there is an increase in follicle stimulating hormone 
(FSH) with menopause that appears to have independent effects on risk (45). This may be 
related to the effects of FSH on lipid metabolism (169), although this avenue remains 
largely unexplored.  
The changes in CVD risk with menopause appear to adversely affect endothelial 
cell function (123). Endothelial dysfunction is a subclinical marker for cardiovascular 
disease and is involved in the initial stages of atherosclerosis (195). Endothelial 
dysfunction is prognostic of cardiovascular events in postmenopausal women (147) and 
has been proposed as a novel risk factor for cardiovascular disease (195).  
In a non-menopausal (i.e. premenopausal women and men), healthy population, 
exercise improves endothelial function by decreasing inflammation and reactive oxygen 
species and increasing vascular tone and nitric oxide bioavailability (39). In a healthy, 
menopausal (i.e. perimenopausal and postmenopausal) population, the impact of exercise 
on endothelial function is not well established (Figure 2.3). Exercise-training studies 
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provide evidence that there may be resistance to the expected improvements in 
endothelial function across the menopausal transition (124, 139). Data from our 
laboratory show that peri- and postmenopausal women have different endothelial and 
inflammatory responses to an acute bout of exercise (158). Therefore, continued 
evaluation of the role of menopausal status and exercise is warranted. Evaluating the 
vascular changes in women across the menopausal transition with differing 
cardiorespiratory fitness levels will allow us to better understand whether exercise, other 
therapeutic approaches, or both in combination, may be beneficial in this population. This 
chapter will provide a general overview of menopause and changes in CVD risk with 
menopause. As a central feature of this dissertation, endothelial function, assessment of 
endothelial function, and the impact of exercise on endothelial function in a healthy, non-
menopausal and menopausal populations will be reviewed. 
 
Menopause 
Thirty-four percent of women die from cardiovascular disease (58), which is the 
leading cause of death of women in developed countries (111). As women age, their risk 
factors for cardiovascular disease increase (108, 189) and 67% of sudden deaths occur in 
women with no history of the disease (126). Menopause marks a change in 
cardioprotection in women. This change is generally attributable to the increase in CVD 
risk factors surrounding the final menstrual period. Importantly, this increase in CVD risk 
is independent of age and begins during the menopausal transition, when hormone levels 
start to change (110) (Figure 2.4).  
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Menopausal Stages 
Menopause occurs at approximately 51 years old in most women and is a multi-
stage transition around the final menstrual period (205). The menopausal transition is 
composed of early and late perimenopause. During this time, estrogen levels decline (67). 
In early perimenopause, the menstrual cycle becomes variable in length. This variability 
is defined by a menstrual cycle that is more than 7 days different from what an individual 
considers normal and occurs at least twice within 10 menstrual cycles. Early 
perimenopause is also marked by variably elevated follicle stimulating hormone (FSH) 
levels. Late perimenopause is marked by intervals of amenorrhea, or a lack of menstrual 
cycle, that last for at least 60 days but less than one year. During this time, FSH values 
are variable but are typically greater than 25 IU/L (67).  
After perimenopause, a woman transitions to early and then late postmenopause. 
Early postmenopause is defined as 1 to 5 years of amenorrhea. This is typically 
accompanied with an elevation in FSH, while estradiol decreases for the first 2 years of 
amenorrhea and then stabilizes. Late postmenopause is defined as more than 5 years of 
amenorrhea. Although estrogen levels may not change significantly during this time, FSH 
levels, while still elevated compared to premenopausal women, may decline (67).  
Menopausal Changes in CVD Risk Factors 
The changes in hormone levels with menopause negatively impact CVD risk. In a 
longitudinal study of women progressing from pre- to peri- to post-menopause there were 
increases in low-density lipoprotein cholesterol (LDL-C), triglycerides, body mass index 
(BMI), fasting plasma glucose, and pulse pressure, with the most dramatic changes in 
LDL-C, triglycerides and BMI occurring during perimenopause. Further, there was an 
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increase in intima media thickness, an independent predictor of CVD (110), which was 
corroborated in a separate longitudinal analysis (201). Many of these changes appear to 
be independent of aging (108). Women who go through menopause at a later age have 
better CVD outcomes (35) and increased longevity (159); women have 18% lower risk of 
developing CVD if they go through menopause at age 52 vs. 44 (35).  
Compared to perimenopausal women, postmenopausal women have higher 
cardiovascular disease risk. This may be attributable to continued increases in lipids, 
body mass index, insulin resistance, and total cholesterol (110, 172). Postmenopausal 
women have higher rates of central adiposity (49), with up to a five times greater risk of 
developing central adiposity (i.e. visceral adiposity) compared to premenopausal women. 
This risk doubles during the menopausal transition (42). Following the final menstrual 
period, lipid levels are estimated to increase by 1.75%, insulin by 2.84% and systolic 
blood pressure by 0.26mmHg per year, independent of age and weight (108). While there 
is a shift in the cardiovascular profile at the initiation of, and throughout, the menopausal 
transition, the reasons behind this shift are still poorly understood. Possible explanations 
for this change are linked to changes in estrogen and FSH levels. 
Effects of Menopausal Hormonal Changes on CVD Risk 
Estrogens. A decline in estrogen is one of the most commonly associated changes 
with menopause. Although, estrogen levels are not stable in premenopausal women and 
vary with menstrual cycle (94, 146), diet, alcohol, and stress (107). Despite these 
fluctuations, premenopausal estrogen levels remain higher than in postmenopausal 
women (67). Estrogen is present in circulation as estrone, estradiol, or estriol (135) and is 
synthesized from cholesterol and carried in the blood via sex hormone binding globulin 
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(SHBG) (107). Sex hormone binding globulin levels may change with menopause. Some 
studies have reported relatively stable levels of SHBG with menopause (136, 166), while 
others have shown a significant reduction (18, 143). Therefore, not only estrogen levels, 
but also the delivery of estrogen may change with menopause.  
 The location of estrogen production varies in premenopausal compared to 
postmenopausal women. In premenopausal women, estrogen is primarily produced in the 
ovaries, but also in the liver and peripheral tissues (64). In postmenopausal women, the 
majority of estrogen is synthesized from circulating androstenedione, testosterone, and 
estrone in peripheral tissues, such as adipocytes (165). The difference in synthesis 
between premenopausal and postmenopausal women may be attributable to the cessation 
of ovarian function with menopause. Once produced, estrogen binds to estrogen receptors 
throughout the body and in the vasculature (112).  
Estrogen receptors are pervasive throughout the body, including in the 
vasculature, and are present as nuclear and g-protein coupled receptors. There are two 
nuclear receptor types, ERa and ERb. When estrogen binds to either receptor, the 
receptor translocates to the nucleus, activating gene transcription. The activation of ERa 
and ERb lead to different responses. In general, ERa leads to cardioprotective effects, 
while ERb is associated with an inflammatory response. The plasma bound estrogen 
receptor, GPER, was more recently discovered, and like ERa, appears to be 
cardioprotective and anti-inflammatory. The effects of estrogen through its receptors can 
be genomic or non-genomic, causing both short and long-term effects (4, 23). With 
menopause, there is an overall reduction in circulating estrogen levels and there may be a 
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shift in estrogen receptor phenotype, with an increase in the proportion of ERb vs. ERa, 
potentially contributing to the increase in CVD risk (132). 
While sex hormones levels and changes in receptor phenotype may affect CVD 
risk, the trajectory of sex hormone changes with menopause also impact cardiovascular 
outcomes. It has been demonstrated that women who have higher estrogen levels prior to 
their final menstrual period (FMP) and lower levels immediately after the FMP have 
lower risk of developing carotid plaque (i.e. atherosclerosis) than women who have 
higher estrogen levels after the FMP and 43% lower risk compared to those who have 
chronically low levels of estrogen pre-and post-FMP (45); however, further research 
needs to be done in this area. This seemingly contradictory effect of estrogen from pre- to 
post-menopause may be related to changes in the effects of estrogen. In vivo work 
suggests that estrogen has anti-inflammatory effects in early stages of menopause and 
pro-inflammatory effects in later stages of menopause, potentially due to changes in 
receptor phenotype, with a shift towards ERb (132). Similarly, higher levels of estrogen 
after menopause are related to increased incidence of insulin resistance (59) and higher 
lipid levels (188)(188). The negative effects of changes in estrogen levels, and potentially 
of estrogen receptor phenotype, are relatively well established, but there is also evidence 
to suggest that changes in follicle stimulating hormone may impact CVD risk.  
Follicle Stimulating Hormone. Unlike estrogen, follicle stimulating hormone 
(FSH) levels remain elevated following menopause. FSH is mainly produced in the 
anterior pituitary and in premenopausal women is involved in regulating the menstrual 
cycle by up-regulating estrogen production and stimulating follicle maturation. As 
estrogen levels decline with menopause, FSH levels rise. The effects of chronically high 
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FSH following menopause are still poorly understood. Women with lower FSH after 
menopause have been reported to have lower risk of developing CVD than those with 
higher FSH (45); however, a recent report suggests that higher FSH is associated with 
reduced CVD risk (198). Higher postmenopausal FSH has also been related to lower 
incidence of type 2 diabetes (12) and lower intima media thickness (11). Interestingly, the 
relationship between FSH and intima media thickness also appears to be influenced by 
age, with an inverse relationship between FSH and intima media thickness that was 
present in older (age 64-73), but not younger (age 53-62) postmenopausal women (11). 
This data suggests that the relationship between FSH and CVD risk may be influenced by 
a variety of factors including age and menopausal status, and the mechanisms behind 
these relationships remain unclear. 
 The influence of FSH on lipid metabolism is one potential mechanism by which 
FSH influences CVD risk (27, 100). High FSH levels reduce LDL-receptor number in 
hepatocytes, leading to a sharp increase in circulating LDL-C in vitro. In vivo, high levels 
of FSH are related to higher LDL-C and total cholesterol in postmenopausal women 
(169). FSH also stimulates lipid biosynthesis (32, 100), as well as the release of leptin in 
adipocytes (100), potentially contributing to postmenopausal weight gain and adverse 
changes in lipid levels (32). Based on this evidence, FSH may independently impact 
CVD risk through effects on lipid metabolism; however, this possibility has been largely 
uninvestigated.  
Overall, there is evidence to suggest that estrogen and FSH independently affect 
CVD risk (45); however, the magnitude of and mechanisms behind these effects have yet 
to be fully elucidated, suggesting that more complex characteristics than absolute 
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hormonal levels are at play. For example, the trajectory of change in hormones through 
the FMP, age at menopause, and premenopausal hormonal levels also affect CVD risk 
after menopause (44, 45). The changes in cardiovascular disease risk with menopause, 
either through effects of estrogen. follicle stimulating hormone, or others factors, may 
lead to changes in endothelial cell function. 
Vascular Endothelium 
Endothelial cells are found lining blood vessels throughout the body. These cells 
have many dynamic properties that maintain vascular homeostasis (194). This includes, 
but is not limited to, the modulation of vaso-constriction and -dilation, blood viscosity, 
and the release of, and response to, inflammatory factors. Endothelial cells are also semi-
permeable to fluids and proteins. These factors are transported either through endothelial 
membranes via vesicle-mediated transport mechanisms or between cells through 
paracellular junctions. The permeability of the cells is largely affected by intra- or extra-
cellular calcium concentration (192). Endothelial cells act as a physical barrier between 
blood and the vessel wall (20), but also release substances that include vasodilators, 
vasoconstrictors, plasminogen activators and inhibitors, and platelet modulators. The 
most recognized of these substances are nitric oxide, prostacyclin, endothelin-1, Von 
Willebrand factor, and plasminogen activator. These factors are predominantly paracrine; 
they act locally on the blood vessel walls in which the cells are located and do not affect 
other vessels (162).  
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Vasodilators 
Nitric oxide (NO) is one of the most extensively studied factors that endothelial 
cells release. Nitric oxide is formed when the amino acid l-arginine is converted to l-
citrulline and NO through activation of nitric oxide synthase (NOS) (Figure 2.5). Nitric 
oxide synthase is present as endothelial NOS (eNOS), inducible NOS (iNOS), found in 
circulating immune cells, and neuronal NOS (nNOS), and is activated through its 
coupling with tetrahydrobiopterin (BH4). Under ischemic conditions, NO may also be 
formed through the reduction of nitrite, although this pathway is less common (101). 
Nitric oxide is a powerful vasodilator that is released in response to factors such as shear 
stress, acetylcholine, substance P, alpha-adrenergic stimulation, bradykinin, serotonin, 
thrombin, and platelet-aggregation. Shear stress is a commonly used technique to study 
nitric oxide release. Shear stress triggers vasodilation when nitric oxide causes guanylate 
cyclase to form cyclic guanosine monophosphate (GMP), which then stimulates calcium 
activated potassium channels. The influx of potassium leads to hyperpolarization of the 
adjacent smooth muscle, causing smooth muscle relaxation. Beyond vasodilation, nitric 
oxide also inhibits superoxide generation, monocyte adhesion, smooth muscle 
proliferation, and platelet aggregation (129). 
Nitric oxide is only one of several vasodilators released by endothelial cells. 
Prostacyclin also contributes to vasodilation through smooth muscle relaxation. 
Prostacylin is formed when phosholipase A is activated and is converted first to 
prostaglandin through the action of cyclo-oxygenase enzymes and then to prostacyclin 
via prostacyclin synthatase (116). Prostacylin inhibits platelet aggregation and smooth 
muscle proliferation (119), and decreases cholesterol accumulation in endothelial cells 
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(203). Like nitric oxide, prostacyclin is released in response to shear stress (53), 
bradykinin, and thrombin (193). Prostacyclin is up-regulated by leukocyte contact, 
arterial wall stretching, interleukin-1, and platelet-derived growth factor (52) and is 
down-regulated by glucocorticoids, age, diabetes mellitus, and coronary artery  
disease (31). 
Vasoconstrictors 
Endothelial cells do not exclusively release vasodilatory factors; they also release 
vasoconstrictive factors. Endothelin-1 (ET-1) is the most powerful of these substances 
and is 10 times more potent than the endothelial-released vasoconstrictor, angiotensin II 
(193). Endothelin-1 is formed in endothelial cells when the 39-amino acid peptide, big 
endothelin-1 is converted to ET-1, a 21-amino acid peptide via endothelin converting 
enzyme. Endothelin-1 can act on smooth muscle cells to stimulate calcium release, 
causing smooth muscle contraction. Endothelin-1 can also bind to receptors on 
endothelial cells, triggering the release of NO and can increase smooth muscle 
proliferation (148). Endothelin-1 is released in response to stimuli such as thrombin, 
epinephrine (207), insulin, hypoxia, and angiotensin II (187). Unlike nitric oxide and 
prostacyclin, endothelin-1 has a dual response to shear stress; it is up-regulated in 
response to low levels of shear stress and is down-regulated in response to high levels of 
shear stress (93). Endothelin-1 is inhibited in the presence of its antagonists, nitric oxide 
(15) and prostacyclin (37) through the suppression of the transcription factor nuclear 
factor kappa b, NFkB (133). 
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Other Factors 
Endothein-1, nitric oxide, and prostacyclin are a few of the factors released by 
endothelial cells; however, they are a small number of many. Other factors are involved 
in smooth muscle migration and proliferation, platelet adhesion, and blood viscosity. A 
few examples of these are: plasminogen activator, which is anti-thrombolytic; and Von 
Willebrand factor, which mediates platelet adhesion in response to endothelial injury. 
Endothelial cells can also express adhesion molecules, which allow immune cells to 
interact with the endothelium (187).  
Endothelial Dysfunction 
Endothelial cells are key regulators of vascular health; therefore, anything that 
disrupts endothelial function can impact basic cellular function and change the balance of 
factors that the cells release. Factors such as coronary artery disease, hypertension, 
dyslipidemia, diabetes, aging, and other cardiovascular disease risk factors may also 
contribute to endothelial dysfunction. This dysfunction is characterized by symptoms 
such as vasospasm, exercise-induced hypertension, or unstable coronary syndrome, but 
can also go unrecognized (162). In the presence of endothelial dysfunction there is 
typically a shift in balance between vasoconstrictors and vasodilators (36). With normal 
endothelial cell function, the balance between vasodilators (e.g. nitric oxide and 
prostacyclin) and vasoconstrictors (e.g. endothelin-1) favors vasodilation. In a 
dysfunctional state, this balance favors vasoconstriction, thereby changing vascular tone.  
The changes in vascular tone that occur with endothelial dysfunction may be 
related to changes in smooth muscle reactivity or endothelial cell function. For example, 
nitric oxide hyperpolarizes smooth muscle, leading to vasodilation. Endothelial 
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dysfunction, assessed via nitric oxide-mediated vasodilation, may therefore be due to 
impaired nitric oxide release or reduced smooth muscle reactivity to nitric oxide. Since 
the function of smooth muscle and endothelial cells are intimately tied together, due to 
shared signaling mechanisms and anatomical location, decreased arterial stiffness is 
impacted by and may impact endothelial function (130). Similar risk factors lead to the 
dysfunction of both tissues, making a causative relationship difficult to determine. 
Despite a lack of clarity as to the full nature of the interactions between the two, 
endothelial dysfunction is predictive of the progression of coronary intima media 
thickening and therefore coronary artery disease (66). This dysfunction can be assessed 
using flow-mediated dilation or by evaluating circulating endothelial microparticles or 
other circulating factors such as cellular adhesion molecules. Flow-mediated dilation is 
dependent on the function of endothelial cells as well as smooth muscle, while 
endothelial microparticles are found in circulation, allowing each to provide unique and 
complimentary information about endothelial cell health. 
Flow-mediated Dilation 
Flow-mediated dilation (FMD) is a relatively quick, non-invasive test that allows 
for an assessment of endothelial function in response to shear stress. Flow-mediated 
dilation is a peripheral test that provides insight into the disease process and is reflective 
of coronary artery function (3, 180). Low FMD has been related to a variety of disease 
states including hypertension (99), hyperlipidemia (171), diabetes (105), and smoking 
(22). Lower FMD is also present in sedentary compared to active older men (139) and is 
prognostic of cardiovascular events in postmenopausal women (147). 
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Flow-mediated dilation utilizes ultrasound and Doppler imaging of a peripheral 
artery before, during, and after blood vessel occlusion with the use of an inflatable cuff. 
The magnitude of dilation of the occluded vessel after the cuff has been released, relative 
to baseline, is a measure of endothelial function (Figure 2.6); dilation should occur in 
response to the increased shear stress caused by reactive hyperemia due to nitric oxide 
release. Despite the simplicity of the technique, FMD can be influenced by a variety of 
factors including cuff position (10), artery choice, the magnitude and duration of the 
stimulus (140), diet (10), exercise (34, 68), caffeine and alcohol consumption, and 
medications (68, 103). Given the many factors that can affect FMD, measurement 
technique is important. 
To date, no organization has published universal guidelines on how to perform 
FMD. Various review articles by experts in the field have provided recommended 
guidelines (51, 63, 182), but until one unified guideline is accepted, discrepancies in 
practice between researchers can make data difficult to compare and interpret. Thijssen, 
et al. (2011) and Flammer, et al. (2012) published independent guidelines that aimed to 
minimize the potential sources of error that were discussed above and a recent article by 
Greyling, et al. (2016) identified factors and provided a grading system to evaluate if an 
FMD study is of high enough quality to be included in a systematic review. While these 
guidelines were published independently, the recommendations are consistent.  
All groups recommend that the study be completed in a warm, quiet room to 
minimize participant distractions and sympathetic activation due to cold or excitement. 
The inflatable cuff should be placed 1 to 2 cm distal to the elbow crease and to the 
ultrasound probe, so that the area being measured is not responding to an ischemic 
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stimulus (51, 182). Occlusion should last for 5 minutes to elicit a predominately nitric 
oxide mediated response. The occlusion should take place either at the brachial or radial 
artery, which is associated with coronary artery endothelial function (180). When the 
technician is completing a flow-mediated dilation study, technical errors in flow velocity 
and imaging can be minimized by using a probe insonation angle of 60° and by 
measuring peak diameter continuously for 180 seconds after cuff release. In order to 
minimize vascular changes due to lifestyle habits, participants should be fasted, refrain 
from exercise, smoking, caffeine, alcohol, and medication for six hours before the study 
(51, 182). The assessment of endothelial function using FMD can help to provide insight 
into changes in endothelial function that can impact cardiovascular risk. 
 
Endothelial Microparticles 
Endothelial microparticles (EMPs) also provide insight into the state of the 
endothelium, but unlike FMD, these particles are assessed in circulation (Figure 2.7). 
High levels of EMPs have been related to a variety of disease states including end stage 
renal disease (2), acute coronary syndrome (9), diabetes (186), and cardiovascular disease 
(161). In fact, EMP levels have been proposed as a potential novel biomarker for 
cardiovascular disease (2). Endothelial microparticle levels are lower in groups with low 
cardiovascular disease risk, such as premenopausal women (92) and normal weight 
individuals (46).  
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Endothelial microparticles are small vesicles (100nm-1µm), which contain 
surface markers from their cell of origin and carry proteins and miRNA. The surface 
markers on EMPs give an indication of the state of their cell of origin. These markers can 
include cellular adhesion molecules or membrane receptors, such as nitric oxide synthase; 
however, many of these markers are non-specific to endothelial cells and therefore are 
difficult to isolate and interpret. The main markers that are specific to EMPs are markers 
of endothelial activation (CD62E+) and endothelial apoptosis (CD31+/42b-)(41). There 
are small numbers of EMPs in circulation at all times, but levels may increase in response 
to both acute and chronic stimuli such as inflammation, exercise, or disease (41). 
Although, still not fully understood, EMPs may also contribute to cellular processes such 
as cell survival and angiogenic capacity (41). 
 Endothelial microparticles are able to act on other cells within the vascular 
network. They enhance inflammatory cascades either through recruitment of white blood 
cells, through their membrane markers, or by fusing with other nearby cells and releasing 
their content. Endothelial microparticles are also involved in angiogenesis, thrombosis, 
and cell regeneration (138). Endothelial microparticles can be taken up by endothelial 
cells and appear to influence cell function. For example, EMPs have been shown to be 
protective of endothelial apoptosis (79, 196). Despite these many roles, the effect that 
EMPs have on other cells is still not fully understood. Therefore, although they are 
generally considered markers of endothelial status, their role appears to be more 
complicated (33, 73, 154, 208).  
Similar to FMD there are no universal guidelines for measuring EMPs and the use 
of this technique to assess endothelial health is still relatively new. Endothelial 
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microparticle levels are affected by factors such as inflammation, reactive oxygen species 
(41), centrifugation speed during preparation, duration of sample storage (38), storage 
temperature (160), lipid levels (190), and even vascular damage due to venipuncture 
(210). Endothelial microparticle levels also change in response to exercise (196) or to 
changes in physical activity patterns (16). The many factors that influence EMPs makes 
the interpretation and comparison of EMPs across studies challenging. Despite this, 
EMPs are related to a variety of disease states and may provide unique information on the 
overall state of endothelial cells that cannot be determined via FMD or can be used to 
complement physiological measures of endothelial function. 
Endothelial Function and Menopause 
Endothelial function appears to decline with menopause. A significant reduction 
in FMD has been seen even during the menopausal transition after accounting for other 
CVD risk factors and worsens with prolonged estrogen deficiency (123). Endothelial 
microparticle levels also appear to change with menopause. Compared to low-active 
postmenopausal women, perimenopausal women have lower levels of CD62E+ EMPs 
(158) and when comparing postmenopausal women with high vs. low estrogen levels, 
women with high estrogen have lower levels of CD62E+ EMPs (43). These findings 
suggest changes in endothelial function with menopause and that these changes may 
negatively impact CVD risk.  
Effects of Estrogen  
Estrogen deficiency is a unique factor that contributes to endothelial dysfunction 
and vascular changes in menopausal women. Throughout the menopausal transition, 
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estrogen levels fall. This decline has been correlated with endothelial dysfunction in 
postmenopausal women (84, 149, 179) and prolonged estrogen deficiency may hinder 
improvements in endothelial function (124). Lower estradiol levels can lead to structural 
changes such as a larger adventitial diameter (201) or an increase in intima media 
thickness (110). An increase in adventitial diameter has been associated with an adverse 
cardiovascular disease profile (30, 83) and is increased most between late perimenopause 
and postmenopause (201). A decline in estrogen can also increase vasoconstriction and 
shear stress levels, potentially leading to structural changes such as increased intima 
media thickness. This increase has been seen in women across the menopausal transition 
and is related to higher premenopausal levels of systolic blood pressure, pulse pressure, 
triglycerides, glucose, body mass index, and high-density lipoproteins (110). These 
changes combined can all adversely affect endothelial function. 
Estrogen modulates endothelial function through a variety of roles and can cause 
vasodilation, by increasing nitric oxide (87, 113), endothelial nitric oxide synthase, and 
prostaglandin synthesis (74). Estrogen further contributes to vasodilation by inhibiting 
vasoconstriction and sympathetic activation (114). There is also evidence to suggest that 
not just estrogen, but also estrogen receptors modulate nitric oxide production (148). 
Estrogen also decreases low-density lipoprotein cholesterol oxidation, which is a 
precursor to atherosclerosis and endothelial dysfunction. Finally, estrogen is both anti-
oxidative and anti-inflammatory, therefore indirectly effecting endothelial function (174). 
 Estrogen therapy consistently improves endothelial function in postmenopausal 
women (71, 104, 124, 175). Following 8 weeks of estrogen therapy, early 
postmenopausal women had improved basal NO release, with no change in endothelial 
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independent vasodilation (175). This suggests that estrogen deficiency reduces NO 
bioavailability, a finding that has been corroborated in animal studies (17, 50). While 
aging may compound many of the primary and secondary effects due to estrogen 
deficiency, there was reduced endothelial function in young women one week following 
oophorectomy (134). There is also reduced function in young women with premature 
ovarian failure (84), in amenorrhoeic athletes (145), and following ovariectomy in 
rodents (17, 50). The anti-inflammatory and anti-oxidative effects of estrogen deficiency 
can also impact endothelial function. When postmenopausal women were treated with an 
inhibitor for the inflammatory cytokine tumor necrosis factor-α, there was in 
improvement in FMD (121). Similarly, the use of ascorbic acid, an anti-oxidative 
therapy, improved FMD in postmenopausal women (124).  
Effects of Follicle Stimulating Hormone 
Unlike estrogen, follicle stimulating hormone (FSH) levels remain elevated 
following menopause. Although less studied, there is evidence to suggest that FSH may 
also impact endothelial function and CVD risk. FSH receptors are present on some 
endothelial cells  (e.g. from tumors and the umbilicus) (142, 173), though they may not 
be present on all endothelial cells, and when stimulated, promote angiogenesis; this 
benefit is attenuated with supra-physiologic FSH levels (173). FSH may also affect 
endothelial progenitor cells, which are involved in endothelial cell repair; high levels of 
FSH promote bone marrow derived osteoclast activity (56), potentially disrupting 
endothelial progenitor cell formation. There is also evidence to suggest that FSH may 
adversely impact lipid levels (27, 100), and in a regression analysis, menopausal status, 
but not estradiol was related to the endothelial response to acute exercise (158). FSH may 
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independently affect endothelial function; however, this possibility has been largely 
uninvestigated.   
Treatment 
Endothelial function appears to decline with menopause, thereby negatively 
impacting CVD risk; however, clinicians have struggled to find an effective treatment 
method to improve cardiovascular outcomes in this population. In the past, hormone 
therapy was commonly used in menopausal women; estrogen supplementation improves 
factors such as blood pressure and basal nitric oxide release (175). Despite the positive 
effects of estrogen on the cardiovascular system, hormone therapy (HT) in 
postmenopausal women did not improve CVD risk (77, 206). In fact, the Women’s 
Health Initiative study, a longitudinal study investigating the effects of HT in 
postmenopausal women, was terminated early following reports of adverse outcomes, 
such as increased incidence of stroke and breast cancer (206). Evidence suggests that the 
type (e.g. conjugated equine estrogen vs. oral estradiol) (164, 168), delivery method (e.g. 
transdermal vs. oral) (118, 152), and the timing of HT (e.g. early vs. late postmenopause) 
(7) may affect outcomes; however some of these hypotheses are still being tested. 
Currently, HT is most commonly used to acutely treat women who are in the early stages 
of menopause for conditions such as menopausal symptoms and is generally not 
recommended for women in later stages of menopause (5). Exercise shares similar 
signaling pathways to estrogen and improves cardiovascular outcomes (65, 106), making 
it a potential therapeutic candidate to improve endothelial function in this population.  
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Cardiovascular Risk and Exercise 
Exercise is a potent stimulus to improve endothelial function through its 
multifaceted effects on vascular tone, inflammation, reactive oxygen species, thrombosis 
and platelet aggregation (39). These benefits are well-established in healthy men and 
non-menopausal women, but may not remain in a menopausal population (122) 
Non-menopausal Population 
Improved Vascular Tone. In a non-menopausal population, chronic exercise 
training increases secretion of vasodilatory factors in response to exercise-induced shear 
stress. This may be attributed to an increase in nitric oxide and endothelial nitric oxide 
synthase production (eNOS). This adaptation has been seen with aerobic training studies 
(62, 85) and is illustrated by a two times greater vasodilatory capacity in runners versus 
sedentary individuals (72). Increased endothelial production of nitric oxide is 
hypothesized to be due to shear stress as well as increased catecholamines, adenosine 
triphosphate, and eNOS circulation (129). Exercise training can also enhance vasodilation 
through increased prostacyclin release and high-density lipoprotein synthesis. High-
density lipoproteins up-regulate the synthesis of prostaglandin-2 and contribute to 
increased vasodilation (53). 
Although increases in vasodilatory factors are beneficial to endothelial function, 
in order for vasodilation to improve, a positive balance must exist between vasodilatory 
and vasoconstrictive factors like endothelin-1. Chronic exercise training decreases 
endothelin-1 levels, which may be inversely related to increases in nitric oxide 
production (39). This reduction is only seen with endurance (i.e. aerobic) exercise 
training and the adaptation is lost with training cessation (102). Beyond changes in 
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vasodilatory and vasoconstrictive factors, exercise can also affect inflammatory factors 
and reactive oxygen species.  
Decreased Reactive Oxidative Species and Inflammation. Exercise acutely 
increases the production of reactive oxygen species (ROS), such as NADPH oxidase. 
Chronic elevation of ROS can damage endothelial cells and cause nitric oxide 
degradation. However, due to the transient increase in ROS after an acute bout of 
exercise, endothelial damage does not typically occur. With chronic exercise training, the 
body begins to adapt to the increased oxidative burden with increased expression of 
antioxidant enzymes such as superoxide dismutase and glutathione peroxidase (24, 76). 
This increase in antioxidant species can have a protective effect on the endothelium by 
increasing nitric oxide bioavailability. However, even with the protective effects from 
antioxidant species, ROS production continues through aerobic metabolism and the 
oxidation of pre-existing molecules such as nitric oxide  
synthase (19).  
Much like ROS, acute exercise can lead to an increase in inflammation, although 
this response is reduced in trained individuals (1). This inflammatory response is 
typically attributed to muscle damage from either heavy exercise or novel activities. 
Inflammation disrupts endothelial function and increases the expression of vascular cell 
adhesion molecules, C-reactive protein, and intracellular adhesion molecules, all of 
which increase platelet adhesion. With chronic exercise training, these factors decrease, 
allowing for improved endothelial function (184).  
Acute exercise can also lead to changes in circulating cytokine levels. Most 
studies investigating the response of cytokines to acute exercise have been completed 
  28 
men, making findings difficult to extrapolate to women. In 20 young, healthy men, 30 
minutes of treadmill exercise at 75% of VO2max lead to increased levels of the 
inflammatory cytokines interleukin-8 and interleukin-6 and growth factors involved in 
angiogenesis, such as vascular endothelial growth factor, all of which may impact 
endothelial cell function. These increases were independent of exercise training status 
(96). Cytokine responses to acute exercise may be independent of intensity and training 
status (156, 157), but effected by body mass and gender. Two hours of acute exercise 
completed by sedentary and obese and/or overweight participants showed an increase in 
IL-8, but in female subjects only (26).  
Decreased Thrombosis and Platelet Activity. Although vasomodulation and 
inflammatory responses are an important component of endothelial function, endothelial 
cells have other roles in promoting normal vascular function. Platelet aggregation and 
activation can lead to endothelial dysfunction and thrombus formation. Chronic exercise 
training decreases platelet aggregation (144), while acute exercise in sedentary 
individuals increases platelet activation (86). Conversely, chronic exercise training 
increases tissue plasminogen activator, allowing for improved clot lysis (144). This is 
thought to be in response to increased intracellular calcium levels, shear stress, and an 
upregulation of tissue plasminogen activator mRNA from exercise (40, 91). Tissue 
plasminogen activator typically declines with age; however, chronic aerobic exercise 
training has been shown to halt this decline (167). 
Menopausal Population 
The benefits of exercise on endothelial function in a non-menopausal population 
are well established; however, the data in healthy women across the menopausal 
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transition is limited. The majority of studies focus on a single stage during the 
menopausal transition, menopausal symptoms, or the impact of hormone therapy (71, 90, 
98, 124). This makes the identification of when changes in vascular function occur, and 
therefore, when an intervention may be most effective difficult. Further, there has been a 
scarcity of research on the effects of a single bout of acute exercise on endothelial 
function. Overall, our understanding of changes in the vasculature across the menopausal 
transition is limited. 
Endothelial Benefits of Exercise. Endothelial function may improve following 
exercise training. After 12 weeks of aerobic exercise, initially targeting 250 kcal/session 
and progressing to 350 kcal/session, FMD improved in previously sedentary 
postmenopausal women, but only in those with significant impairment (<4.5% or <50th 
percentile FMD) prior to the intervention (177). Similarly, FMD improved in 
postmenopausal women after 6 months of aerobic training at 50%, 100% or 150% of 
physical activity guidelines, with those with the greatest initial impairment experiencing 
the greatest improvement (178). In a separate trial, following 24 weeks of aerobic 
exercise, beginning at 30% of heart rate reserve (HRR) and progressing to 60% HRR, 
previously sedentary postmenopausal women improved FMD, but there were no changes 
in similarly aged-men. Importantly, women had lower function initially, again suggesting 
that significantly impaired endothelial function may be necessary for exercise-induced 
improvements (13). In a similar study, after 24 weeks of aerobic training (30-60% HRR), 
postmenopausal women had improved microvascular vasodilatory capacity (75). Further, 
when comparing overweight sedentary to active postmenopausal women, active women 
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had higher FMD (150), suggesting that chronic training attenuates declines in endothelial 
function following menopause.  
Rodent studies also support the benefits of exercise training on endothelial 
function. Following 8 weeks of aerobic training, endothelial dependent vasodilation 
improved in the aortas of ovariectomized (OVX) rats. This improvement was 
accompanied by a reduction in reactive oxygen species production (17). Similarly 
following 8 weeks of swim training, there was an improvement in endothelial dependent 
vasodilation and an increase in antioxidant enzymes in OVX rats (28). OVX rats were 
also able to improve endothelial dependent vasodilation following 14 weeks of isometric 
strength training (50).  
The improvements observed with exercise training may be due to the acute effects 
exercise has on endothelial function. Although less commonly employed than exercise 
training studies, acute exercise studies may provide additional insight into the 
adaptability of the endothelium in response to the hemodynamic challenge of an exercise 
bout. An acute exercise model may also elucidate differences in FMD in groups with 
differing CVD risk that are not apparent prior to exercise. For example, FMD was similar 
prior to acute exercise in sedentary vs. active middle-aged and older men; however, 
following an acute bout of exercise, active men had higher FMD than sedentary men, 
highlighting the differences in CVD risk between the groups (68). Two separate studies 
showed that following an acute bout of exercise; postmenopausal women improved 
FMD, while premenopausal women did not. However, like the previous studies, the 
postmenopausal group had significantly lower FMD at baseline (70, 71).  
  31 
Overall, there is evidence that suggests that endothelial function may improve 
following aerobic exercise in healthy postmenopausal women; however, there are 
methodological limitations that make the interpretation of these results challenging. As 
discussed previously, FMD is influenced by a variety of factors, and when not done 
following published guidelines, may be capturing a non-NO mediated response. Many of 
the studies showing the beneficial effects of exercise used varying methodologies, with 
several studies using cuff placement proximal to the probe, initiating a non-NO mediated 
vasodilation (70, 71, 150). Further, subject restrictions prior to FMD were largely 
unreported or varied considerably across trials; for instance, one trial provided 
participants with a meal prior to measurement (70). In addition, not all studies controlled 
for the time of day that measurements were taken, ignoring the potential effects of diurnal 
variations on FMD. Further, inclusion criteria varied across studies, with at least one 
study including women who were on CVD-related medication (178) or were 
overweight/obese (150). Importantly, no study classified women into specific 
menopausal stages, potentially washing out differences between early and late 
postmenopausal women, and several studies included women who had undergone 
surgical menopause (70, 71). In the cross-sectional analysis showing higher FMD in 
active compared to sedentary women, physical activity status was based on self-report 
and VO2max did not differ between groups (150), suggesting that cardiorespiratory fitness 
may not have been the sole contributor to the observed differences between groups. 
While some rodent studies have supported the benefits of training on endothelial function 
(17, 28, 50), most utilized ovariectomized (OVX) young animals, a model that has 
several limitations as a direct correlate for menopause in humans.  
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Endothelial Resistance to Exercise. There is also a strong body of evidence to 
suggest that following menopause, there is a reduction in endothelial benefits associated 
with exercise; although, some of the methodological issues discussed above are present in 
this literature as well. Improvements in FMD as a result of exercise may only occur when 
estrogen supplementation is concurrently delivered. In previously sedentary 
postmenopausal women, FMD only improved after 12 weeks of aerobic training (65-80% 
maximum heart rate, MHR) in those who were given estrogen (124). This has also been 
shown in vessels from OVX rats subjected to chronic high shear stress, as might occur 
with exercise training; only arteries from rats treated with estrogen improved NO-
mediated vasodilation and showed functional remodeling, with no, or adverse changes in 
the non-estrogen treated group (181). Several studies that did not include estrogen 
supplementation found no effect of training on FMD. Following 8 weeks of brisk walking 
(70-75% MHR), there was no change in FMD in postmenopausal women, while there 
was an improvement in age-matched men (139). Similarly, there was no improvement in 
FMD following 18 weeks of aerobic training (60-85% MHR) in postmenopausal women 
(21). Preliminary data from a randomized controlled trial showed no improvement in 
FMD in postmenopausal women with 8 weeks of moderate intensity continuous training 
or high intensity interval training (209) or in a separate study, after 2 weeks of continuous 
or high-intensity interval training (89). In cross-sectional analyses comparing highly-
active postmenopausal women to their sedentary age-matched peers, there was no 
difference in FMD (139, 151), while similarly-aged sedentary men had worse FMD 
compared to their active peers (139) (Figure 2.8). This suggests that long-term training 
confers no endothelial protection following menopause. The lack of benefit from training 
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on endothelial function in menopausal women has also been shown at the microvascular 
level (151), indicating that resistance may be pervasive throughout the vascular network.  
The acute exercise literature also supports the hypothesis that there may be 
endothelial resistance to exercise with menopause. In early peri-, late peri- and early post-
menopausal women there was increased vascular conductance (i.e. greater resistance) and 
reduced blood flow during leg extension exercise with progressive menopausal stages 
(120). Postmenopausal women did not exhibit a change in FMD in response to varying 
intensities of acute exercise (209). Similarly, we previously showed that following an 
acute bout of aerobic exercise, postmenopausal women demonstrated no change in FMD, 
while perimenopausal women had a trend for enhanced FMD, which was accompanied 
with lower levels of EMPs related to endothelial activation and apoptosis. The FMD 
response to acute exercise was related to menopausal status, LDL-C, DBP, and 
cardiorespiratory fitness, suggesting that menopause itself, as well as changes in CVD 
risk factors that may accompany menopause impact endothelial function (158). This 
acute response may provide insight into the adaptability of the endothelium and together, 
these studies support the concept that changes in the vasculature may be occurring early 
during menopause. While the argument can be made that the exercise stimulus in some 
studies was not enough to elicit improvements in endothelial function, almost all 
protocols improved VO2max, suggesting an appropriate stimulus to improve 
cardiorespiratory fitness; further, the cross-sectional analyses of sedentary vs. active 
women, most of whom had been highly active for decades (139, 151), suggests that 
intensity and intervention duration are not a limiting factor. 
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Hormonal changes may contribute to the endothelial resistance to exercise seen 
with menopause. As discussed previously, estrogen acts directly on the vasculature to 
increase NO production. As estrogen levels decline, there may be an overall reduction in 
NO bioavailability, hindering the ability of the endothelium to respond to acute and 
chronic exercise. This is supported by the observation that NO production is reduced 
following OVX (17), that FMD is reduced with acute exercise and repeated FMD trials in 
postmenopausal women (158), and that FMD in postmenopausal women improves with 
BH4 treatment (125), a cofactor involved in the coupling of eNOS, as well as with l-
arginine treatment, a cofactor involved in the production of NO (88). Further, ERα 
expression is reduced with lower levels of estrogen (6, 55, 78), potentially perpetuating 
the negative effects of estrogen deficiency on the endothelium, as this receptor phenotype 
is generally associated with the cardioprotective effects of estrogen (23). The increase in 
inflammation (156, 157) and oxidative stress (141) with a single bout of exercise may 
also be exacerbated by estrogen deficiency, hindering the ability of the endothelium to 
adapt. Along with estrogen, other factors may also mediate the endothelial response to 
exercise. FSH stays consistently high following menopause (67). As discussed 
previously, FSH may affect endothelial cell function (142, 173), either directly through 
endothelial progenitor cells (56) or indirectly through effects on lipid metabolism (169). 
The decline in FMD (123) and the reduced conductance with acute exercise (120) 
following menopause were both related to high FSH levels, and high postmenopausal 
FSH levels have also been related to CVD risk (44, 45); therefore, FSH likely exerts an 
independent effect on endothelial function and responses to exercise, but this has largely 
been uninvestigated.  
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 Overall, endothelial resistance to the benefits of exercise may occur following 
menopause; however, the literature is conflicting and difficult to interpret due to 
variability across studies in measurement technique, classification of menopausal stage, 
and subject population. Further, most studies have small sample sizes, making results 
difficult to generalize. Future research investigating this question with more controlled 
experimental designs are needed. Finally, if this resistance does occur, it is unclear when 
this resistance begins (e.g. during perimenopause or postmenopause) and how to treat it.   
Summary 
During the menopausal transition, women experience a decline in 
cardioprotection, leading to adverse cardiovascular profiles. This decline may be partially 
attributable to declines in endothelial function. In a healthy, non-menopausal population, 
exercise training and acute exercise improve endothelial function. In a healthy 
menopausal population, the response to acute and chronic exercise has not been well 
characterized. While there have been several studies evaluating responses to exercise 
training, there are limited data across the menopausal transition and acute exercise studies 
are sparse. This dissertation was designed to characterize changes in endothelial function 
and responses to exercise with menopause, and the modulatory role of cardiorespiratory 
fitness on these responses. These outcomes could have important clinical implications. 
Specifically, they may inform when an intervention is appropriate, and if there is a point 
at which some of these changes may be irreversible with exercise. Further, we aimed to 
determine whether FSH is related to lipid levels in postmenopausal women, evaluating 
another potential therapeutic target to improve CVD risk in this population.  
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Figures 
 
 
Figure 2.1. Conceptual Framework.  
Menopause leads to a reduction in estrogen and an increase in follicle stimulating 
hormone (FSH), which adversely affect cardiovascular disease (CVD) risk factors; 
however, the mechanisms behind the effects of FSH on CVD risk factors are still unclear. 
Changes in risk factors for CVD adversely affect endothelial function and change 
endothelial microparticle levels. While cardiorespiratory fitness is generally considered 
protective of endothelial health, potentially through its influence on risk factors for CVD, 
whether this benefit remains in a menopausal population is unclear. 
 
 
 
Figure 2.2. Changes in Estrogen and Follicle Stimulating Hormone. 
Prior to a woman’s final menstrual period, represented by the red line, estrogen levels 
begin to decline, while follicle stimulating hormone (FSH) levels rise. Estrogen remains 
low following the final menstrual period while FSH remains elevated (Adapted from 
Harlow et al., 2013). 
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Figure 2.3. Nitric Oxide Formation.  
In endothelial cells, l-arginine is converted to l-citrulline and nitric oxide when 
endothelial nitric oxide synthase (eNOS) is activated through its coupling with 
tetrahydrobiopterin (BH4). This pathway is typically stimulated by shear stress on the 
endothelial cell surface. 
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Figure 2.4. Flow-mediated Dilation Technique. 
During each flow-mediated dilation study (FMD) an ultrasound and Doppler probe is 
used to image the brachial artery, with a small inflatable cuff placed around the 
participant’s forearm (upper panel). Throughout the study artery diameter (bottom left) 
and flow rate (bottom right) are continuously tracked during 2 min of rest, 5 min of 
forearm blood flow occlusion, and 4 min following cuff release. When the cuff is 
released, vasodilation should occur and FMD is calculated as the change in artery 
diameter from baseline to maximum vasodilation (bottom panel). 
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Figure 2.5. Endothelial Microparticle Formation. 
Endothelial microparticles (EMPs) are released from the endothelium when it undergoes 
an acute stress. Microparticles are formed from the membrane of endothelial cells and 
contain markers that indicate the state of the endothelial cell of origin. These markers 
include markers of endothelial activation (CD62E+) and of endothelial apoptosis 
(CD31+/42b-) (Adapted from Yong et al., 2013). 
 
 
Figure 2.6. Sex Differences in the Relationship Between Cardiorespiratory Fitness 
and Endothelial Function.  
In a cross-sectional analysis, endurance trained postmenopausal women and age-matched 
men were compared to their sedentary peers. While there was a benefit of 
cardiorespiratory fitness on endothelial function in men, this benefit was not present in 
postmenopausal women (Adapted from Pierce et al., 2011). 
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CHAPTER 3 
 METHODS 
Introduction 
The aims of this study were to determine 1) if there are differences in endothelial 
health in women in progressive menopausal stages before and after acute exercise; 2) if 
endothelial health and endothelial responses to acute exercise are affected by 
cardiorespiratory fitness; and 3) if follicle stimulating hormone (FSH) is related to lipid 
levels in a large cohort of postmenopausal women. These aims were addressed by: 
examining the magnitude of difference in brachial artery flow mediated dilation (FMD) 
and endothelial microparticles (EMPs) before and after an acute bout of exercise in 
women in progressive menopausal stages and with high and low cardiorespiratory fitness; 
and by determining whether FSH is associated with lipid levels in postmenopausal 
women participating in the Kuopio Ischaemic Heart Disease Risk Factor Study. These 
aims were evaluated using an experimental study (Aims 1 & 2) and an analysis of data 
from the Kuopio Ischaemic Heart Disease Risk Factor Study (Aim 3).  
Experimental Study (Aims 1 and 2) 
This study evaluated difference in endothelial function in women in progressive 
menopausal stages before and after acute exercise. The study included perimenopausal 
and late postmenopausal women with differing cardiorespiratory fitness levels and a 
high-fit premenopausal referent group.  
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Participant Characteristics: 
Sample Size. The study was originally powered to include high-fit 
premenopausal, perimenopausal, and late postmenopausal women (n=12 per group). This 
number was based on sample size estimations using a power of 0.80 and an alpha of 0.05 
and was powered to detect changes in the primary outcome, flow-mediated dilation. 
Flow-mediated dilation was calculated as both absolute (i.e. mm) and relative (i.e. 
percent relative to baseline) change in artery diameter. In order to detect changes in FMD 
in progressive menopausal stages, a sample size estimate was calculated based on FMD 
differences in women (mm change in brachial artery diameter) across the menopausal 
transition (mean ± SD; premenopause: 0.33 ± 0.05 mm; early perimenopause: 0.30 ± 0.08 
mm; late perimenopause: 0.21 ± 0.08 mm; late postmenopause: 0.16 ± 0.04 mm) (123). 
Based on this estimate, 5 participants were needed per group to detect a difference 
between premenopausal and late perimenopausal women, while 31 were needed to detect 
a difference between premenopausal and early perimenopausal women; therefore, 
perimenopausal groups were combined. Twelve participants were needed per group to 
detect a difference between early and late perimenopausal women. Three participants 
were needed per group to detect a difference in premenopausal vs. late postmenopausal 
women and 6 participants were needed per group to detect a difference between late peri- 
and late post-menopausal women. A sample size estimate was also calculated from a 
study evaluating the FMD response to acute exercise in postmenopausal women, 
measured as percent change in brachial artery diameter (%FMD) from pre- (5.3 ± 1.3%) 
to post-exercise (9.9 ± 1.4%) (70). This estimate showed that 9 participants were needed 
per group. Finally, a sample size estimate was completed based on the FMD response to 
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acute exercise in 7 low-fit perimenopausal and 8 low-fit late postmenopausal women 
(141). To detect a difference in the FMD response to acute exercise in perimenopausal 
women (pre-exercise: 6.4 ± 1.6%; post-exercise: 8.5 ± 3.0%) 11 participants were needed 
per group, while 435 were needed to detect a difference in postmenopausal women. 
Given the lack of response to acute exercise in the postmenopausal group, this number 
was not included in the final sample size determination (pre-exercise: 6.5 ± 1.4%; post-
exercise: 6.2 ± 2.9%). The final sample size was chosen based on the highest number of 
participants needed per group to detect either outcome. Calculations were completed with 
a one-tailed test, using means and standard deviations, as we hypothesized that FMD 
would decrease across the menopausal transition. Data collection was previously 
completed in low-fit women and included 7 perimenopausal and 8 late  
postmenopausal women.  
Inclusion Criteria. Participants were stratified into menopausal stages based on 
STRAW+10 guidelines (67): 
• Premenopause: regular menstrual cycles; women in the premenopausal group 
were at least 40 years old, to keep the average age similar to the perimenopausal 
group 
• Early perimenopause: variable menstrual cycle length (more than 7 days different 
from normal and occurring at least twice within 10 consecutive cycles) 
• Late perimenopause: 60 days or more, but less than 1 year of amenorrhea 
• Late postmenopause: more than 5 years of amenorrhea 
Early postmenopausal women were not included as a group based on work by 
Moreau et al. (2012) and Moore et al. (2012). Moreau et al. (2012) examined baseline 
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changes in flow-mediated dilation in women in progressive menopausal stages; the 
smallest difference in FMD between groups was between late perimenopausal and early 
postmenopausal women (123) (Figure 2.9). Moore et al. (2012) examined vascular 
responses to acute exercise and found that there was a blunted response beginning in late 
perimenopause and continuing into early postmenopause (120). There was no reason to 
believe that this blunting effect would not continue into late postmenopause. By selecting 
these groups, we were able to highlight changes in endothelial function that may occur 
during early menopausal stages, while also evaluating more prolonged trends that may 
occur over time with the inclusion of late postmenopausal women.  
 
In addition to menstrual cycle criteria, participants also met the following inclusion 
criteria: 
• 65 years old or younger 
• Normal blood pressure (<140/90 mmHg) 
• Non-diabetic (fasting plasma glucose <126 mg/dl) 
• Participation in less than 150 min/week of moderate intensity physical activity or 
less than 75 min/week of vigorous intensity physical activity, accumulated in 10 
minute bouts (i.e. low-fit) OR participation in at least 300 min/week of moderate 
intensity physical activity or at least 150 min/week of vigorous intensity physical 
activity, accumulated in 10 minute bouts, with a similar level of activity over the 
past 2 years (i.e. high-fit) 
• Nonsmokers 
• Normal lipid levels (LDL-C ≤159 mg/dl, HDL-C >40 mg/dl, TG<150 mg/dl) 
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• VO2peak ≥80th percentile, if classified as high-fit 
Exclusion Criteria. 
• Hormone replacement therapy, menopausal symptom treatment, or oral 
contraceptive use in the past 6 months 
• History of heart or blood vessel diseases (e.g. peripheral arterial disease, coronary 
artery disease) 
• Previous heart attack or cardiovascular intervention (e.g. pacemaker implant) 
• Hysterectomy prior to menopause or not have undergone natural menopause 
• Self-reported long-term menstrual irregularities prior to menopause 
• Use of certain vitamin/supplements, lipid lowering and/or anti-inflammatory 
medications in the past 4 weeks 
• Current and/or history of breast cancer (with radiation or chemotherapy 
treatment), vaginal bleeding, abnormal uterine/ovary structure, blood clots, acute 
liver or gallbladder diseases 
• Muscle, bone, or other condition that limits ability to exercise 
• Contraindication to an exercise test 
• Absolute or relative termination criteria during exercise test  
• History of fainting with blood draws 
• Pregnancy 
• Participation in a research study that conflicted with this study's protocols 
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Protocol: 
Study Overview: 
All participants completed three study visits. The first visit involved testing of 
cardiovascular disease risk factors, a bone mineral density & body composition scan, and 
screening for other potential exclusion criteria. The second visit included a maximal 
exercise test and an FMD familiarization trial. The third visit was used for the majority of 
data collection on the primary outcome, FMD. The visit began with a blood draw and 2 
FMD trials, followed by 30 minutes of moderate-intensity treadmill exercise, a period of 
rest and then a second blood draw and two more FMD trials. Study protocols are outlined 
in Table 3.1, along with potential exclusion time points (Table 3.2) and are discussed in 
detail below. There was no set time between visits. 
Study Location: 
Most experimental procedures were completed in the Molecular and 
Cardiovascular Physiology Lab, located in the Totman Building at the University of 
Massachusetts Amherst. A Lunar DEXA machine (Madison, WI) located at University 
Health Services on the Amherst campus was used for all DEXA scans. EMP analyses 
were completed in the Flow Cytometry Core on the Amherst campus.  
Equipment: 
Flow-mediated Dilation Equipment. A Philip’s HDXE11 Ultrasound System 
(Bothell, WA) with an L-12-5 probe with an insonation angle set to 60° was used for all 
vascular imaging. All images were streamed directly to version 2.8.0 of the FMD Studio 
Software (Quipu, Pisa). The software collected continuous data on vessel diameter, shear 
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stress rate, and blood flow velocity. This software has been compared to the commonly 
used software, Brachial Analyzer, and was found to give measurements with a difference 
of less than 1% (47). Further, in a multicenter reproducibility study, the coefficient of 
variation for the software was 9.9 ± 8.4% for intra-session measurements and 12.9 ± 
11.6% for inter-session measurements (57). The variability for inter-session 
measurements has been as low as 5.2% (153). This variability was minimized in this 
study by using the same imager for all FMD measurements, by using rapid cuff 
inflation/deflation (D.E. Hokanson, Bellevue, WA), and by monitoring blood pressure 
and ECG (G.E. Dash 2000, Milwaukee, WI) every minute during each study. The 
average variance for repeated pre- and post-exercise FMD trials in this study was 0.1%.  
Blood Processing Equipment. Serum and plasma were isolated from blood 
samples using a Sorvall Legend X1R centrifuge (Osterode, Germany) and were stored in 
a Fisher Scientific Isotemp freezer (Asheville, NC) at -80°C until analysis. Estradiol and 
FSH were analyzed on a Multiskan MS Microplate Reader (Vaanta, Finland) using 
commercially available ELISA kits. Endothelial microparticles were analyzed using a BD 
Dual LSR Fortessa (San Jose, CA).  
Exercise Equipment. A Cybex 550T treadmill (Medway, MA) was used for all 
graded exercise tests and exercise sessions. The Parvo Medics TrueOne 2400 (Sandy, 
UT) collected oxygen consumption data and was calibrated for gas analysis and flow 
volume before each test. Data output was computed using associated software. During the 
exercise test (Visit 2), 12-lead ECG was monitored using the Cardio-Card system 
(Brewerton, NY). During the exercise session (Visit 3), heart rate was monitored with a 
Polar FT1 Heart Rate Monitor (Kempelle, Finland).  
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Testing: 
All study protocols were approved by the University of Massachusetts Amherst 
Institutional Review Board (protocol # 2014-2028). 
Visit 1 (1 hour) 
Orientation, Informed Consent, Questionnaires and Baseline Measurements. 
Participants were contacted by phone or email before the first visit and instructed to 
arrive fasted for 12 hours and to wear loose non-metallic clothing. Before beginning any 
testing protocols, participants signed an informed consent document (Appendix A). The 
document was explained to the participant and she was given time to review and ask any 
questions before signing. After signing the informed consent, the participant filled out a 
health history form (Appendix B), a quality of life questionnaire (Appendix C), and three 
physical activity questionnaires. The health history form was used to assess menopausal 
status and menopausal symptom history. The physical activity questionnaires included: 
International Physical Activity Questionnaire (Appendix D), to assess self-reported time 
spent in moderate and vigorous physical activity; Stanford Brief Activity Questionnaire 
(Appendix E), to assess occupational and leisure time physical activity; Physical Activity 
and Performance Questionnaire (Appendix F), to provide a detailed assessment of a 
participant’s average weekly exercise routine. The physical activity questionnaires were 
used as an initial screening to verify the participant’s physical activity level. Laboratory 
personnel explained the procedures for the day, and any questions participants had were 
answered. Baseline height, weight, and blood pressure were taken. Blood pressure was 
taken according to established guidelines (137), and after the participant had been seated 
and relaxing for several minutes. Blood pressure was taken 2-3 times and averaged. 
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Blood draw. The participant was instructed to sit in a reclining chair. A tourniquet 
was tied around the arm and trained laboratory personnel located the desired vein. Using 
sterile procedures, a needle was inserted into the target vein and ~5 ml of blood was 
extracted. The blood vial was labeled with de-identified participant information and 
brought to University Health Services for verification of inclusion/exclusion criteria for 
lipid levels and fasting plasma glucose.  
DEXA. The participant was escorted to University Health Services Radiology 
Department to undergo a DEXA scan. This scan delivers a dose of radiation equivalent to 
approximately 1/20th that of a chest x-ray and is considered safe (131). Before each scan, 
a quality control check was performed to ensure that the machine could accurately 
identify the density of different tissues. The scan took approximately 5 minutes. The 
participant was asked to lie supine on the machine during the measurement. At the end of 
the scan, the participant was instructed to follow standard exercise testing restrictions, 
which included refraining from drinking caffeine, alcohol or eating for 3 hours and 
vigorous exercise for 24 hours prior to the second visit. The participant was also 
instructed to follow a 3-day low nitrate diet (Appendix G) to familiarize her with the diet 
protocol in preparation for the final visit. This helped to eliminate any nitrates in the diet 
that could affect measures of endothelial function. 
Visit 2 (1.5 hours) 
Flow-mediated Dilation Familiarization. When the participant arrived, she was 
informed of the procedures for the day and was given the opportunity to ask any 
questions. An FMD measurement was completed. This test was used as a familiarization 
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trial, to avoid potential heart rate and blood pressure changes due to the novelty of the 
FMD technique. The testing room was set to a comfortable temperature, with the lights 
dimmed. An automated blood pressure cuff was placed on the dominant arm and 3 
electrodes were placed on the torso to monitor heart rate and blood pressure throughout 
the study. The test began with the participant relaxing on the bed in a supine position for 
~10 minutes, with the non-dominant arm propped up with pillows to be level with the 
heart. A small ball was placed in the hand to maintain finger position and to avoid 
excessive movement that could have impacted results. A small inflatable cuff was placed 
around the widest part of the forearm and laboratory personnel took 3 resting blood 
pressure measurements and used an ultrasound and Doppler probe to image the brachial 
artery. After 2 minutes of baseline measurements, the cuff was inflated to 200 mmHg for 
5 minutes and the technician continued to image the artery and take blood pressures every 
minute. After the 5 minute period, the cuff was deflated, and 4 minutes of measurements 
were recorded. Throughout the study, blood velocity, shear rate, and artery diameter were 
streamed digitally and captured with the FMD Studio Suite software. 
The FMD technique can be influenced by a variety of factors including time of 
measurement, hormonal fluctuations, cuff placement, inflation duration, medication use, 
diet, and exercise. Multiple guidelines have been published to standardize the FMD 
technique (51, 63, 182), with a recent paper summarizing the necessary techniques for an 
FMD study to be of a high enough quality to be included in a systematic review (63). 
Using these guidelines, a study can score between 0-10, with 10 representing the best 
evidence. Our technique scored a 9.6 and we adhered to FMD measurement guidelines in 
the following ways: 
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1) Participants completed FMD studies in the morning.  
2) Menstruating women (i.e. premenopausal and early perimenopausal) completed visit 3 
during menstrual cycle days 1-6.  
3) Participants refrained from eating for 6 hours, exercise, caffeine, smoking, and alcohol 
for 12 hours, and any vitamins/supplements for 72 hours prior to the third visit.  
4) During each FMD study, imaging was completed on the non-dominant arm, with cuff 
placement distal to the imaging probe.  
5) The forearm cuff was inflated to 200 mmHg during the five-minute occlusion period. 
6) Continuous measurements of artery diameter and shear rate were taken throughout the 
study and using an insonation angle of 60°. 
7) Each study was competed in a quiet, temperature-controlled room and did not begin 
until the participant had been resting supine for at least 10 minutes. 
VO2 max. This test was utilized to determine maximal oxygen uptake, maximal 
heart rate, and if any electrocardiogram (ECG) or blood pressure abnormalities existed 
that would exclude the participant from the study. Maximal oxygen uptake and heart rate 
data were used to prescribe intensity during the acute exercise bout on visit 3. Prior to the 
visit, participants were stratified as low or moderate risk based on American College of 
Sports Medicine (ACSM) guidelines (Appendix H). A physician (Dr. Gregory Little) 
supervised exercise tests for moderate risk participants, while trained laboratory 
personnel supervised tests for low risk participants. 
The testing protocol was explained to the participant and electrodes were placed 
on the chest in a modified 12-lead electrocardiogram (ECG) position (Appendix I). 
Resting blood pressure and heart rate/rhythm were recorded with the participant in a 
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supine, seated, and standing position. The Borg scale for rating of perceived exertion 
(RPE) was explained, as well as hand signals for communication during the test. The 
participant was fitted with a facemask and given several minutes to become accustomed 
to it, while being familiarized with the use of the treadmill. After this time, the testing 
protocol began. The participant began by self-selecting a brisk walking or comfortable 
jogging pace. The treadmill grade was increased by 2% every 2 minutes, and speed was 
increased as needed, until VO2max was achieved, the participant indicated she did not 
want to continue, or an absolute or relative termination criterion occurred that 
necessitated an early termination of the test (Appendix J). Throughout the test, RPE and 
blood pressure were recorded every 2 minutes and heart rate was recorded every minute.  
At the end of the test, the facemask was removed and the participant continued to 
walk on the treadmill at a comfortable speed for 2-4 minutes before sitting down. 
Measurements of heart rate and blood pressure continued every 2 minutes until heart rate 
and/or rhythm and blood pressure began to return to pre-test conditions, and for a 
minimum of 6 minutes. At this time, electrodes were removed. The participant was given 
a second low nitrate diet log and was instructed to refrain from eating for 6 hours, 
exercise, smoking, caffeine, and alcohol for 12 hours, and any vitamins/supplements for 
72 hours before the final visit. If participants did not achieve a true VO2max, according to 
standard criteria (Appendix J), VO2peak values were recorded. VO2peak was defined as the 
highest VO2 value achieved during the exercise test. For all analyses, VO2max and VO2peak 
were treated as the same variable. 
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Visit 3 (3.5 hours) 
The visit began with a blood draw and two baseline flow-mediated dilation 
studies (see visits 1 and 2 for protocol). Flow-mediated dilation and blood draws were 
also completed after acute exercise.  
Acute Exercise Bout. The participant was asked to complete 30 minutes of 
exercise on the treadmill at the heart rate that was achieved during the VO2max test 
corresponding to 60-64% of peak oxygen uptake. The participant began and ended the 
exercise session with a 5 minute warm up and cool down. Laboratory personnel used a 
heart rate monitor to verify that the participant maintained the desired intensity 
throughout the exercise session. Thirty minutes after the end of the cool down, a blood 
draw and two more flow-mediated dilation tests were performed.  
Data Analysis: 
Blood Analyses. Blood samples were centrifuged to separate serum or plasma, 
and then frozen at -80°C until analysis. Serum was analyzed for estradiol and follicle 
stimulating hormone (FSH) using 96-well colorimetric ELISA assays. All samples were 
run in duplicate. Plasma was analyzed for CD31+/42b- and CD62E+ endothelial 
microparticles using fluorescent activated cell sorting. Briefly, samples were collected in 
acid citrate dextrose tubes and spun to obtain platelet free plasma, and later, cell-free 
plasma. Cell free plasma was incubated with antibodies for CD62E (BV421), CD31 
(APC), and CD42b (PE). CountBright beads (Life Technologies) were added prior to 
analysis, to allow for calculations of EMPs/µl plasma. Samples were fixed with 2% 
paraformaldehyde and analyzed using fluorescent activated cell sorting within 24 hours. 
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Data was analyzed using FACS DIVA software, with 900 nm calibration beads used to 
set the forward and side-scatter parameters.  
Flow-mediated Dilation Analysis 
Brachial artery diameter was analyzed using the FMD Studio software. Brachial 
artery data was digitized during data collection and streamed to the software from the 
Philip’s HDXE11 Ultrasound System during the flow-mediated dilation studies. To 
determine the most accurate FMD values for each study, videos were re-analyzed until a 
region of interest was selected that allowed for a clear analysis of baseline and peak 
diameter. When this was not possible, separate analyses were completed with a video that 
optimized the region of interest for baseline diameter and a separate video for peak 
diameter. These analyses were reviewed and edited until two independent analyses 
determine the same artery diameter at each time point within 0.02 mm. In this case, the 
average of the two values was used. Percent change in brachial artery diameter was 
calculated for all studies.  
Kuopio Ischaemic Heart Disease Risk Factor Study (Aim 3) 
The Kuopio Ischaemic Heart Disease Study is a prospective cohort study 
including midlife and older men and postmenopausal women in Finland. This analysis 
only included postmenopausal women who completed a baseline visit and did not report 
hormone therapy use (n=588). Participants were classified as postmenopausal if they had 
experienced at least one year of amenorrhea. Women were recruited into four distinct age 
groups: 53-56 years old, 59-62 years old, 64-68 years old and 71-73 years old. All 
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participants underwent a comprehensive screening for biological variables including, but 
not limited to, blood pressure, lipid levels, menstrual status, and diabetes status.  
Statistical Analyses: 
All data are presented were analyzed using SPSS software with a significance 
level of alpha = 0.05. Data were evaluated for the adherence to assumptions for each 
statistical test proposed. Shapiro Wilk tests were used to assess normality and Levene’s 
tests were used to assess equal variance. When necessary, data was transformed to meet 
the assumptions of the statistical tests. Differences between group baseline characteristics 
were analyzed with an ANOVA, chi-squared or independent t-tests. The specific aims 
were evaluated using the following approach:  
 
Aim 1a: To determine whether there are differences in endothelial health, assessed via 
flow-mediated dilation and CD31+/42b- and CD62E+ endothelial microparticles, in 
women in progressive menopausal stages. 
Aim 1b: To determine whether cardiorespiratory fitness affects differences in endothelial 
health in women in progressive menopausal stages. 
 
Aim 2a: To determine whether there are differences in endothelial responses, assessed 
via flow-mediated dilation and CD31+/42b- and CD62E+ endothelial microparticles, to 
acute exercise in women in progressive menopausal stages. 
Aim 2b: To determine whether cardiorespiratory fitness affects differences in endothelial 
responses to acute exercise in women in progressive menopausal stages. 
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Differences in FMD and EMPs were assessed using repeated measure ANOVAs. 
Differences by menopausal status were evaluated in high-fit women (exercise x 
menopausal status). Differences by menopausal status and fitness were also evaluated in 
perimenopausal and postmenopausal women combined (menopausal status x fitness x 
exercise). To evaluate differences at each time point between groups, one-way ANOVAs, 
independent t-tests, or an equivalent non-parametric test were used. To evaluate 
differences between time points within each group, paired t-tests or an equivalent non-
parametric test were used.  
 
Aim 3: To evaluate the relationship between FSH and lipid levels in women in  
a large cohort of postmenopausal women. 
 
The relationship between FSH and lipid levels was evaluated in postmenopausal 
women participating in the Kuopio Ischaemic Heart Disease Risk Factor Study. 
Participants were stratified into quartiles based on baseline FSH levels and any 
differences in baseline characteristics between groups were assessed using an ANOVA or 
chi-squared tests. Linear regression was used to evaluate the relationship between FSH 
and lipid levels. Covariates included years since final menstrual period, length of 
estrogen exposure (e.g. age at menarche, oral contraceptive use, hormone therapy use, 
parity, hysterectomy, oophorectomy), estradiol, testosterone, sex hormone binding 
globulin, physical activity and cardiovascular disease risk factors, such as smoking 
history, blood pressure, body mass index (BMI) and waist-to-hip-ratio (WHR). All 
variables were checked for normality and transformed, if necessary. Model 1 evaluated 
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the relationship between lipid levels and FSH after adjusting for age, date of examination, 
and hormonal factors. Model 2 adjusted for cardiovascular disease risk factors. Model 3 
adjusted for use of lipid lowering medications. Models were assessed to determine which 
variables were most related to lipid levels and FSH to form the final model. Logistic 
regression was used to evaluate odds ratios in women who had signs of dyslipidemia (i.e. 
medication use or values indicative of dyslipidemia) compared to those who did not, 
using the linear regression models to inform which covariates to include. Groups were 
also stratified by age and BMI to evaluate if any effect modification was present.  
Summary 
Data from these studies have the potential to enhance knowledge about factors 
that may influence CVD risk with menopause. Findings will allow for a characterization 
of the magnitude and timing of changes in endothelial health that may accompany 
menopause. These results will also identify whether cardiorespiratory fitness remains 
beneficial for endothelial health during and after the menopausal transition. Finally, the 
characterization of the relationship between FSH and lipid levels will help to enhance our 
understanding of the influence of FSH on CVD risk in postmenopausal women. Together 
with future research, these outcomes may allow for more targeted interventions to reduce 
the increase in CVD risk factors with menopause.  
 
 
 
 
  57 
Tables 
Table 3.1. Study Overview 
*FMD: flow mediated dilation (vessel function study); DEXA: dual energy x-ray 
absorptiometry (body composition study); QOL: quality of life 
 
 
 
 
 
 
 
Visit Number Tasks 
Before Visit 1 • Pre-screening interview 
• Refrain from eating and drinking, except water for 12 hours 
• Wear loose fitting, nonmetallic clothing 
• If desired, fill out questionnaires and read informed consent 
Visit 1 • Review:  
o Informed consent 
o Health History 
o Physical Activity Questionnaires 
o Quality of Life Questionnaire 
• Measure height, weight, blood pressure 
• Complete blood draw (lipids and glucose) 
• Complete DEXA scan 
 
Before Visit 2 • Follow low nitrate diet for 3 days 
• Refrain from eating, drinking, and smoking 3 hours before, and 
vigorous exercise 24 hours before visit 2 
 
Visit 2 • Familiarization FMD* 
• VO2 max test  
 
Before Visit 3 • Follow low nitrate diet for 3 days 
• Early perimenopausal and premenopausal women arrive for 
visit 3 between cycles days 1-6 
• Refrain from eating for 6 hours prior to the visit 
• Refrain from exercise, smoking, caffeine, alcohol for 12 hours 
before the visit 
• Refrain from taking vitamins/supplements for 72 hours before 
the visit 
Visit 3 • Baseline FMD and blood draw  
• Exercise session 
• Post-exercise FMD and blood draw 
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Visit Possible exclusion 
Before visit 1 Age; does not fit criteria for menopausal groups; history of 
cardiovascular disease, diabetes or other exclusion criteria listed on pre-
screening form; unable to exercise; participating in another research 
study that may confound results 
Visit 1 Blood pressure; physical activity questionnaire suggests participant does 
not meet physical activity criteria; answers on health history that affect 
inclusion/exclusion criteria; pregnancy 
Before Visit 2 Elevated plasma glucose levels or abnormal lipid profile  
Visit 2 Absolute or relative contraindication during or before graded exercise 
test; VO2peak below the 80th percentile for high-fit women 
 
Table 3.2. Possible Exclusion Time Points. 
 
Figures 
 
Figure 3.1. Endothelial Function in Women in Progressive Menopausal Stages.  
Data from a cross-sectional analysis showed that the smallest difference in FMD between 
groups in progressive menopausal stages is between early and late postmenopause 
(Moreau et al., 2012). 
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CHAPTER 4 
 CARDIORESPIRATORY FITNESS MAY NOT ATTENUATE THE DECLINE 
IN ENDOTHELIAL FUNCTION WITH MENOPAUSE 
Introduction: 
Cardiovascular disease (CVD) is the leading cause of death in women in 
developed countries and accounts for approximately 400,000 deaths per year in women in 
the United States (58). Menopause, or the cessation of ovarian function, represents a time 
during which risk factors for cardiovascular disease (CVD) increase dramatically. The 
increase in CVD risk has been attributed to the reduction in estrogen and increase in 
follicle stimulating hormone (FSH) that accompany menopause (44). These changes 
begin during the menopausal transition and continue into postmenopause (108, 109).  
Endothelial dysfunction is a preclinical marker for CVD (3) and has been shown 
to be prognostic of cardiovascular events in postmenopausal women (147). Despite this, 
few studies have evaluated changes in endothelial function with menopause. Several 
studies have demonstrated reduced endothelial function in postmenopausal compared to 
premenopausal women (70, 71, 151); however, there is limited evidence on women 
undergoing the menopausal transition. Given that the years surrounding menopause are a 
time of dramatic physiological changes, midlife is a key time to evaluate CVD risk.  
 Evaluating endothelial responses to acute exercise may reveal differences in 
endothelial function in populations with differing CVD risk that are not otherwise 
apparent. We have previously shown lower endothelial function in post- compared to 
peri-menopausal women that was not detectable until after acute exercise (158).  This 
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divergent response has also been shown in sedentary vs. active men, with lower function 
in the sedentary men that was only detectable after an acute bout of exercise (68). 
 High cardiorespiratory fitness (CRF) is generally considered protective of 
endothelial function and higher levels of endothelial dysfunction have been shown in 
sedentary compared to active men (139). However, the benefits of cardiorespiratory 
fitness on endothelial function in transitioning and postmenopausal women have yet to be 
established. Two cross-sectional analyses showed no differences in endothelial function 
in trained vs. sedentary postmenopausal women (139, 151), suggesting that the benefits 
of fitness on endothelial function may not remain after menopause. Whether this lack of 
benefit occurs in perimenopausal women is unknown.  
Overall, there are limited data evaluating differences in endothelial function in 
women at different menopausal stages. Further, the effect of CRF on endothelial function 
in this population is also unclear. Therefore, the aim of this study was to evaluate 
differences in endothelial function in high- and low-fit perimenopausal and 
postmenopausal women before and after an acute bout of exercise. 
Methods: 
Healthy high-fit premenopausal (n=11), perimenopausal (n=12), and 
postmenopausal women (n=13) and low-fit perimenopausal (n=7) and postmenopausal 
women (n=8) were recruited for this study. FMD data on low-fit women has been 
previously published (158). All participants were between 40 and 65 years old and were 
non-smokers. Participants were excluded according to resting blood pressure (>140/>90 
mmHg), fasting plasma lipids (LDL-C >160 mg/dl, HDL-C <40 mg/dl, TG> 150 mg/dl), 
and fasting plasma glucose (>126 mg/dl). Participants were also excluded if they reported 
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a history of cardiovascular diseases, long-term menstrual irregularities, breast cancer with 
radiation or chemotherapy treatment, vaginal bleeding, abnormal uterine/ovary anatomy 
that negatively impacted fertility, if they used medications and/or supplements that are 
known to influence endothelial function, or if they had any exercise limitations.  
 Menopausal status was defined using STRAW+10 (67) criteria based on self-
reported menstrual cycle. Premenopausal women were experiencing regular menstrual 
cycles, perimenopausal women were experiencing irregular cycles or 2-11 months of 
amenorrhea, and postmenopausal women had experienced at least 5 years of amenorrhea. 
All participants were between 40 and 65 years old, non-smokers and had not taken 
hormone therapy within the 6 months prior to study enrollment. Postmenopausal women 
had to undergo natural menopause to qualify for the study. Follicle stimulating hormone 
(FSH, http://www.abcam.com/human-follicle-stimulating-hormone-elisa-kit-
ab108641.html) and estrogen (17-beta–estradiol, 
https://www.thermofisher.com/order/catalog/product/KAQ0621) levels were assessed in 
all participants as a complement to menstrual cycle criteria. Estradiol and FSH were not 
evaluated in 2 low-fit perimenopausal women, as blood samples were not taken in those 
participants. 
Participants were initially stratified by CRF based on self-reported physical 
activity levels assessed via the International Physical Activity Questionnaire (IPAQ). 
Low-fit women were not meeting physical activity guidelines (150 minutes/week of 
moderate intensity activity, 75 minutes/week of vigorous intensity activity, or an 
equivalent combination of the two, accumulated in 10 minute bouts). High-fit women 
were, on average, at least doubling guidelines and had been doing so for 2 years prior to 
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study enrollment. High-fit participants had to achieve a VO2peak of at least the 80th 
percentile for their age, based on American College of Sports Medicine guidelines (183) 
to qualify for the study. After initial screenings, each participant completed three study 
visits. The University of Massachusetts Amherst Institutional Review Board approved all 
study protocols and participants signed an informed consent document before beginning 
any study visits.  
Study Overview 
On the first visit, participants underwent a dual energy x-ray absorptiometry scan 
(DEXA) to assess body composition, anthropometric measurements, a blood pressure 
screening, and measurements of fasting plasma glucose and cholesterol. During the 
second visit, participants underwent an FMD familiarization trial and a ramped treadmill 
VO2max test (Parvo Medics TrueOne 2400, Sandy, UT) with 12 lead electrocardiogram. 
Heart rate and VO2 data from the test was used to prescribe exercise intensity on the third 
visit.   
On the third visit, participants underwent 2 initial FMD trials. Following the 
trials, they were fitted with a chest-worn heart rate monitor (Polar FT1, Polar Electro, 
Lake Success, NY) and then exercised on a treadmill for 30 min at the heart rate 
corresponding to 60-64% VO2peak. Throughout the exercise session, heart rate, blood 
pressure and rate of perceived exertion were assessed every 2 min. Workload was 
adjusted as necessary to maintain the desired heart rate. Each session began and ended 
with a 5 min warm-up and cool-down.  
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Flow-mediated Dilation 
Brachial artery flow-mediated dilation (FMD) was measured following 
established guidelines (182), and as previously published (158).  Briefly, participants 
were instructed to arrive for the third visit having followed a three-day low nitrate diet 
and having refrained from taking any vitamins/supplements for 72 hours, from 
consuming any alcohol or caffeine or completing any exercise for 12 hours, and from 
consuming any foods or beverages, with the exception of water, for 6 hours prior to the 
visit. Menstruating women (i.e. early perimenopausal and premenopausal women) were 
measured between menstrual cycle days one and six.  
All FMD measurements took place in a quiet temperature-controlled room and 
began in the morning. The study began following a 10 min supine rest. Measurements 
were taken on the non-dominant arm with an ultrasound and Doppler probe (Philip’s 
HD11XE Ultrasound System, Bothell, WA) placed proximal to an inflatable cuff on the 
participant’s forearm (D. E. Hokanson, Bellevue, WA) and with an insonation angle of 
60°. Blood pressure was taken on the non-dominant arm every minute using an automatic 
cuff and heart rate was recorded throughout the study with a 3-lead electrocardiogram 
(GE Dash 2000, Friedurg, Germany). Throughout the study, brachial artery diameter was 
continuously tracked during 2 min baseline, 5 min forearm cuff occlusion (200 mmHg) 
and 4 min following cuff release.   
Data Analysis: 
All statistical analyses were completed in SPSS v24.  Significance was set at an 
alpha level of 0.05. All data was evaluated for adherence to the assumptions of each 
statistical test. Some variables were not normally distributed due to a few extreme data 
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points (e.g. a constrictor response to FMD). Analyses were performed with and without 
the extreme values included. Given that the outcomes were the same, analyses performed 
in all participants are reported. Differences in baseline characteristics were assessed using 
one-way ANOVAs, t-tests, or an equivalent non-parametric test.  Differences were 
evaluated in high- and low-fit women within the perimenopausal and postmenopausal 
groups and in high-fit premenopausal, perimenopausal, and postmenopausal women.   
All FMD trials were analyzed using Cardiovascular Suite Software (FMD Studio, 
Quipu, Pisa, Italy). Each trial was evaluated to determine the average baseline and peak 
diameter achieved during the study. FMD was calculated as (Diameterpeak-
Diameterbaseline)/ Diameterbaseline) * 100. To capture full vasodilatory capacity (i.e. max-
FMD), studies were also evaluated for the minimum artery diameter following cuff 
release. Max-FMD was calculated as (Diameterpeak-Diameterminimum)/ Diameterbaseline) * 
100. Differences in FMD parameters were evaluated using repeated measure ANOVAs 
and post-hoc testing. Given that there was only a high-fit premenopausal group, the 
overall effect of fitness was assessed in perimenopausal and postmenopausal women 
only. To evaluate the influence of menopausal status, data was also assessed in the high-
fit groups. FMD data was not obtained in one premenopausal participant due to 
equipment failure. In order to perform repeated-measure ANOVAs, max-FMD was 
natural log transformed. Non-transformed data are presented for ease of interpretation. 
Pearson correlations were evaluated in all participants to assess if age, FSH, or estradiol 
were related to FMD or max-FMD. Data are presented as mean ± SEM.  
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Results 
Participant characteristics: 
Participants were healthy, had few risk factors for cardiovascular disease, and had 
similar baseline characteristics across menopausal stage and fitness categories (Table 
4.1).  Within perimenopausal women, the only differences between groups were lower 
body fat percentage and body mass index (BMI) and higher time spent in moderate-to-
vigorous physical activity (MVPA) and VO2peak in high-fit women. Within 
postmenopausal women, the only differences were higher MVPA, VO2peak, and HDL-C 
and lower body weight and body fat percentage in high-fit women. Within high-fit 
women, there was a significant difference in age across all groups, though the overall age 
range was only 16 years. All other risk factors were similar across high fit-
premenopausal, perimenopausal, and postmenopausal women, with the exception of 
lower FSH in premenopausal women, higher HDL-C in perimenopausal compared to 
premenopausal women, and lower estradiol in postmenopausal compared to 
premenopausal women.   
Flow-mediated dilation 
There was a main effect of menopausal status on FMD within high-fit women 
(p=0.005) and within perimenopausal and postmenopausal women combined (p=0.047). 
Within high-fit women, FMD was lower in the postmenopausal compared to the 
premenopausal group (p=0.004, Figure 4.1A). Within perimenopausal and 
postmenopausal women, FMD was lower in postmenopausal women (p= 0.047, Figure 
4.1B). There was a main effect of fitness (p=0.006); within high- and low-fit 
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perimenopausal and postmenopausal women; FMD was lower in the high-fit women 
(high: 5.0±0.4%, low: 6.9±0.5%, Figure 4.2). In perimenopausal women, there was no 
difference in FMD before exercise (high: 6.1±1.3%, low: 6.4±0.6%, p=0.773); however, 
in response to acute exercise, the high-fit women had lower FMD compared to the low-fit 
women (high: 5.5±0.6%, low: 8.5±1.1%, p=0.021). Conversely, in postmenopausal 
women, there was a difference in FMD before (high: 4.2±0.7%, low: 6.5±0.5%, 
p=0.043), but not after acute exercise (high: 4.2±0.5 %, low: 6.2±1.0% p=0.08; Figure 
4.3).  There was no difference in baseline artery diameter within or between groups at 
any time point (Table 4.2).   
In all participants combined, pre- and post-exercise FMD was negatively related 
to age (pre-exercise: r=-0.421, p=0.003; post-exercise: age: r=-0.455, p=0.001) and FSH 
(pre-exercise: r=-0.308, p=0.038; post-exercise, r=-0.372, p=0.009 Figure 4.4A), but not 
estradiol (pre-exercise: r=0.093, p=0.40; post-exercise: r=0.205, p=0.16, Figure 4.4B)  
Max-FMD 
There was no effect of menopausal status on max-FMD in high-fit women 
(p=0.285). However, there was an effect of menopausal status in perimenopausal and 
postmenopausal women combined (p=0.009, Fig 4.5), with lower max-FMD in 
perimenopausal vs. postmenopausal women (perimenopause: 6.9±0.7%, postmenopause: 
9.8±0.7%) and no effect of fitness (p=0.422) or exercise (p=0.553). Within low-fit 
women, there was a main effect of menopausal status (p=0.005), with lower max-FMD in 
postmenopausal compared to perimenopausal women, both before (perimenopause: 
9.8±1.0%, postmenopause: 6.6±0.9%, p=0.029) and after exercise (perimenopause: 
12.7±3.9%, postmenopause: 6.4±0.7%, p=0.029, Figure 4.6). 
  67 
Similar to FMD, in all participants combined, max-FMD was negatively related to 
age (pre-exercise: r=-0.292, p=0.04; post-exercise: r=-0.342, p=0.016). Max-FMD was 
related to FSH before, but not after exercise (pre-exercise: r=-0.315, p=0.029; post-
exercise: r=-0.130, p=0.384). There was no relationship between max-FMD and estradiol 
(pre-exercise: r=0.157, p=0.287; post-exercise: r=0.039, p=0.794).  
Discussion 
 The aim of this study was to evaluate differences in endothelial function in 
women at different menopausal stages and with differing levels of cardiorespiratory 
fitness (CRF). The primary findings were: 1) FMD was lower in postmenopausal 
compared with premenopausal women, 2) CRF did not have a beneficial effect on FMD 
in healthy perimenopausal or postmenopausal women, 3) CRF affected the FMD 
response to acute exercise in perimenopausal women, 4) follicle stimulating hormone 
(FSH) was negatively associated with FMD, 5) max-FMD was not influenced by 
menopausal status, but may have been influenced by cardiorespiratory fitness.  
 There is clear evidence to suggest that endothelial function declines in the 
postmenopausal years. Multiple cross-sectional analyses have shown reduced FMD in 
postmenopausal compared to premenopausal women (70, 71, 151). However, few studies 
have evaluated changes in endothelial function that may occur during the perimenopausal 
years- when important physiological changes are occurring. In a cross-sectional analysis 
of healthy, low-fit women at different menopausal stages, there was a stepwise reduction 
in FMD with progressive menopausal stage (123). Our data support and extend these 
findings. We show that in highly fit healthy women, endothelial function is lower in the 
postmenopausal years. We further demonstrate lower function in healthy postmenopausal 
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compared to perimenopausal women. Together, these data suggest that there is a decline 
in endothelial function with menopause that is not mitigated by high levels of 
cardiorespiratory fitness.     
Endurance exercise training is considered a potent stimulus to improve 
endothelial function in most populations; however, the response to exercise training in 
postmenopausal women is controversial (204). Some studies have reported improvements 
in FMD with training (13, 176), while others have shown no benefit of training (89, 139). 
These conflicting results may be due to differences in menopausal classification, study 
populations, and FMD protocols across studies. When solely evaluating the effect of CRF 
on FMD, there is increasing evidence to suggest that it may not have an effect on FMD in 
a postmenopausal population. When comparing postmenopausal sedentary women to 
postmenopausal active women, there was no difference in FMD between the two (151).  
This lack of benefit was also shown in a separate study in which older active men had 
enhanced FMD compared to age-matched sedentary men, but there was no difference 
between active and sedentary age-matched postmenopausal women (139). Although the 
resistance to the benefits of fitness on endothelial function have been shown in 
postmenopausal women, whether this benefit remains in perimenopausal women had not 
been investigated to this point.   
Our data suggest that there is no protective effect of fitness on endothelial 
function in perimenopausal or in postmenopausal women. This may indicate that the 
effects of a changing hormonal environment outweigh the effects of exercise. In support 
of this, Moreau et al. reported that postmenopausal women did not improve FMD with 
exercise training unless they were supplemented with estradiol (124). Interestingly, we 
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found no relationship between FMD and estradiol, but a significant negative relationship 
between FSH and FMD. During perimenopause, prior to the final menstrual period, FSH 
levels rise and then remain elevated in postmenopause (67). Increasing evidence suggests 
that FSH may have an effect on CVD risk that is independent of the effects of changing 
estrogen levels (11, 198). The relationship between FSH and endothelial function is 
unclear; however, Moore et al., reported a negative relationship between vascular 
conductance and FSH in women at different menopausal stages (120). Further, a negative 
relationship between FSH and FMD was also reported in women in progressive 
menopausal stages (123) and together with our data, suggests that FSH may influence 
endothelial function in aging women.   
 The endothelial response to acute exercise may provide further insight into 
differences in endothelial function that are not otherwise apparent. We have previously 
reported no difference in FMD in low-fit perimenopausal vs. postmenopausal women 
before exercise; however, perimenopausal women showed a trend for higher FMD after 
acute exercise (158). In the current analysis, we also found a divergent response to acute 
exercise in perimenopausal women, such that low-fit perimenopausal women had higher 
FMD than high-fit women following exercise. This divergent response may be driven by 
habituation to the exercise stimulus in the high-fit women. This hypothesis is supported 
by the lack of response to acute exercise in the high-fit premenopausal, perimenopausal, 
and postmenopausal groups. Interestingly, neither postmenopausal group responded to 
acute exercise. This may suggest that the lack of an effect of long-term exercise training 
in postmenopausal women may be due to the lack of an acute response to exercise.  
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Brachial artery FMD is a well-validated technique and is considered a gold 
standard for assessing nitric-oxide mediated vasodilatory capacity. FMD is traditionally 
measured by assessing the difference in baseline artery diameter compared to the peak 
vasodilatory diameter. However, there is increasing recognition that constriction may 
occur during the cuff occlusion period of an FMD trial (i.e., low-flow mediated 
constriction)(60, 69, 199). If artery diameter is lower than baseline following cuff release, 
this may lead to an underestimation of vasodilatory capacity, and therefore, endothelial 
function. Since we observed trials with diameters less than baseline following cuff 
release, we calculated the change in artery diameter from the minimum value achieved 
following cuff release to peak vasodilation (max-FMD). This analysis eliminated all 
differences by menopausal status that we observed in high-fit women when analyzing 
FMD in the traditional manner. However, in low-fit women an effect of menopausal 
status remained. Therefore, contrary to the results of the traditional FMD analysis, these 
data indicate that fitness is protective of the decline in endothelial function in 
postmenopause.  
When assessing max-FMD, values across all groups were significantly enhanced 
compared to the traditional FMD calculations. Most notably, the average FMD in high-fit 
postmenopausal women was approximately 4.2%, which would indicate significant 
endothelial dysfunction. Our participants had a low cardiovascular disease risk profile 
and the FMD values we report are in line with what others have reported in high-fit 
postmenopausal women (151). Therefore, max-FMD may better represent endothelial 
function in this population. Taken together, the differing interpretation based on our FMD 
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data vs. max-FMD data suggest that further evaluation should be made regarding the 
contribution of total vessel dilatory capacity in FMD studies. 
Limitations 
While this study provides novel insight into changes in endothelial function with 
menopause and the role of cardiorespiratory fitness, it has several important limitations. 
Participants in this study were selected to have few risk factors for cardiovascular 
disease, to allow us to better evaluate the independent effects of menopause and 
cardiorespiratory fitness on FMD. While this may be considered a strength of the study, it 
is possible that women in both fitness categories were too healthy to see a significant 
difference in FMD between groups. Sample sizes in this study were small, particularly in 
the low-fit groups, therefore we may be underpowered for some analyses.  Finally, given 
that this study was cross-sectional and designed to characterize differences in endothelial 
function across groups, we are unable to determine causation or evaluate what factors 
may be contributing to the observed responses. For examples, we may not have found a 
benefit of fitness due to remodeling of the vasculature that has occurred in high-fit 
women, leading to a larger lumen:wall ratio with no change in FMD or that high-fit 
women are relying on other vasodilatory factors; these warrant further investigation. 
Given that menopause and aging are intimately connected, it is possible that some of the 
differences that we observed between groups were due to differences in age; however, the 
range of ages across groups was as narrow as possible. Further, we separated participants 
into quartiles based on age and found that there was no effect of age when evaluating 
FMD in perimenopausal and postmenopausal women. There was an effect of age when 
evaluating high-fit women, with a significant difference in the youngest compared to the 
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oldest women (p=0.018).  There was no difference in age within each menopausal stage 
by fitness, therefore we do not believe that age influenced these results.    
Conclusion  
Data from this study suggests that postmenopause is associated with a reduction 
in endothelial function and that fitness is not protective of endothelial function in 
perimenopausal or in postmenopausal women. This reduction may be associated with the 
increase in FSH that accompanies menopause. This may suggest that factors other than 
cardiorespiratory fitness may be important targets for improving CVD in aging women.  
It also highlights the need for further research to better understand changes in endothelial 
function and the role of cardiorespiratory fitness in perimenopausal and postmenopausal 
women.  
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Tables 
 
Table 4.1. Participant Characteristics. 
FSH: follicle stimulating hormone, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density 
lipoprotein cholesterol, TG: triglycerides, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP: diastolic blood pressure; 
MVPA: moderate-to-vigorous physical activity *different than low-fit group; # different than high-fit premenopausal group; $ 
different than high-fit perimenopausal group, ^Serviente et al., 2016, data are presented as mean±SEM 
 
Premenopause Perimenopause Postmenopause
High-fit (n=11) Low-fit (n=7)^ High-fit (n=12) Low-fit (n=8)^ High-fit (n=13)
Age (yrs) 44.5 ± 1.0 47.3 ± 1.5 50.8 ± 1.0# 58.9 ± 1.4 60.5 ± 1.0#$
Height (cm) 163.5 ± 1.2 163.7 ± 3.1 165.4 ± 2.0 166.5 ± 3.1 161.6 ± 2.3
Weight (kg) 61.8 ± 2.2 72.9 ± 7.2 62.5 ± 3.0 69.0 ± 4.3 58.2 ± 2.5*
Estradiol (pg/ml) 58.7 ± 10.7 117.3 ± 27.1 75.2 ± 32.7 16.5 ± 9.0 6.7 ± 4.2#
FSH (mIU/mL) 8.5 ± 2.2 49.9 ± 14.0 66.6 ± 17.9# 104.2 ± 8.1 102.6 ± 9.5#
Body Fat (%) 29.6 ± 2.5 40.8 ± 2.6 26.9 ± 2.1* 41.9 ± 1.5 28.0 ± 2.1*
BMI (kg/m2) 23.1 ± 0.7 27.0 ± 2.3 22.7 ± 0.7* 24.8 ± 1.3 22.2 ± 0.7
HDL-C (mg/dL) 71.2 ± 4.9 70.4 ± 9.7 82.0 ± 4.8 78.4 ± 4.8 94.7 ± 2.8*#
LDL-C (mg/dL) 101.9 ± 7.0 84.7 ± 8.4 98.8 ± 6.1 116.5 ± 9.5 117.1 ± 7.2
TG (mg/dL) 50.1 ± 5.8 52.0 ± 6.9 40.6 ± 7.1 46.4 ± 5.7 42.8 ± 3.6
FPG (mg/dL) 94.5 ± 2.0 92.4 ± 3.0 93.9 ± 1.8 99.5 ± 1.7 96.5 ± 1.9
SBP (mmHg) 102.7 ± 2.4 104.6 ± 5.6 106.0 ± 2.8 117.3 ± 5.2 106.3 ± 3.7
DBP (mmHg) 58.9 ± 1.5 64.6 ± 4.5 59.2 ± 1.8 64.6 ± 2.7 61.9 ± 2.3
MVPA (MET-min/wk) 3446.6 ± 429.5 293.1± 98.0 3695.9 ± 528.5* 100.3 ± 40.9 4107.1 ± 684.1*
VO2 peak (ml/kg/min) 47.0 ± 2.4 30.1 ± 1.6 49.1 ± 2.4* 28.3 ±1.1 43.8 ± 1.8*
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Table 4.2. Baseline Artery Diameter.  
Baseline artery diameter did not differ between groups, before or after exercise. data are presented as mean±SEM 
 
Premenopause Perimenopause Postmenopause
High-fit (n=11) Low-fit (n=7) High-fit (n=12) Low-fit (n=8) High-fit (n=13)
Average pre-
exercise 
diameter (mm)
3.4 ± 0.1 3.2± 0.1 3.3 ± 0.1 3.3 ± 0.1 3.4 ± 0.1
Average post-
exercise 
diameter (mm)
3.4 ± 0.1 3.2 ± 0.1 3.3 ± 0.1 3.3 ± 0.1 3.4 ± 0.1
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Figure 4.1. The Influence of Menopausal Status on FMD.  
There was a main effect of menopausal status on FMD in high-fit women, with lower values in postmenopausal compared to 
premenopausal women (A). In perimenopausal and postmenopausal women, there was lower FMD in postmenopausal women (B). 
*compared to premenopausal group, data are presented as mean±SEM 
 
 
0%
1%
2%
3%
4%
5%
6%
7%
8%
Perimenopause Postmenopause
FM
D
Pre-exercise Post-exercise
Main effect of status, p=0.0471B
B 
76 
 
  
 
 
Figure 4.2. The Influence of Fitness on FMD.  
There was a main effect of fitness on FMD, with lower values in high-fit compared to low-fit women, 
 data are presented as mean±SEM 
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Figure 4.3. The Influence of Aerobic Fitness and Menopausal Status on FMD.  
Overall, FMD was lower in postmenopausal compared to perimenopausal women and in high-fit compared to low-fit women. High-fit 
perimenopausal women had lower FMD following acute exercise compared to low-fit perimenopausal women. High-fit 
postmenopausal women had lower FMD compared to low-fit postmenopausal women before acute exercise. *p<0.05, data are 
presented as mean±SEM 
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Figure 4.4. Associations between Sex Hormones and FMD. 
Follicle stimulating hormone (FSH) was negatively related to flow-mediated dilation (FMD) before and after acute exercise (A). 
Estradiol was not related to FMD before or after acute exercise (B). 
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Figure 4.5. The Influence of Menopausal Status on Pre-dilation-FMD.  
There was a main effect of menopausal status on max-FMD in perimenopausal and postmenopausal participants, with lower function 
in postmenopausal women, data are presented as mean±SEM 
Main effect of status, p=0.009
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Figure 4.6. The Influence of Aerobic Fitness and Menopausal Status on Max-FMD.  
While there was a main effect of menopausal status on max-FMD, there was no difference in max-FMD by menopausal status within 
high-fit women. Within low-fit women there was lower max-FMD before and after acute exercise in postmenopausal compared to 
perimenopausal women. *p<0.05, data are presented as mean±SEM
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CHAPTER 5 
 MODERATE INTENSITY EXERCISE REDUCES ACTIVATED AND 
APOPTOTIC ENDOTHELIAL MICROPARTICLES IN HEALTHY MIDLIFE 
WOMEN 
Introduction: 
 Endothelial microparticles (EMPs) serve as biomarkers of endothelial status, a 
key indicator of cardiovascular health. Endothelial microparticles are small vesicles 
(100nm-1µm) that are released from endothelial cells in response to stimuli such as 
inflammation, shear stress, or oxidative stress. High levels of EMPs related to endothelial 
activation (CD62E+ EMPs) and apoptosis (CD31+/42b- EMPs) have been found in 
individuals with disease or heightened disease risk (2, 9, 46, 161, 186). 
Midlife represents a time during which there is accumulating CVD risk in women, 
in part due to menopause. Menopause is a female-specific condition associated with a 
dramatic increase in traditional risk factors for CVD, such as blood pressure, cholesterol 
and fasting plasma glucose (108). These changes are generally attributed to the reduction 
in estrogen that accompanies menopause. There is some evidence to suggest that the 
hormonal and cardiovascular-related changes associated with menopause influence EMP 
levels. In data from the Kronos Early Estrogen Prevention Study (KEEPS), in 
perimenopausal (i.e. transitioning) and early postmenopausal women at low risk for 
CVD, microparticles, including activated EMPs, explained 24% of the increase in carotid 
intima media thickness over 4 years (115). Further, estrogen status appears to directly 
influence EMP levels. For example, postmenopausal women with lower levels of 
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estrogen had higher levels of activated EMPs compared to postmenopausal women with 
higher levels of estrogen (80). Similarly, premenopausal women had higher levels of 
activated EMPs during the luteal compared to the follicular phase of the menstrual cycle 
(185). Together, this evidence suggests that EMP levels may be affected by menopausal 
stage; however, research is limited in this area.  
High cardiorespiratory fitness and regular exercise are generally considered 
protective of cardiovascular health and would therefore be expected to influence EMP 
levels. Following a six-month training intervention there was a reduction in apoptotic 
(CD31+/42-) and activated (CD62E+) EMPs in midlife and older men and women (48). 
Further, in a study directly evaluating the influence of fitness on EMPs, there was no 
difference in activated (CD62E+) EMPs prior to exercise in trained vs. untrained men, but 
only trained men had an increase in EMPs following acute exercise (170). Finally, 
following an acute bout of exercise, low-fit postmenopausal women had higher levels of 
apoptotic (CD31+/42b-) EMPs in circulation compared with perimenopausal women 
(158). These data suggest that fitness and menopause may influence EMP levels and that 
an acute bout of exercise may be required to reveal these differences; however, further 
studies are needed to evaluate these relationships. Therefore, the purpose of this study 
was to investigate differences in CD31+/42b- and CD62E+ EMPs in women at different 
menopausal stages and with high and low levels of cardiorespiratory fitness before and 
after an acute bout of moderate intensity exercise. 
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Methods: 
Protocols were approved by the University of Massachusetts Amherst 
Institutional Review Board and participants provided written informed consent before 
beginning any study protocol. 
Study Overview: 
Participants completed three study visits. Height, weight, and blood pressure were 
measured on the first visit, along with fasting plasma glucose, cholesterol, and body fat 
percentage, via a dual energy x-ray absorptiometry (DEXA) scan. To evaluate 
cardiorespiratory fitness and to prescribe acute exercise intensity, participants completed 
a graded treadmill VO2max test on the second visit. On the third visit, venous blood was 
collected before and 30 minutes after an acute bout of treadmill exercise (30 min, 60-64% 
VO2 peak) to evaluate differences in EMP levels by menopausal status and CRF. 
Participant Characteristics 
Participants were recruited based on menopausal status and cardiorespiratory 
fitness. High-fit premenopausal women were recruited to serve as a reference group 
(n=11). High and low-fit perimenopausal (high: n=12; low: n=5) and postmenopausal 
women (high: n=13; low: n=8) were recruited to evaluate the influence of menopausal 
status and fitness on EMPs. Blood was not collected at pre-exercise for one 
premenopausal participant and at post-exercise for one high-fit perimenopausal 
participant. Data on low-fit participants were previously published (158). EMP analyses 
were performed in all participants for this study for batch analysis.  
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Participants were categorized by menopausal status using STRAW+10 guidelines 
(67). Premenopausal women were experiencing regular menstrual cycles. Perimenopausal 
women were experiencing irregular cycles (i.e., early perimenopausal) or 2-11 months of 
amenorrhea (i.e., late perimenopausal). Postmenopausal women were at least 5 years 
postmenopausal and had undergone natural menopause. High-fit participants achieved a 
VO2peak of at least the 80th percentile for their age (137). Low-fit participants were not 
meeting physical activity guidelines (61) based on self-report (International Physical 
Activity Questionnaire) and had an average VO2peak of approximately the 40th percentile.  
Participants were healthy and had low risk for CVD. Participants were 
normotensive (<120/<80mmHg), non-diabetic (fasting plasma glucose<126mg/dl), had 
normal lipid levels (LDL-C <160 mg/dl, HDL-C >40 mg/dl, TG< 150 mg/dl), and were 
non-smokers. Participants were excluded if they reported long-term menstrual 
irregularities, abnormal uterine or ovary anatomy that affected fertility, acute liver or 
gallbladder disease, breast cancer with radiation or chemotherapy treatment or if they 
were taking medications, vitamins, or supplements known to influence endothelial 
function. Participants were also excluded if they reported hormone therapy use within six 
months prior to study enrollment or if they had any exercise limitations.  
Blood Assessments 
Fasting plasma glucose and cholesterol were measured using standard techniques. 
Follicle stimulating hormone (Abcam, Cambridge, Massachusetts) and 17-beta-estradiol 
(Life Technologies, Frederick, Maryland) were measured from stored (-80°C) serum 
samples using commercially available ELISA assays and standard procedures.  
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Endothelial microparticles were measured from samples taken before and 30 
minutes after acute exercise. Whole blood was collected in acid citrate dextrose tubes, 
and after other blood collection tubes were drawn, to avoid potential effects due to the 
initial venipuncture. Whole blood was gently and continuously mixed until processing, 
spun at 1200 x g for 15 min to separate plasma, and then aliquoted and stored at -80°C 
until analysis. 
For analysis, plasma was thawed at room temperature and then spun, initially at 
4500 x g for 15 min (20°C) and then at 13,000 x g for 2 min (20°C). Aliquots of each 
sample (12.5 µl) were added to 96-well plates in duplicate and incubated with 5 µl of 
CD31 (APC, Biolegend, San Diego, California), 42b (PE, Biolegend, San Diego, 
California) and 62E (BV421, Becton Dickson and Company, San Jose, California) 
antibodies for 20 min and then fixed with 2% paraformaldehyde. Antibody and sample 
volumes were selected based on titration experiments (data not shown). Samples were 
stored overnight at 4°C and then analyzed by flow cytometry (BD Dual LSR Fortessa) 
the following morning. Prior to flow cytometric analysis, 12.5 µl of CountBright 
Absolute Counting Beads (Molecular Probes, Eugene, Oregon) were added to each well.  
To identify microparticle populations, gates were set according to size using 900 
nm NIST beads (Polysciences, Warrington, PA) to select events that were <900 nm 
(Figure 5.1). CD31+/42b- and CD62E+ EMPs were selected using fluorescent minus one 
gating strategies. Total events/µl of plasma was calculated using standard protocols for 
CountBright beads and the number of events/total microparticle events (EMP%) were 
calculated. 
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Statistical analyses: 
All analyses were completed in SPSS v24, with an alpha level of 0.05 for 
statistical significance. Despite attempting multiple transformations, not all variables 
were normally distributed. Natural log transformation of all variables was closest to a 
normal distribution; therefore, data were natural log transformed for analysis. Non-
transformed data are presented for interpretation. To account for the lack of normality for 
some variables, values on the extreme ends of the distribution were removed to achieve a 
normal distribution. Analyses with and without these values gave the same outcome; 
therefore, analyses run in all participants are reported. Repeated measure ANOVAs were 
used to evaluate differences in EMPs, EMP%, and total microparticle events across 
groups, before and after acute exercise. To evaluate the effect of menopausal status, 
differences were evaluated in high-fit women and in perimenopausal and postmenopausal 
combined. The influence of fitness was evaluated in perimenopausal and postmenopausal 
women only. Differences between groups were evaluated using one-way ANOVAs, 
independent t-tests, or an equivalent non-parametric test. Differences within groups were 
evaluated using paired t-tests or an equivalent non-parametric test. Data are presented as 
mean±SEM 
Results: 
Participants were healthy, had few risk factors for CVD and had similar risk 
factor profiles between groups (Table 5.1). Blood pressure, estradiol, follicle stimulating 
hormone, low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose, and 
triglycerides did not differ by fitness within each menopausal stage. Within 
perimenopausal women, body fat percentage was lower, while high-density lipoprotein 
  89 
cholesterol (HDL-C), time spent in moderate-to-vigorous physical activity (MVPA) and 
VO2peak were higher in high-fit women. Within postmenopausal women, body mass and 
body fat percentage were lower, while HDL-C, MVPA, and VO2peak were significantly 
higher in high-fit women.  
Total Microparticles 
All values for total microparticles and EMPs are presented in Table 5.2. In high-
fit women, there was a main effect of exercise on total number of microparticles 
(p<0.001), with lower levels 30 min after acute exercise. There was no effect of 
menopausal status on total microparticles (p=0.461). Within perimenopausal and 
postmenopausal women there was also a main effect of exercise (p<0.001), but not 
menopausal status (p=0.485) or fitness (p=0.772, Figure 5.2). 
CD62E+ EMPs  
Within high-fit women, there was a main effect of exercise (p=0.003), with lower 
EMPs/µl of plasma following acute exercise. There was no effect of menopausal status 
(p=0.521). Within perimenopausal and postmenopausal women, there was a main effect 
of exercise (p=0.021), but no effect of fitness (p=0.912) or menopausal status (p=0.818) 
on CD62E+ EMPs/µl plasma (Figure 5.3A). 
Within high-fit women, the percentage of microparticles that were CD62E+ was 
greater after acute exercise (p<0.001), but this response was not influenced by 
menopausal status (p=0.706). Within perimenopausal and postmenopausal women there 
was a main effect of exercise (p=0.001) and no effect of menopausal status (p=0.531) or 
fitness (p=0.804) on the percentage of EMPs that were CD62E+ (Figure 5.3B).  
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CD31+/42b- EMPs 
Within high-fit women, there was a main effect of exercise (p<0.001), with lower 
EMPs/µl of plasma following acute exercise. There was no effect of menopausal status 
(p=0.401). Within perimenopausal and postmenopausal women, there was a main effect 
of exercise (p=0.001) and no effect of menopausal status (p=0.435) or fitness (p=0.777, 
Figure 5.4A). 
Within high-fit women, the percentage of EMPs that were CD31+/42b- was not 
influenced by exercise (p=0.528) or menopausal status (p=0.535). Within perimenopausal 
and postmenopausal women, there was no effect of menopausal status (p=0.317), fitness 
(p=0.672) or exercise (p=0.690), on the percent of total events that were CD31+/42b- 
(Figure 5.4B).  
Discussion 
 The aim of this study was to evaluate the influence of menopausal status and 
cardiorespiratory fitness on two EMP populations before and after acute exercise. The 
results indicate that acute moderate intensity aerobic exercise reduces total circulating 
microparticles, CD31+/42b- EMPs, and CD62E+ EMPs in healthy midlife women. We 
further show that the percentage of CD62E+ EMPs increased with acute exercise.  These 
responses occurred across groups, despite difference in menopausal status and 
cardiorespiratory fitness.  
Our results show a clear reduction of EMPs in response to acute moderate 
intensity exercise. This reduction may represent one of the mechanisms by which long-
term training is beneficial for cardiovascular health. The effect of acute exercise on EMPs 
is equivocal in the literature. The differences in study results may be due to a variety of 
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factors including differences in participant characteristics (e.g. physical activity levels, 
age, sex), sampling time points, EMP population, and exercise mode (e.g. cycle 
ergometer, treadmill) across studies. In men, almost all studies have reported either an 
increase (43, 97) or no change in EMPs (117, 163, 202) in response to acute exercise. 
Although, one study did report an increase in activated EMPs in trained, but not untrained 
young men following acute moderate intensity exercise, suggesting a potential role of 
fitness (170). Studies in women have reported increases (43, 158), reductions (163), and 
no change in EMPs in response to acute exercise (43, 97, 158). For example, in 
overweight and obese inactive young women, there was an increase in activated EMPs 
and no change in apoptotic EMPs the morning following acute high-intensity cycle 
ergometer exercise (43). Conversely, in young aerobically fit women, there was no 
change in apoptotic or activated EMPs 5 minutes following an acute bout of moderate-to-
vigorous cycle ergometer exercise (97). Given the many differences between study 
designs, it is difficult to evaluate which specific factor is leading to the variability in 
responses across studies. This study compared multiple groups across the same time 
point, allowing for a clearer evaluation of the effects of acute exercise on EMPs in 
different populations.   
Beyond discrepancies in measurement time point and participant characteristics, 
most studies in women have evaluated a young population. High levels of EMPs are 
related to a variety of disease states including end stage renal disease (2), acute coronary 
syndrome (9), diabetes (186), and cardiovascular disease (161), among others. 
Menopause is associated with an increase in risk factors for cardiovascular disease (108); 
however, whether EMP levels change with menopause is still unclear. Higher levels of 
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CD62E+ EMPs have been reported in postmenopausal women with lower compared to 
higher levels of estrogen (80). We also reported higher activated EMPs/µl plasma in 
postmenopausal compared to perimenopausal women and higher levels of apoptotic 
EMPs/µl plasma following acute exercise in postmenopausal women (158). This 
evidence suggests that menopause may have an adverse effect on EMPs and EMP 
responses to acute exercise. However, our current results suggest that acute exercise, but 
not menopausal status, influences EMP levels in healthy women. The discrepancy in 
results may be due to differences in the protocol to isolate and assess EMPs between the 
studies; however, when we evaluated the percent change in EMPs in response to acute 
exercise, rather than events/µl plasma, the direction of the response in this study 
compared to the prior evaluation were similar.  
In addition to an effect of menopausal status, we also anticipated a beneficial 
effect of cardiorespiratory fitness on EMP levels, given the protective effects of fitness on 
cardiovascular health; however, we found no effect of cardiorespiratory fitness on EMPs 
in our population. This lack of effect may be due to the fact that both high- and low-fit 
women recruited for this study were healthy and had low CVD risk. Therefore, 
cardiovascular disease risk factors other than fitness may have a greater effect on EMP 
levels and responses to acute exercise. This is supported by findings from the KEEPs 
trial, which showed higher CD62E+ EMPs in postmenopausal women with higher 
Framingham risk and coronary artery calcification scores (81).  
Exercise intensity may also influence EMP levels. Moderate intensity exercise is 
generally associated with less of an inflammatory response and lower shear stress than 
high intensity exercise. Given that EMP release can be triggered by inflammation (29) 
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and shear stress (82), it is likely that different intensities of exercise may elicit a different 
EMP response. Similar to our results, Shill et al. reported a decrease in activated EMPs 
following moderate intensity treadmill exercise in young active women. Conversely, they 
found no change in EMP levels following high intensity (10 x 1 min intervals) treadmill 
exercise (163). Further, the high intensity, longer duration exercise of marathon running 
increased apoptotic EMPs in middle-aged men and women (155). Therefore, these data, 
in combination with that presented herein, suggest that acute moderate intensity exercise 
reduces EMP levels in healthy women of different ages. 
Another consideration regarding the reduction in circulating EMPs in response to 
acute exercise is increased EMP clearance. EMP clearance is still poorly understood, but 
is at least partially explained through uptake by endothelial cells. Jansen et al. reported 
uptake of EMPs to endothelial cells (79). Further, Wahl et al. reported a reduction in 
CD31+/42b- EMPs in highly trained men 60 minutes following varying intensities of 
acute cycle ergometer exercise. They also reported greater uptake of EMPs to endothelial 
cells (196). Together, these studies may suggest that the reduction in EMPs that we found 
with acute exercise may be due to enhanced clearance of EMPs to endothelial cells. 
Further, the increase in percentage of EMPs that were CD62E+ might indicate faster 
clearance of apoptotic EMPs relative to activated EMPs or greater appearance of 
activated EMPs in response to exercise. 
Endothelial microparticles are circulating markers of endothelial status but are 
also recognized as important signaling factors. Low levels of EMPs have been shown to 
promote angiogenesis, while high levels may inhibit it (127). EMPs have also been 
shown to be protective of endothelial apoptosis (79, 196) and CD62E+ EMPs may have 
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positive effects on inflammation and neovascularization, among other effects (8). Acute 
exercise may alter EMP signaling mechanisms; however, it is challenging to separate the 
contribution of other microparticle populations, such as platelet-derived microparticles, 
from the effects of EMPs. Endothelial cells exposed to post-exercise serum, containing 
apoptotic EMPs, had reduced apoptosis compared to cells exposed to pre-exercise serum 
(196). Similarly, exposure to post-exercise microparticles increased proliferation, 
migration, tube formation, and wound closure in cultured endothelial cells (202). 
Procoagulant activity of microparticles has also been shown to increase following acute 
moderate intensity cycle ergometer exercise in young men (170). Finally, miRNAs of 
endothelial origin were increased after acute cycle ergometer exercise in young, trained 
men; these miRNAs have been found in EMPs and can act on smooth muscles cells, 
potentially changing endothelial-smooth muscle communication (197). Therefore, there 
may be a functional benefit of acute exercise on EMPs; however, this warrants further 
investigation.  
Limitations 
This study provides novel insight into the influence acute moderate intensity 
exercise on EMP levels; however, there are several limitations worth noting. While this 
study shows a clear effect of acute exercise on EMPs, the study is underpowered for the 
effects of menopausal status and fitness. Further, EMPs levels are sensitive to storage and 
centrifugation speed. Longer storage at -80°C has been shown to increase the number of 
CD31+/42b- and CD62E+ EMPs, while high speed centrifugation may lead to some EMP 
loss (191). Both of these factors could potentially influence our results, particularly since 
data collection for this study occurred over several years. However, given the consistency 
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in our findings across groups and time points, we do not believe these limitations had a 
large effect on our outcomes.  
Conclusions 
  Overall, these data indicate that acute moderate intensity aerobic exercise leads to 
a reduction in total microparticles, as well as activated and apoptotic EMPs in healthy 
midlife women. This effect occurred despite differences in cardiorespiratory fitness and 
menopausal status across groups. The reduction in EMPs that we report may suggest that 
some of the beneficial effects of long term aerobic exercise on cardiovascular health in 
this population are due to the acute effects of exercise on EMP levels.  
 
Funding Sources: American College of Sports Medicine Foundation Doctoral Student 
Research Grant & University of Massachusetts Amherst Faculty Research Grant 
   
Tables 
 
 
Table 5.1. Participant Characteristics.  
FSH: follicle stimulating hormone; BMI: body mass index; HDL-C: high-density lipoprotein cholesterol; LDL-C low-density 
lipoprotein cholesterol; TG: triglycerides; FPG: fasting plasma glucose; SBP: systolic blood pressure; DBP; diastolic blood pressure; 
MVPA: moderate-to-vigorous physical activity. *different than low-fit, #Serviente et al., 2016, data are presented as mean±SEM 
Premenopause Perimenopause Postmenopause
High-fit (n=11) Low-fit (n=5)# High-fit (n=12) Low-fit (n=8)# High-fit (n=13)
Age (yrs) 44.5  1.0 48.4  1.6 50.8  1.0 58.9  1.4 60.5  1.0
Height (cm) 163.5  1.2 164.1  3.9 165.4  2.0 166.5  3.1 161.6  2.3
Weight (kg) 61.8  2.2 65.2  5.7 62.5  3.0 69.0  4.3 58.2  2.5*
Estradiol (pg/ml) 58.7  10.7 117.3  27.1 75.2  32.7 16.5  9.0 6.7  4.2
FSH (mIU/mL) 8.5  2.2 49.9  14.0 66.6  17.9 104.2  8.1 102.6  9.5
Body Fat (%) 29.6  2.5 37.4 1.8 26.9  2.1* 41.9  1.5 28.0  2.1*
BMI (kg/m2) 23.1  0.7 24.1  1.6 22.7  0.7 24.8  1.3 22.2  0.7
HDL-C (mg/dL) 71.2  4.9 62.4  8.0 82.0  4.8* 78.4  4.8 94.7  2.8*
LDL-C (mg/dL) 101.9  7.0 93.0  8.4 98.8   6.1 116.5  9.5 117.1  7.2
TG (mg/dL) 50.1  5.8 51.8  8.1 40.6  7.1 46.4  5.7 42.8  3.6
FPG (mg/dL) 94.5  2.0 95.4  2.6 93.9  1.8 99.5  1.7 96.5  1.9
SBP (mmHg) 102.7  2.4 101.0  6.3 106.0  2.8 117.3 5.2 106.3  3.7
DBP (mmHg) 58.9  1.5 61.6  4.7 59.2  1.8 64.6  2.7 61.9  2.3
MVPA (MET-min/wk) 3446.6  429.5 354.7  122.2 3695.9  528.5* 100.3  40.9 4107.1  684.1*
VO2 peak (ml/kg/min) 47.0  2.4 30.4  2.1 49.1  2.4* 28.3  1.1 43.8   1.8*
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Total MP events CD31+/42b- Events/ul plasma CD31+42b- Events/Total EMP 
events
CD62E+ Events/ul plasma CD62E+ Events/Total EMP 
events
Pre-exercise Post-exercise Pre-exercise Post-exercise Pre-exercise Post-exercise Pre-exercise Post-exercise Pre-exercise Post-exercise
Premenopause 12003.0±3972.7 
(10)
5911.8±1277.8* 
(11)
101.0±33.9 
(10)
50.1±10.3* 
(11)
17.5±0.1% 
(10)
17.6±0.2% 
(11)
52.8±12.1 
(10)
39.2±5.8* 
(11)
10.6±0.7% 
(10)
14.9±1.1%*
(11)
Low-fit 
perimenopause
15703.9±10426.9
(5)
7115.5±1733.1
(5)
128.2±85.8
(5)
59.1 ± 14.2 
(5)
17.1 ± 0.2% 
(5)
17.6±0.4%
(5)
65.7 ± 36.8
(5)
43.5 ± 10.8 
(5)
10.4 ± 1.1 % 
(5)
13.4 ± 1.0% 
(5)
High-fit 
perimenopause
13155.8±2655.7
(12)
7966.6±1561.9* 
(11)
107.5±20.5
(12)
66.5±12.8*
(11)
17.4±0.2% 
(12)
17.3±0.2% 
(11)
65.0 ±14.6 
(12)
51.9± 12.5* 
(11)
10.7±0.8%
(12)
13.1±1.1%*
(11)
Low-fit
postmenopause
10547.3±2975.5 
(7)
6047.1±669.3
(8)
84.8±24.7 
(7)
51.4±5.4
(8)
17.0±0.4% 
(7)
17.2±0.2%
(8)
84.7±31.0 
(7)
38.7±4.6
(8)
15.5±2.5% 
(7)
13.2±1.3%
(8)
High-fit 
postmenopause
9904.8±1474.2
(13)
5752.7±933.9*
(13)
79.4±13.1 
(13)
47.2±7.7*
(13)
17.3±0.4% 
(13)
17.1±0.1%
(13)
47.8±5.9
(13)
38.6±5.8*
(13)
10.8±0.4%
(13)
15.2±1.4%*
(13)
Table 5.2. Microparticle Variables. 
Microparticles were measured before and 30 minutes following acute exercise in an all participants. Data are presented as 
Mean±SEM (n). MP: microparticles; *p<0.05 compared to pre-exercise 
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Figure 5.1. Size Gating.  
Microparticle events selected using 900nm NIST beads. P2 represents microparticle events. 
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Figure 5.2. Total Microparticle Events. 
Total microparticle events were significantly reduced 30 minutes following acute exercise, independent of menopausal status or 
fitness. MP: microparticles, data are presented as mean±SEM 
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Figure 5.3. Activated Endothelial Microparticles. 
The number of activated microparticles/µl plasma was reduced with acute exercise (A), while the percentage of activated 
microparticles was increased with acute exercise (B). EMPS: endothelial microparticles, MPs: microparticles, data are presented as 
mean±SEM 
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Figure 5.4. Apoptotic Endothelial Microparticles.  
The number of apoptotic microparticles/µl plasma was reduced with acute exercise (A), while the percentage of apoptotic 
microparticles did not change with acute exercise (B). EMPs: endothelial microparticles, MP: microparticles, data are presented as 
mean±SEM
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CHAPTER 6 
 FOLLICLE STIMULATING HORMONE IS ASSOCIATED WITH LIPIDS IN 
POSTMENOPAUSAL WOMEN 
Introduction 
 Menopause is associated with changes in sex hormone levels. Although many of 
the physiological changes with menopause have been attributed to changes in estrogens, 
there is increasing evidence to suggest that follicle stimulating hormone (FSH) may have 
an independent effect on cardiovascular disease risk (45, 198). FSH levels being to rise 
during the perimenopausal years. FSH levels remain elevated postmenopause, although 
there is considerable variability in postmenopausal FSH levels. The influence of the rise 
in FSH on cardiovascular disease risk is controversial. Some studies have suggested that 
high FSH levels may negatively influence cardiovascular disease risk (44, 45), while 
others have suggested that it is beneficial (11, 12, 198). Regardless of the direction of the 
influence of FSH on CVD risk, there is compelling evidence to suggest that FSH may 
exert an effect on CVD risk through its influence on lipid levels. 
 Animal research has shown that FSH can act on low-density lipoprotein 
cholesterol receptors (169), demonstrating a direct effect of FSH on lipids. Furthermore, 
an increase in FSH, independent of estrogen levels, led to an increase in both total 
cholesterol and low-density lipoprotein cholesterol (169). While an association between 
lipids and FSH has been shown in several human studies (27, 169), there is a scarcity of 
evidence in this area, especially regarding the relation in older, postmenopausal women. 
Therefore, the aim of this study was to evaluate whether FSH levels are related to lipid 
levels in postmenopausal women.   
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Methods 
Study Population 
Participants were members of the Kuopio Ischaemic Heart Disease Risk Factor 
Study (KIHD). This is a prospective cohort study in men and women in Eastern Finland 
designed to identify risk factors for metabolic and cardiovascular diseases. Female 
participants were enrolled in the KIHD study between March 1998 and February 2001. 
Eligible women were a random sample of 1,173 postmenopausal women living in Kuopio 
or the surrounding area. Women were recruited into four age categories: 53 to 56 years, 
59 to 62 years, 64 to 68 years, and 71 to 73 years. Ultimately, 920 women (87.4% of 
those invited) completed the baseline clinical assessments and were enrolled in the 
cohort.  
For the present analysis, women were excluded if they reported current hormone 
therapy use or if FSH or lipid values were missing. The final sample size for this analysis 
was 588. The Research Ethics Committee at the University of Kuopio approved study 
procedures and participants provided written informed consent before beginning any 
study procedures. 
Blood Collection and Biochemical Measurements 
Blood samples were collected from participants at a clinic visit between 8 and 10 
AM, while participants were fasted and had abstained from smoking cigarettes for 12 
hours, and alcohol consumption for 3 days. Plasma and serum was separated and then 
stored, within 1 hour of venipuncture, at -20°C or -80°C until analysis. Biochemical 
measures, including hormonal factors such as FSH, 17-beta estradiol, sex-hormone 
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binding globulin (SHBG), and testosterone were assessed between June 2001 and 
February 2002.  
Follicle stimulating hormone, 17-beta estradiol, and testosterone were measured 
using commercially available immunoradiometric assays. Serum FSH was determined 
with sandwich technique, applying an immunoradiometric assay manufactured by 
Diagnostic Product Corporation (Coat-A-Count FSH IRMA). Serum 17-beta-estradiol 
was assayed between 1999 and 2001 with a radioimmunoassay manufactured by 
DiaSorin. Serum testosterone (17b-hydroxy-4-androsten-3-one) was determined with 
Spectria Testosterone (125I) radioimmunoassay kit (Orion Diagnostica Espoo, Finland). 
125I label measurements for FSH, E2, and testosterone were carried out by gamma 
counter (Wallac 1261 MultiGamma) using a RiaCalc LM Evaluation Program. 
Coefficients of variation were 5%, 7.6-12%, and 7.9-12.2% respectively. Sex hormone 
binding globulin was measured with a fluoroimmunoassay (AutoDELFIA SHBG, Wallac 
Co., Turku, Finland). Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were assessed 
enzymatically (CHOD-PAP method, Boehringer Mannheim, Mannheim, FRG). 
Coefficients of variation were 2.3%, 5.2%, 9.2% and 1.9% respectively. 
Clinical Measures and Questionnaire Assessments 
 Clinical and reproductive outcomes such as time since the final menstrual period, 
oral contraceptive use, history of hormone therapy, hysterectomy and oophorectomy were 
evaluated based on self-report. Participants were asked about behavioral factors such as 
smoking and physical activity on validated questionnaires (95). A trained interviewer 
then reviewed all questionnaire responses. History of cardiovascular and metabolic 
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diseases, along with medication use, were assessed during physician administered 
interviews.  
 Resting blood pressure was measured 6 times during the clinic visit, and mean 
blood pressure was calculated by averaging three supine, one standing, and two seated 
measurements, with 5 minutes rest in between measures. Height, weight, and waist and 
hip circumference were measured. Height and weight were used to calculate body mass 
index (BMI) as weight (kg) divided by height (m2). Waist-to-hip ratio (WHR) was 
calculated from circumference measurements. 
Statistical Analyses 
 All statistical analyses were completed in SPSS v24. Significance was set at an 
alpha level of 0.05. Participants were divided into quartiles based on FSH levels. Baseline 
characteristics were compared across quartiles using ANOVAs or chi-squared tests. 
 Linear regression was used to evaluate the relationship between FSH and lipid 
levels. Lipid variables were log transformed to improve normality and included TC, 
LDL-C, HDL-C, and TG. Model 1 adjusted a priori for age, date of examination, 
estradiol, SHBG and testosterone levels, age of menarche, last menstruation age, oral 
contraceptive use, and history of hysterectomy or oophorectomy. Model 2 included all 
covariates in model 1 as well as waist-to-hip ratio, body mass index, systolic and diastolic 
blood pressure, physical activity levels, and smoking status. The fully adjusted model 
included covariates in model 2 and use of lipid-lowering medications. Model 2 was also 
run in participants not taking lipid lowering medications. The median FSH value for each 
quartile was modeled as a continuous variable to assess linear trends. To evaluate if 
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relations of FSH and lipids varied by age and body mass index, we conducted analyses 
stratified by these factors and tested for effect modification.  
 We then used logistic regression to evaluate whether FSH levels were associated 
with dyslipidemia, as well as high TC (>6.20mmol/L), high LDL-C (≥4.1 mmol/L), low 
HDL-C (<1.0 mmol/L) and high TG (≥2.30 mmol/L)(128). Dyslipidemia was defined as 
meeting any of the criteria for abnormal lipid levels, as defined above, or the use of lipid-
lowering medications. All abnormal lipid outcomes also included use of lipid lowering 
medications. Covariates were selected based on which variables led to the greatest 
change in the odds ratio for FSH. FSH was included as a continuous variable. Covariates 
meeting selection criteria included body mass index, waist-to-hip ratio, SHBG, estradiol, 
and age. 
Results 
 When comparing participant characteristics based on FSH quartiles, there were 
significant, though modest, differences across groups (Table 6.1). BMI, WHR, estradiol, 
and SHBG were lower at higher FSH quartiles. Physical activity was higher at higher 
FSH quartiles. Despite these differences, many variables were similar across groups 
including age at menopause, past hormone therapy use, smoking status, and parity. 
 There was an increase in non-adjusted LDL-C (P=0.15) and TC (P<0.001) levels 
with increasing FSH quartiles (Table 6.2). We observed a positive linear relationship 
between FSH and TC (model 3, P for trend 0.001), and LDL-C (model 3, P for trend 
0.007). Results from minimally and fully adjusted models for these lipids were virtually 
identical.  
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 HDL-C levels were higher among women in quartiles 2-4 for FSH than quartile 1 
in model 1 (P for trend = 0.03), with results somewhat attenuated in our fully adjusted 
model (P = 0.06). FSH was not consistently associated with triglyceride levels. We also 
evaluated model 2 in participants not taking lipid-lowering medications and found that 
this did not influence our results for any lipid variable (data not shown).  
 We assessed the FSH–lipids relation in fully adjusted models stratified by age 
(younger: 53-62 years; older: 64-73 years, Appendix I). Similar to the main analysis, 
there was no relationship between FSH and HDL-C (younger, P for trend 0.41, older; P 
for trend 0.09) or TG (younger, P for trend 0.54; older, P for trend 0.28). We did not 
observe evidence of significant effect modification by age (all P >0.05), but results varied 
slightly between older and younger women. The relationship between FSH and TC and 
LDL-C was only significant in older women, though there appeared to be a stronger 
association in younger women, as suggested by larger beta coefficients (Table 6.3). We 
found no evidence of effect modification based on body mass index (all P>0.05; data not 
shown).  
 Finally, we assessed the association of continuous FSH levels with risk of 
dyslipidemia and abnormal levels of each lipid (Table 6.4). In addition to presenting 
betas for a 1-unit increase in FSH, Table 6.4 presents OR for a 40 IU/L increase in FSH, 
equivalent to the difference in the medians of quartiles 1 and 4. Follicle stimulating 
hormone levels were not associated with prevalent dyslipidemia. However, FSH was 
significantly associated with higher risk of high TC and LDL-C. A 40-unit increase in 
FSH was associated with a 62% higher risk of high total cholesterol and a 55% higher 
risk of high LDL-C. Results suggested that higher FSH was associated with lower risk of 
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abnormal HDL-C and TG, but were not significant. We also found no evidence of effect 
modification based on body mass index or age (all P>0.05; data not shown).  
Discussion 
 Menopause is associated with adverse changes in cardiovascular disease risk 
factors, including lipid levels (108). While these changes have largely been attributed to 
changing estrogens, increasing evidence suggests that FSH may play an independent role. 
The findings from this study suggest that FSH is positively related to total cholesterol 
(TC) and low-density lipoprotein cholesterol (LDL-C) in postmenopausal women. We 
further show that FSH is not associated with dyslipidemia but has a significant positive 
relationship with elevated LDL-C and TC. The results also suggest that higher FSH is 
associated with better high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) 
levels, although these associations did not reach statistical significance. Relations 
persisted even after adjustment for hormonal factors, CVD risk factors, and lipid 
lowering medication use. Finally, our data suggests that these relationships may vary 
somewhat by age, though our power to detect significant differences was low due to the 
small samples sizes of individual strata.  
 Rodent studies demonstrate that FSH may have direct effects on LDL-C and TC 
production. In ovariectomized mice, when FSH was elevated independent of estradiol, 
there was an increase in both TC and LDL-C. This increase was associated with reduced 
LDL-receptor expression. FSH receptors are also present in human liver tissue, and when 
exposed to FSH, there is reduced expression of LDL-receptors (169). FSH has also been 
shown to stimulate lipid biosynthesis in chicken adipose tissue (32) and lipid droplet 
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formation in human adipose tissue (100), again demonstrating that FSH may have direct 
effects on lipid metabolism and specifically on TC and LDL-C.  
 Few human studies have evaluated the effect of FSH on lipids. An analysis 
comparing Chinese postmenopausal women with high vs. low levels of FSH found that 
higher FSH was associated with higher levels of LDL-C and TC (169). Further, a 30% 
reduction in FSH due to hormone therapy, equivalent to ~25IU/L change, led to a 
reduction in LDL-C of 0.14mmol/L and a reduction in TC of 0.19 mmol/L. While these 
results show the same directional relationships as our current analysis, the relation of 
FSH with lipid levels is more modest than in our study. When comparing FSH quartile 1 
to quartile 3 (23.3 IU/L difference in median FSH) there was a 0.2 mmol/L difference in 
LDL-C and a 0.2 mmol/L difference in TC in our analysis. The difference in magnitude 
of effect may be due to differences in FSH levels between populations. For example, the 
50th percentile cutoff in our sample was 50.0 IU/L compared to 78.3 IU/L in their sample. 
Therefore, a 25 IU/L difference in FSH represents a greater relative change in FSH in our 
study. Further, women in our study were older, also potentially contributing to the 
difference in magnitude of study results.  
 A changing relationship between FSH and CVD risk factors with age is supported 
by the literature. For example, in longitudinal data from the Study of Women’s Health 
Across the Lifespan (SWAN) study, a lower compared to a higher rise in FSH from 
perimenopause to approximately 8 years after menopause was associated with reduced 
CVD risk (45). Conversely, in older postmenopausal women, higher FSH has been 
associated with lower cardiovascular disease risk (11, 198) and lower risk of diabetes 
(12). Further, Wide et al., reported differences in FSH isoforms in postmenopausal 
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compared to premenopausal women, potentially leading to a higher FSH half-life in 
postmenopausal women and therefore influencing its biological effects (200). Our data 
shows a stronger relationship between FSH and TC and LDL-C in younger compared to 
older postmenopausal women, further indicating a possible change in the effects of FSH 
with increasing age.  
 While we show a positive association between FSH and abnormal levels of TC 
and LDL-C, we observed an inverse association of FSH levels with abnormal (i.e, low) 
HDL-C and (i.e. high) TG. This is in line with data in the literature that has suggested a 
positive effect of high levels of FSH on cardiovascular disease risk. In postmenopausal 
women in China, there was a positive association between FSH and HDL-C and a 
negative relationship with TG and LDL-C (198). The difference in the relationship 
between FSH and LDL-C in that study compared to our current analysis may be due to 
the wider FSH range in our study and that we controlled for more variables, including 
WHR, in our analyses. Among postmenopausal women in the KIHD study, high levels of 
FSH have also been associated with reduced incidence of type two diabetes (12) and with 
lower carotid artery intima media thickness, especially in older women (11). The positive 
association of FSH with TG and HDL-C may represent one of the mechanisms by which 
FSH impacts CVD risk; however, given the positive relationships that we found with TC 
and LDL-C, the overall effects of FSH on CVD risk, through its impact on lipid levels 
remains questionable.   
Limitations 
 While this study provides some novel insight into the relationship between lipid 
levels and FSH in postmenopausal women, it has several limitations. As study 
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participants were postmenopausal women in Finland, results may not be generalizable to 
other populations with greater racial and ethnic diversity. Further, this is a cross-sectional 
analysis; therefore, we were unable to evaluate the temporality of the relationship 
between FSH and lipid levels.  
Conclusions 
 Overall, this study indicates that FSH may be associated with lipid levels in 
postmenopausal women and that relations vary between lipids. Consequently, the results 
suggest that FSH may be associated with chronic conditions related to lipid levels, 
including CVD.  Further study of these relations and the physiologic mechanisms 
underlying them is warranted as this may allow for a clearer understanding as to whether 
FSH may be an important physiological target for reducing CVD risk with menopause.
 Tables 
 
Table 6.1. Participant Characteristics. 
FSH: follicle stimulating hormone, BMI: body mass index, SHBG: sex hormone binding globulin, SBP: systolic blood pressure, DBP: 
diastolic blood pressure: HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, HT: hormone 
therapy 
 
FSH Quartile (n) 
Quartile 1 
(n=147) 
Quartile 2 
(n=149) 
Quartile 3 
(n=145) 
Quartile 4 
(n=147)  
FSH range (IU/l) 1-39.3 39.4-50.0 50.1-61.8 61.9 to 136.8  
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) P 
Age (yrs) 64.5 (6.9) 65.1 (5.9) 64.4 (6.1) 62.8 (6.9) 0.02 
BMI (kg/m2) 31.1 (5.7) 29.0 (5.4) 28.7 (5.0) 26.8 (4.4) <0.001 
WHR 0.87 (0.07) 0.85 (0.06) 0.84 (0.06) 0.83 (0.06) <0.001 
Estradiol (pmol/ml) 55.8 (77.6) 35.1 (19.8) 32.5 (12.5) 34.1 (19.5) <0.001 
Testosterone (nmol/l) 1.5 (2.9) 1.1 (0.5) 1.1 (0.5) 1.1 (0.5) 0.06 
SHBG  (nmol/L) 45.6 (23.2) 49.5 (21.2) 55.0 (24.3) 58.4 (28.0) <0.001 
SBP (mmHg) 140.8 (20.4) 141.1 (17.3) 136.2 (16.4) 135.8 (16.4) 0.01 
DBP (mmHg) 80.9 (9.7) 80.5 (8.7) 79.6 (8.3) 80.4 (8.5) 0.66 
Physical Activity (MET-hr/day) 45.2 (5.9) 46.1 (7.1) 46.3 (6.1) 47.4 (7.5) 0.05 
Parity 2.8 (1.4) 2.7 (1.6) 2.8 (1.7) 2.3 (1.3) 0.08 
 n (%) n (%) n (%) n (%)  
Age at menopause (yrs) 49.7 (4.4) 49.4 (4.3) 48.9 (4.8) 49.2 (4.3) 0.50 
Current Smoker 12 (8%) 14 (9%) 16 (11%) 7 (5%) 0.25 
Past Smoker 19 (13%) 15 (10%) 11 (8%) 19 (13%) 0.37 
Past HT use 38 (26%) 45 (30%) 48 (33%) 49 (33%) 0.58 
 
 
 
 
Table 1. Participant Characteristics. FSH: follicle stimulating hormone, BMI: body mass index, SHBG: sex hormone binding 
globulin, SBP: systolic blood pressure, DBP: diastolic blood pressure: HDL-C: high-density lipoprotein cholesterol, LDL-C: low-
density lipoprotein cholesterol, HT: hormone therapy 
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    Model 1b Model 2c Model 3d 
  Mean (SD)a Beta SE p Beta SE p Beta SE p 
Total Cholesterol     
FSH Q1 5.6 (0.7) Ref Ref Ref 
FSH Q2 5.8 (0.9) 0.014 0.008 0.09 0.014 0.008 0.10 0.014 0.008 0.08 
FSH Q3 5.8 (0.9) 0.016 0.008 0.05 0.015 0.008 0.04 0.018 0.008 0.04 
FSH Q4 5.9 (1.0) 0.025 0.008 0.004 0.025 0.009 0.003 0.025 0.009 0.004 
p for trend 0.01*   0.002   0.001   0.001 
LDL-C           
FSH Q1 3.6 (0.7) Ref Ref Ref 
FSH Q2 3.8 (1.0) 0.013 0.013 0.29 0.014 0.013 0.26 0.015 0.013 0.23 
FSH Q3 3.8 (0.9) 0.022 0.013 0.09 0.025 0.013 0.05 0.026 0.013 0.05 
FSH Q4 3.9 (1.0) 0.031 0.013 0.02 0.035 0.013 0.01 0.035 0.013 0.01 
p for trend 0.15*   0.01   0.01   0.007 
HDL-C           
FSH Q1 1.3 (0.3) Ref Ref Ref 
FSH Q2 1.3 (0.3) 0.021 0.011 0.06 0.018 0.011 0.12 0.018 0.011 0.12 
FSH Q3 1.4 (0.3) 0.021 0.012 0.07 0.019 0.012 0.11 0.019 0.012 0.11 
FSH Q4 1.4 (0.6) 0.025 0.012 0.04 0.018 0.012 0.13 0.018 0.012 0.13 
p for trend <0.001*   0.02   0.06   0.06 
Triglycerides          
FSH Q1 1.4 (0.7) Ref Ref Ref 
FSH Q2 1.3 (0.8) 0.015 0.021 0.47 0.025 0.02 0.23 0.021 0.02 0.29 
FSH Q3 1.2 (0.5) 0.01 0.022 0.66 0.021 0.021 0.49 0.014 0.021 0.50 
FSH Q4 1.2 (0.6) 0.014 0.022 0.51 0.021 0.022 0.09 0.037 0.021 0.08 
p for trend 0.01*   0.67   0.21   0.17 
 
Table 6.2. Association of Follicle Stimulating Hormone and Lipid Levels.  
aUnadjusted, untransformed mean total cholesterol (mmol/l), low-density lipoprotein cholesterol (LDL-C, mmol/L), 
high-density lipoprotein-cholesterol (HDL-C, mmol/L), and triglycerides (mmol/l). 
bCovariates included in model 1: age (continuous), date of study entry (continuous), estradiol (quartiles), testosterone 
(quartiles), sex-hormone binding globulin (quartiles), starting menstruation age (above and below median), last 
menstruation age (above and below median), oral contraceptive use (yes, no: yes-above and below median), uterus 
eliminated (yes, no), ovaries eliminated (yes, no), hormone therapy use (yes, no: yes-above and below median). 
cCovariates included in model 2: model 1 covariates, systolic blood pressure (continuous), diastolic blood pressure 
(continuous), smoking status (pack-years+past, current, never; current-above and below median for pack-years), 
physical activity (quartiles), BMI (continuous), waist-to-hip ratio (continuous). 
dCovariates included in model 3: model 2 covariates, lipid lowering medication use (yes, no)  
*indicates p-value from ANOVA 
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Younger women  
(n=244, 53-62 years) 
  
                             Older women 
                            (n=344, 64-73 years) 
  
  
Model 3b                                    Model 3b 
  Mean (SD)a Beta SE p   Mean (SD)a Beta SE p 
Total Cholesterol       Total Cholesterol         
FSH Q1 5.6 (0.7) Ref FSH Q1 5.5 (0.8) Ref 
FSH Q2 5.8 (1.0) 0.023 0.013 0.11 FSH Q2 5.7 (1.0) 0.005 0.011 0.64 
FSH Q3 5.8 (0.9) 0.026 0.013 0.06 FSH Q3 5.7 (0.8) 0.008 0.011 0.49 
FSH Q4 5.9 (1.0) 0.021 0.013 0.10 FSH Q4 6.0 (1.0) 0.024 0.012 0.06 
p for trend       0.22 p for trend       0.05 
LDL-C         LDL-C         
FSH Q1 3.6 (0.7) Ref FSH Q1 3.6 (0.7) Ref 
FSH Q2 3.8 (1.0) 0.022 0.022 0.33 FSH Q2 3.8 (1.0) 0.002 0.016 0.89 
FSH Q3 3.8 (0.9) 0.048 0.021 0.03 FSH Q3 3.7 (0.8) 0.003 0.017 0.84 
FSH Q4 3.9 (1.0) 0.041 0.021 0.05 FSH Q4 3.9 (1.0) 0.026 0.019 0.16 
p for trend       0.14 p for trend       0.01 
HDL-C         HDL-C         
FSH Q1 1.3 (0.3) Ref FSH Q1 1.2 (0.3) Ref 
FSH Q2 1.3 (0.3) 0.027 0.018 0.13 FSH Q2 1.3 (0.3) 0.011 0.016 0.48 
FSH Q3 1.4 (0.3) 0.014 0.017 0.42 FSH Q3 1.4 (0.3) 0.024 0.017 0.15 
FSH Q4 1.4 (0.3) 0.008 0.017 0.57 FSH Q4 1.4 (0.4) 0.022 0.018 0.23 
p for trend       0.42 p for trend       0.09 
Triglycerides       Triglycerides       
FSH Q1 1.4 (0.7) Ref FSH Q1 1.4 (0.7) Ref 
FSH Q2 1.4 (0.8) -0.018 0.035 0.61 FSH Q2 1.4 (0.6) 0.032 0.026 0.23 
FSH Q3 1.2 (0.6) -0.001 0.033 0.98 FSH Q3 1.2 (0.6) 0.021 0.028 0.46 
FSH Q4 1.2 (0.6) 0.044 0.032 0.17 FSH Q4 1.2 (0.6) 0.03 0.030 0.32 
p for trend       0.54 p for trend       0.28 
 
Table 6.3. Association of Follicle Stimulating Hormone and Lipid Levels by Age.  
aUnadjusted, untransformed mean Total cholesterol (mmol/l), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density 
lipoprotein-cholesterol (HDL-C, mmol/L), and triglycerides (mmol/l). 
bCovariates included in model 3: age (continuous), date of study entry (continuous), estradiol (quartiles), testosterone (quartiles), 
sex-hormone binding globulin (quartiles), starting menstruation age (above and below median), last menstruation age (above and 
below median), oral contraceptive use (yes, no: yes-above and below median), uterus eliminated (yes, no), ovaries eliminated 
(yes, no), hormone therapy use (yes, no: yes-above and below median), systolic blood pressure (continuous), diastolic blood 
pressure (continuous), smoking status (pack-years+past, current, never; current-above and below median for pack-years), physical 
activity (quartiles), BMI (continuous), waist-to-hip ratio (continuous), lipid lowering medication use (yes, no). 
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Table 3. Association of Follicle Stimulating Hormone and Lipid Levels by Age.  
aUnadjusted, untransformed mean Total cholesterol (mmol/l), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density 
lipoprotein-cholesterol (HDL-C, mmol/L), and triglycerides (mmol/l). 
bCoavariates included in model 3: age (continuous), date of study entry (continuous), estradiol (quartiles), testosterone (quartiles), sex-
hormone binding globulin (quartiles), starting menstruation age (above and below median), last menstruation age (above and below 
median), oral contraceptive use (above and below median), systolic blood pressure (continuous), diastolic blood pressure (continuous), 
smoking status (pack-years+past, current, never; current: above and below median for pack-years), physical activity (quartiles), BMI 
(continuous), waist-to-hip ratio (continuous), lipid lowering medication use (yes, no). 
 
  n beta per 1 IU higher SE OR per 40 IU higher P 
Dyslipidemia (all lipids)a           
     No* 294 reference       
     Yes 292 0.003 0.005 1.13 0.57 
Total Cholesterolb           
    ≤ 6.2 mmol/L* 399 reference       
    >6.2 mmol/L 189 0.012 0.005 1.62 0.02 
LDL-Cb           
    <4.1 mmol/L* 374 reference       
    ≥ 4.1 mmol/L 214 0.011 0.005 1.55 0.03 
HDL-Cb           
    ≥1.0 mmol/L* 491 reference       
    <1.0 mmol/L 97 -0.01 0.007 0.67 0.15 
Triglyceridesb           
    <2.3 mmol/L* 520 reference       
    ≥ 2.3 mmol/L 68 -0.012 0.008 0.62 0.17 
 
 
 
Table 3. Association of Follicle Stimulating Hormone and Abnormal Lipid Level. 
OR: odds ratio. Lipid classifications based on ATP II guidelines9.  *includes lipid-lowering medication 
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Table 6.4. Association of Follicle Stimulating Hormone and Abnormal Lipid Levels.  
OR: odds ratio. Lipid classifications based on ATP II guidelines (128).  *includes lipid-lowering medication 
bCovariates included age (continuous), date of study entry, sex hor one binding globulin (continuous), estradiol (continuous), body 
mass index (continuous), waist to hip ratio (continuous). 
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CHAPTER 7 
 SUMMARY 
The aim of this dissertation was to evaluate variables related to changing 
cardiovascular disease risk with menopause. This was accomplished through two primary 
studies. The first evaluated the influence of menopausal status and cardiorespiratory 
fitness on measures of endothelial health before and after an acute bout of exercise. The 
second evaluated the influence of follicle stimulating hormone (FSH) on lipid levels in 
postmenopausal women. Together, these studies filled several important knowledge gaps 
in the literature (Figure 7.1), improving our understanding of how cardiovascular disease 
risk changes with menopause. 
The first study in this dissertation evaluated markers of endothelial health. This 
study found that endothelial function was reduced in postmenopausal women, potentially 
due to the influence of high FSH levels, and that fitness was not protective of endothelial 
function in perimenopausal or in postmenopausal women. These findings corroborate 
what others have shown in the literature: that endothelial function is reduced in 
postmenopause and that there may be a resistance to the benefits of fitness on endothelial 
function in postmenopausal women. It also shows, for the first time, that this resistance 
may be present in perimenopausal women. However, although FMD is a well-validated 
technique, our data suggests that it may underestimate vasodilatory capacity, therefore we 
also evaluated max-FMD. The max-FMD analyses suggest that fitness may be protective 
of endothelial function; however, this technique requires further validation.    
 This study also evaluated endothelial microparticle (EMP) levels. Through this 
analysis, we found that EMPs are reduced with acute exercise, despite differences in 
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menopausal status and fitness.  This corroborates the reduction in EMPs with moderate 
intensity exercise that others have shown in the literature and may suggest that some of 
the benefits of long-term exercise training on EMPs may be due to the acute effects of 
exercise on EMPs. Together, the FMD and EMP data highlight that these independent 
variables provide unique and independent information about endothelial health in 
menopausal women.  For example, the FMD data indicates that both fitness and 
menopausal status influence endothelial function.  Conversely, the EMP data suggests 
that EMPs may not be influenced by these variables, but are highly responsive to acute 
exercise.     
The final study in this dissertation evaluated the relationship between FSH and 
lipid levels in postmenopausal women. This study found that FSH had a positive linear 
relationship with low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) 
and that these relationships may be stronger in younger compared to older 
postmenopausal women.  We also found that higher FSH is associated with increased risk 
of having high TC and high LDL-C, suggesting a clinically relevant relationship.  
Overall, these results suggest that higher levels of FSH in the postmenopausal years may 
have adverse effects on TC and LDL-C.   
Future Directions 
 There are several important areas of future inquiry based on the findings from this 
dissertation. Given the low levels of endothelial function we report in high-fit women, it 
will be important to evaluate potential mechanisms for this reduced function and whether 
other mechanisms may be contributing to these findings. For example, it is possible that 
high-fit women have more compliant blood vessels than low-fit women or that they are 
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relying on vasodilatory factors other than nitric oxide.  It will also be important to 
validate the max-FMD technique. Given that it appears to better match the low 
cardiovascular disease risk profile of the participants in this study, this may be a 
promising new approach for evaluating endothelial function in perimenopausal and 
postmenopausal women. From the EMP data, it will be important to evaluate the 
functional implications of the reduction in EMPs that we report with acute exercise, as 
they may represent a potential mechanism for some of the benefits of long-term exercise 
training.  Finally, it will be important to evaluate the effects of FSH on lipid levels 
longitudinally. 
Conclusions 
 Overall, this dissertation showed that menopause may negatively influence 
endothelial function and lipid levels. It further suggested that the effects of 
cardiorespiratory fitness on endothelial function may not be present in perimenopausal 
and postmenopausal women.  Finally, we showed that acute moderate intensity exercise 
reduces endothelial microparticles in midlife women, despite differences in menopausal 
status and cardiorespiratory fitness. Together, these data suggest that continued 
evaluation of how cardiovascular disease risk changes with menopause and the influence 
of fitness on these markers is warranted.  
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Figures: 
 
 
Figure 7.1. Summary of Findings 
There is an increase in follicle stimulating hormone (FSH) and a reduction in estrogen 
with menopause that change a woman’s cardiovascular disease (CVD) risk. The 
mechanisms behind the effects of estrogen on CVD risk are relatively well established, 
while the effects of FSH are not. This dissertation demonstrated that FSH may be 
exerting its effects on CVD risk through its effects on total cholesterol (TC) and low-
density lipoprotein cholesterol (LDL-C).  The change in CVD risk with menopause 
contributes to reduced endothelial function.  While fitness is considered protective of 
endothelial function, this effect may be diminished in perimenopausal and 
postmenopausal women; however, what this relationship looks like still requires further 
research.  Finally, we found that acute moderate intensity exercise reduces endothelial 
microparticles (EMPs) in perimenopausal and postmenopausal women and that that affect 
occurred despite differences in cardiorespiratory fitness and menopausal status across 
groups. x, indicates no relationship, ?, indicates an unclear relationship. 
 
 
  
   122 
APPENDIX A 
INFORMED CONSENT 
 
Consent Form for Participation in a Research 
Study 
University of Massachusetts 
Amherst 
 
Study Title: Vascular Function across the Menopausal Transition 
 
Principal Investigators: Corinna Serviente, MS & Sarah Witkowski, PhD 
 
Section One Overview of Study 
 
WHAT IS THIS 
FORM? 
This form is called a Consent Form. It will give you information about the study, so you 
can make an informed decision about participation in this research study. This consent 
form will give you the information you will need to understand why this study is being 
done and why you are being invited to participate. It will also describe what you 
will need to do to participate and any known risks, inconveniences or discomforts 
that you may have while participating. We encourage you to take some time to think this 
over and ask questions. If you decide to participate, you will be asked to sign this 
form and you will be given a copy for your records. 
 
WHO IS ELIGIBLE TO 
PARTICIPATE? 
• Participants must meet criteria for either of the following three categories 
and be 
65 years old or younger: 
o Premenopause: regular menstrual cycles 
o Early perimenopause: variable period length (more than 7 days 
different from normal) 
o Late perimenopausal: 60 days or more, but less than 1 year 
without a period 
o Late postmenopause: more than 5 years without a period 
•  Participants should: 
o Have normal blood pressure 
o Be non-diabetic (normal blood sugar levels) 
o Be participating in less than 150 min/week of moderate intensity 
physical activity or less than 75 min/week of vigorous intensity 
physical activity, accumulated in 10 minute bouts OR be 
participating in at least 300 min/week of moderate intensity physical 
activity or at least 150 min/week of vigorous intensity physical 
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activity, accumulated in 10 minute bouts and have been doing so for 
the past 2 years 
o Be nonsmokers 
o Have normal fat levels in the blood 
o Have a VO2 max that is equal to or greater than the 80th percentile for 
their age, if classified as high-active 
•  Participants should not: 
o Have used hormone replacement therapy, menopausal symptom 
treatment, or birth control in the past 6 months 
o Have a history of heart or blood vessel diseases 
o Have had a previous heart attack or cardiovascular intervention 
(e.g.pacemaker implant) 
o Have had a hysterectomy prior to menopause or not have undergone  
natural menopause 
o Have long-term menstrual irregularities 
o Have  used  certain  vitamin/supplements,  fat  lowering  and/or   
anti-inflammatory medications in the past 4 week 
o Currently have and/or have a history of breast cancer (with 
radiation or chemotherapy treatment), vaginal bleeding, abnormal 
uterine/ovary structure, blood clots, acute liver or gallbladder diseases 
o Have high fat levels in the blood 
o Have a muscle, bone, or other condition that limits ability 
exercise 
o Have a reason that limits ability to take part in an exercise test 
o Have a reason to stop the exercise test early 
o Have a history of fainting with blood draws 
o Be pregnant 
o Are currently participating in a research study that conflicts with this 
study's protocols 
 
3. WHAT IS THE PURPOSE OF THIS STUDY? 
The purpose of this research study is to examine blood vessel function across the 
menopausal transition. We aim to determine if vessel function, and the inflammatory 
markers (MCP-1 and IL-8), are different at baseline and in response to a single exercise 
session and whether these responses vary in women who are more or less physically 
active 
 
4. WHERE WILL THE STUDY TAKE PLACE AND HOW LONG 
WILL IT LAST? 
The research for this study will be performed in the Department of Kinesiology at the 
University of Massachusetts in Amherst, MA. You will be asked to come to Amherst 
approximately 3 times for ~1-3 hours per visit. Your total participation will be about 6-8 
weeks, depending on the ease of scheduling, the screening, and testing visits. 
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5. WHAT WILL I BE 
ASKED TO DO? 
Your participation will involve the following procedures outlined below. Detailed 
procedures are described in section 2. 
 
 
Visit Number Tasks 
Before Visit 1 • Pre-screening interview 
• For visit 1 
o Refrain from eating or drinking (except water) for 12 
hours before visit 1 
o Early perimenopausal women arrive between days 2-5 
of menstrual cycle for visits 1 and 3 
o Wear loose fitting, nonmetallic clothing 
o If desired, fill out questionnaires and read informed consent 
 
*FMD: flow mediated dilation 
 
 
 
 
Visit 1 
 
• Fill out and review: 
o Informed consent 
o Health History 
o Physical Activity Questionnaires 
o Quality of life questionnaire 
• Measure height, weight, blood pressure 
• Complete blood draw 
• Receive low nitrate diet  
• Complete dual x-ray absorptiometry scan 
 Before Visit 2 • Fill out low nitrate diet log 
• Refrain from eating, drinking caffeine or alcohol, and smoking 3 hours 
before, and vigorous exercise 24 hours before visit 2 
Visit 2 • Familiarization FMD* 
• VO2 max test (exercise test) 
• Receive low nitrate diet log 
Before Visit 3 • Fill out low nitrate diet log 
• For visit 3: 
o Early perimenopausal women arrive between cycles days 2-5 
o Refrain from eating 6 hours before, exercise, caffeine, smoking 
and alcohol 12 hours before, and any vitamins/supplements for 
72 hours before the visit 
Visit 3 • Baseline FMD and blood draw 
• Exercise session 
• Post-exercise FMD and blood draw 
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Possible Exclusion Time Points 
 
 
Section 2: Details of Study Visits 
Day 1: If you agree to take part in this study, you will be asked to first come to the 
Molecular and Cardiovascular Physiology Laboratory at UMass Amherst. During your 
phone screening you will have been asked to arrive for this visit (today) having refrained 
from eating or drinking, except for water, for 12 hours. If you are classified as 
premenopausal or early perimenopausal, you will have been asked to arrive between 
menstrual cycles day 2-5. You will have been asked to wear loose-fitting non-metallic 
clothing. During this visit you will need to have the following exams, tests, and/or 
procedures. If you had some of these done recently, they may not need to be repeated. 
• Forms that you filled out ahead of time will be reviewed.  If you have not 
completed this paperwork yet, a medical history will be taken to be sure you don’t 
have any conditions that could keep you out of the study. You will also be asked 
to fill out physical activity questionnaires to make a determination of whether you 
meet activity guidelines for this study.  If you are classified as premenopausal or 
early perimenopausal and you are unsure or it is unclear if you are pregnant, you 
will be asked to complete a urine-based pregnancy test. 
 
• Your heart rate, blood pressure, weight and height will be taken. 
o To evaluate your blood pressure, we will ask you to sit quietly for several 
minutes. A cuff will be placed around your upper arm.  Either a lab 
member or a machine will inflate the cuff and then slowly release the 
pressure. If blood pressure is taken manually, we will listen for the blood 
pressure in the vessel with a stethoscope while the cuff deflates. We will 
repeat this procedure a few times to get an accurate reading.  This reading 
will be used to determine if your blood pressure is at an acceptable level 
for this study. 
 
• Blood will be collected for a fasting profile of the fats and sugar in your blood. 
This information will be used to determine if you are still eligible for the study. 
We will use a needle to withdraw blood from the vein in your arm. The amount of 
blood will be approximately 5 milliliters or 1 teaspoon. 
Visit Possible exclusion 
 
Before Visit 1 
Age; does not fit criteria for menopausal groups; history of 
cardiovascular disease, diabetes or other exclusion criteria asked about 
during pre-screening; regular exerciser; unable to exercise 
 
Visit 1 
Blood pressure; physical activity questionnaires suggest participant may be 
more active than inclusion criteria allows; answers on medical history that 
affect inclusion/exclusion criteria; pregnancy 
 
Before Visit 2 
High blood sugar levels or abnormal fat levels in the blood, VO2 max less 
than the 80th percentile, if high active 
Visit 2 Reason not to begin the exercise test; reason to stop the exercise test early 
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• You will be given a quality of life questionnaire to complete and return on the 
next visit. 
 
• You will be given instructions for following a low nitrate diet for the three days 
before your next visit. This will help get rid of any nitrates in your diet that could 
impact your blood vessel function study (flow mediated dilation). You will track 
this diet on a log sheet that will be given to you. 
 
• You will be taken to University Health Services to complete a DEXA scan. 
o You will lie quietly on a machine in loose, non-metallic clothing, during 
which the arm of the machine will pass over your body emitting a very 
low level X-ray. The test takes approximately 15 minutes and allows us to 
measure muscle and fat mass and bone mineral density. 
 
• You will be asked to avoid drinking caffeine, alcohol, or eating for 3 hours before 
your next visit and from exercising heavily for 24 hours before the next visit. 
This will allow us to obtain a more accurate reading of your exercise ability. 
 
Day 2: On the second visit you will be asked to come to the Molecular and 
Cardiovascular Physiology Laboratory at UMass Amherst. You will return your diet log. 
During the visit you will have the following tests/procedures: 
• We will familiarize you with our method for evaluation of blood vessel 
function in your arm, which will be used during the next visit. Before the test 
begins, you will lay quietly for approximately 10 minutes to relax. Your arm will 
be propped up with pillows and a small ball will be placed in your hand. We will 
use an ultrasound and Doppler machine to look at an artery in your arm. We will 
first image your artery at rest for 2 minutes and will then inflate a cuff placed 
around your forearm for 5 minutes. After 4 minutes, the cuff will be deflated and 
we will continue imaging for 3 more minutes. During the study, we will be taking 
blood pressures on your other arm. 
 
• You will have a graded exercise treadmill test to make sure there are no 
problems with your blood pressure and heart rate and rhythm in response to 
exercise. This information will allow us to have you exercise at an appropriate 
intensity on your next visit.  Based on previous screening criteria, your test will 
be supervised by a physician or by trained laboratory personnel. 
o For this test, we will place a blood pressure cuff around your upper arm to 
monitor your blood pressure and sensors on your chest to monitor your 
heart rate and rhythm during the test. The blood pressure cuff will remain 
on your arm for the rest of the test, but will only be inflated at the end of 
each stage of the test. Once we place all of the monitoring devices, we will 
take resting blood pressure and heart rate/rhythm measurements. We will 
explain a scale for how to rate your effort during the test and we will show 
you hand signals so that you can communicate with us throughout the test. 
Next, you will be asked to wear a snorkel-like mouthpiece and nose clip. 
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This allows us to look at how hard you are working. We will then have 
you chose a comfortable walking or jogging pace on the treadmill while 
we monitor you. After you are at a comfortable pace on the treadmill, the 
treadmill grade and/or speed will be increased every 2 minutes until you 
have reached your maximal capacity or until personnel see something that 
warrants them to stop the test. Once the testing is completed, we will have 
you walk for several minutes on the treadmill at a slow speed while we 
continue to monitor you. Then you will sit for several minutes until your 
heart rate and blood pressure start to return to pre-exercise levels. 
 
o If, during the course of the test, laboratory personnel or a physician 
see anything that causes them to stop the test early, you will be advised to 
contact your physician. 
 
• In the case that you remain qualified for the study, or you meet the 
inclusion criteria and do not meet the exclusion criteria, we will schedule you for 
the third visit. If possible, premenopausal and early perimenopausal women will 
be asked to schedule the visit between cycle days 2 and 5. 
 
• We will ask you to follow a low nitrate diet for three days before the last visit 
and to log your food. 
 
• We will ask you to refrain from eating 6 hours before, exercise, caffeine, 
smoking, and alcohol 12 hours before, and any vitamins/supplements 72 hours 
before the visit 
 
 
Day 3: For the third testing visit, you will come to the Molecular and Cardiovascular 
Physiology Laboratory at UMass Amherst. We will check your blood pressure, 
draw blood to look for inflammatory markers (MCP-1 and IL-8), and perform measures 
of blood vessel function in your arm before and after exercise. 
• When you arrive, we will have you rest quietly for about 10 minutes. Then 
we will check your blood pressure. Next, we will draw a sample of blood from 
the vein in your arm to analyze inflammatory factors found in the blood. This 
will be about 50 milliliters, or a little more than 3 tablespoons. Then, we will use 
the ultrasound and Doppler machine to look at blood vessel function in your arm 
(similar to the second visit). After we complete baseline measurements, we will 
inflate a cuff placed on your forearm for 5 minutes. The cuff will then be deflated 
and we will continue imaging for 4 more minutes. This will be repeated twice. 
 
• Next, you will complete 30 minutes of exercise on a treadmill at what should 
feel like a moderate pace.  We will ask you to wear a heart rate monitor 
during exercise so that we can adjust the treadmill to keep you at the desired 
heart rate. You will be given five minutes at the beginning and end of the test 
to warm up and cool down. 
 
• 30 minutes after you cool down we will complete the same tests that were 
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done before the exercise. We will draw a sample of blood from your vein and 
use an ultrasound and Doppler machine to look at your blood vessel function two 
times. 
 
WHAT ARE MY BENEFITS OF BEING IN THIS 
STUDY? 
You may not directly benefit from this research; however, we hope that your 
participation in the study may help investigators to determine whether blood vessel 
function and inflammatory markers (MCP-1 and IL-8) vary across the menopausal 
transition. This information will help to determine if exercise causes short-term 
benefits on blood vessels and related inflammatory factors, and if exercise is a useful 
technique in all menopausal women. 
You may benefit from the information we will gather from the screening, including 
blood pressure, fat levels in the blood, blood sugar, body composition, bone mineral 
density, and cardiovascular fitness. In the event that any of these factors are out of 
normal range, you will be advised to consult your personal physician. You will also be 
told of your results of the different risk factors that we measure and will be provided an 
explanation of these results. 
Upon completion of the study, you will be entered into a raffle drawing. Prizes will 
include two $50 gift cards to a local business of choice, two gym memberships to the 
University of Massachusetts Amherst Body Shop, and two packages of three personal 
training sessions at the University of Massachusetts Amherst Body Shop. This drawing 
will be held once data collection has been completed on low-active participants and 
again when data collection has been completed on high-active participants. 
Your participation in this research is completely voluntary and you may choose 
not to take part at all. You are free to ask questions at any time without penalty. If you 
decide to participate in this research, you may stop participating at any time. If 
you decide not to participate in this project or if you stop participating at any time, 
you will not be penalized or lose any benefits to which you otherwise qualify. 
 
WHAT ARE MY RISKS OF BEING IN THIS 
STUDY? 
The following risks are associated with your participation in this 
study: 
 
1) Blood draw: There is risk of bruising and infection associated with blood drawing. 
These risks will be minimized by the use of sterile techniques and by having experienced 
personnel draw all blood samples. There may also be a chance of fainting during 
the blood draw. We will ask about any history of fainting during your screening visit. To 
minimize the risk of fainting or effects of fainting, blood draws will be performed with 
you in a reclined position. 
 
2) Physical Activity: You may be at risk for injury from exercise. You may have sore 
muscles; you could sprain an ankle or fall and break a bone. When you start an exercise 
program, you could be at risk for heart problems. These risks may include high or low 
blood pressure, dizziness, skipped heartbeats, chest pain or heart attack when you 
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increase your physical activity. All exercise sessions will take place at the Molecular and 
Cardiovascular Physiology Laboratory at UMass Amherst, which is staffed by personnel 
trained in exercise testing and CPR. If necessary, a physician will be present during the 
graded exercise test. Trained personnel will be with you during each exercise session and 
will monitor your heart rate and ask how you are feeling. 
 
3) Vascular Ultrasound: When we look at the blood vessel in your arm with the 
ultrasound, a blood pressure cuff positioned on your forearm will be inflated for 5 
minutes. This might be uncomfortable and will feel tight. You will most likely feel some 
tingling like your hand is falling asleep while the blood pressure cuff is inflated. 
When the cuff is released, the tingling feeling will stop. If you have any discomfort 
during this procedure, let us know and we will do what we can to limit it. 
 
4) DEXA: While radiation is involved in this procedure, the total amount of 
radiation you will be exposed to is relatively small (less than 1/20th of the radiation 
received during a single chest x-ray). 
 
5) Timing: Your involvement may lead to some inconveniences, such as time spent in 
travel and performing the screening and testing procedures. 
 
6) Fasting: You will be asked to fast for 12 hours prior to your first visit and 6 hours 
prior to your third visit. Fasting for this time period may result in some discomfort. You 
will be allowed to drink water during this period. In addition, you will be given a snack 
and beverage on both of these visits. You will be asked to refrain from alcohol and 
caffeine for 3 hours before your second visit and 12 hours before your third visit. This 
can lead to temporary discomfort and irritability. 
 
 
HOW WILL MY PERSONAL INFORMATION BE 
PROTECTED? 
We will do our best to keep your personal information confidential. To help protect your 
confidentiality, all data are kept in a secure locked office with access available only to 
study personnel. Furthermore, all electronic files (e.g., database, spreadsheet, etc.) 
containing identifiable information will be password protected. Computers with 
data from this study will be protected by a password and only available to be accessed 
by authorized personnel involved with the study. Only the members of the research staff 
will have access to the passwords. Participants will be assigned IDs, which will not 
include any personally identifiable information. Medical information created by this 
research study (i.e. blood tests) will be given to the participant for their personal record. 
Blood samples will be labeled with a unique code, not your name or any other 
identifying information. For some analyses, samples cannot be analyzed immediately 
and will need to be stored until all samples from all participants are collected. These 
samples will only be identified by a unique code. The key to the codes will be kept in a 
locked and secure cabinet. 
 
If we write a report or article about this research project, your identity will be protected 
to the maximum extent possible. Information will be presented in summary format and 
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you will not be identified in any publications or presentations. Your information may 
only be shared with representatives of the University of Massachusetts, or government 
authorities if you or someone else is in danger or if we are required to do so by law. 
Records of the research will be maintained for up to 10 years following study 
completion. 
 
WILL I RECEIVE ANY PAYMENT FOR TAKING PART IN THE 
STUDY? 
You will not receive any monetary compensation for participating in this 
study. 
 
WHAT IF I HAVE 
QUESTIONS? 
Take as long as you like before you make a decision. We will be happy to answer any 
question you have about this study. If you have further questions about this project or if 
you have a research-related problem, you may contact the principal investigators, Sarah 
Witkowski at switkows@kin.umass.edu or 413-545-6102 or Corinna Serviente at 
cserviente@kin.umass.edu or 413-577-0392. If you have any questions concerning your 
rights as a research subject, you may contact the University of Massachusetts Amherst 
Human Research Protection Office (HRPO) at (413) 545-3428 or 
humansubjects@ora.umass.edu. 
 
CAN I STOP BEING IN THE 
STUDY? 
You do not have to be in this study if you do not want to. If you agree to be in the study, 
but later change your mind, you may drop out at any time. There are no penalties or 
consequences of any kind if you decide that you do not want to participate. You will be 
notified of all significant new findings during the course of the study that may affect 
your willingness to continue. 
 
WHAT IF I AM 
INJURED? 
The University of Massachusetts does not have a program for compensating subjects for 
injury or complications related to human subjects research, but the study personnel will 
assist you in getting treatment. Medical treatment will be available at the closest medical 
center at the expense of the participant. 
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Section 3 
Subject Statement of Voluntary 
Consent 
 
Release of blood samples is not a requirement of participation in this study. It is entirely 
your decision. Please read the statements below and check the appropriate box to reflect 
your decision about the use of your blood samples: 
 
□YES, I agree to allow the investigators of this study to store my blood samples to use in 
future research 
 
□NO, I do not allow the investigators of this study to store my blood samples for use in 
future research 
 
 
I have read this form and decided that I will participate in the project described 
above. The general purposes and particulars of the study, as well as possible hazards and 
inconveniences have been explained to my satisfaction. I understand that I can 
withdraw at any time. 
 
 
 
Participant Signature:             Print Name           Date 
 
 
By signing below I indicate that the participant has read and, to the best of my 
knowledge, understands the details contained in this document and has been given 
a copy. 
 
 
 
 
 
 
Signature of Person Print Name           Date 
Obtaining Consent 
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APPENDIX B 
 HEALTH HISTORY FORM 
 
Molecular and Cardiovascular Physiology Laboratory 
University of Massachusetts 
School of Public Health 
Department of Kinesiology 
Totman Building, 30 Eastman La, Amherst MA 01003 
(413) 577-0392 
Health History Questionnaire 
 
GENERAL HEALTH  
 
Height__________ Weight__________ 
 
How would you describe your overall physical health? 
     ____ excellent  ____ good  ____ fair ____ poor  
 
Have you undergone a physical examination in the last 5 years?  □Yes   □No  
 
Are you on a special diet?   □Yes  □No    
If yes, what type:__________________________  
 
Have you gained or lost more than 10 lbs in the last 6 months? □ Yes □No  
 
Have you had any illness in the last 2 weeks?  □Yes  □No    
If yes, specify: ___________________________  
 
Do you have documented heart disease?  □Yes  □No  
If yes, how long ago was it documented?     ____________ years  
 
Has a doctor ever told you that you have an ulcer?  □Yes  □No  
 
Has a doctor ever told you that you have any type of bleeding disorder? 
 □Yes  □No  
 
Have you ever experienced dizziness or fainting during a blood draw? 
 □Yes  □No 
 
Have you ever been advised by your doctor or any medical professional that you 
should not exercise or engage in any sort of strenuous physical activity?  
 □ Yes    □ No 
If yes, please explain:_________________________________ 
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How many times a week do you exercise? __________________________ 
 
How many years have you been exercising? _________________________ 
 
What types of activity do you do? 
__________________________________________________ 
 
Do you have any limitations that you feel would hinder your ability to exercise?  
            
     
 
 
 
Have you ever had any of the following conditions/symptoms?  
Leave blank for “ no” . Indicate “ yes” with a check mark and indicate year of 
onset.  
 
Check  Year of  
for yes  Onset   
 _______         High blood pressure  
 _______ Heart attack /coronary problem  
 _______              Heart murmur  
 _______              Heart disease  
 _______  Pain or tightness in the chest  
 _______   Palpitations/rapid heart beat  
 _______                  Phlebitis  
 _______                    Stroke  
 _______    Lung/respiratory problems  
 _______                  Diabetes  
 _______              Varicose veins  
 _______            High cholesterol  
 _______                   Anemia  
 _______           Thyroid problems  
 _______                   Cancer 
 _______               Liver disease 
 _______         Gallbladder disease 
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MEDICATIONS 
 
 Are you currently taking any medications? □Yes  □No  
 If yes, list all being taken. Include daily dosage and indicate for what 
condition. Include over-the-counter drugs (ibuprofen, aspirin, antihistamines, oral 
contraceptives.)  
 
            
            
            
       
 
           
Do you take vitamins or herbal supplements? □Yes  □No  
 If yes, please list :______________________________  
       ______________________________ 
       ______________________________ 
 
Do you have any known drug allergies?  □Yes  □No 
  If yes, please list: :______________________________  
       ______________________________ 
       ______________________________ 
 
FAMILY HISTORY  
To your knowledge, have any immediate relatives (parent, grandparent, brother, 
sister) had a heart attack or been diagnosed with heart disease before the age of 
60?  □Yes  □No 
If so, indicate relative and age:  
 
Have any immediate relatives had a high blood pressure before the age of 60? 
□Yes  □No  
If so, indicate relative and age:  
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MUSCULOSKELETAL/ORTHOPEDIC HISTORY  
Have you ever had any of the following:  
If yes, how long ago?  
      
Complaint   Years Ago 
Hernia or rupture? Yes No  
Present/recurrent 
back injury  
Yes No   
Osteoarthritis 
Arthritis  Yes  No  
 
Rheumatoid 
Arthritis  
Yes  No  
Osteoporosis  Yes  No   
Spinal disc problem  Yes  No   
Joint dislocation  Yes  No   
Ligament strain  Yes  No   
Cartilage tear  Yes  No   
Tendon tear  Yes  No   
Intermittent leg 
cramps  Yes  No  
 
Swollen painful 
joints  
Yes  No   
Polio  Yes  No   
Surgery  Yes  No   
   
If you have had surgery please explain: 
 
SMOKING HISTORY  
Have you always been a non-smoker? □Yes  □No  If yes, go to next section  
 
Do you presently smoke?  
Yes  No  
Are you an ex-smoker?   
Yes  No  
 
If yes, when did you stop? _______________  
 
MENOPAUSE: 
 
How would you describe your menstrual cycle (please check box) 
□Variable (more than 7 days different from normal) 
□No period (60 days or more but less than 1 year) 
□No period (more than 5 years) 
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□Other (please describe)        
Have you been treated for menopause-related symptoms?   □Yes  □No  
If yes, please list type of treatment and dates: 
______________________________  
               
Have you ever taken oral contraceptives?  □Yes  □No  
If yes, please specify the type of contraceptive used and the dates used   
            
            
 
 
Are you currently or do you have a history of menopause related symptoms (e.g. 
hot flashes)? □Yes  □No  
 
If yes, please specify the intensity and frequency:      
            
     
 
Do you have a history of irregular menstrual irregularities, vaginal bleeding, or 
abnormal vaginal or uterine anatomy?  □Yes  □No  
 
 
OTHER  
Please discuss any other significant medical concerns that you consider 
important for us to know:  
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APPENDIX C 
QUALITY OF LIFE QUESTIONNAIRE 
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APPENDIX D 
 INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
 
   
This is the final SHORT LAST 7 DAYS SELF-ADMINISTERED version of IPAQ from the 2000/01 Reliability and Validity Study.  Completed May 2001. 
4
1a. During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, aerobics, or fast bicycling,?  
  
 Think about only those physical activities that you did for at least 10 minutes at a time. 
 
________ days per week  
  
 
 or 
  
   none 
 
 
 
2a. Again, think only about those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 
________ days per week  
  
 or 
  
   none 
 
 
 
3a. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? This includes walking at work and at home, walking to travel from place to place, 
and any other walking that you did solely for recreation, sport, exercise or leisure.  
 
________ days per week  
  
or 
  
   none 
 
 
 
The last question is about the time you spent sitting on weekdays while at work, at 
home, while doing course work and during leisure time.  This includes time spent 
sitting at a desk, visiting friends, reading traveling on a bus or sitting or lying down to 
watch television.  
 
4. During the last 7 days, how much time in total did you usually spend sitting on a  
 week day? 
 
 ____ hours ______ minutes 
 
 
 
This is the end of questionnaire, thank you for participating. 
1b. How much time in total did you usually 
spend on one of those days doing 
vigorous physical activities? 
 
_____ hours ______ minutes 
2b. How much time in total did you usually 
spend on one of those days doing 
moderate physical activities? 
 
_____ hours ______ minutes 
3b. How much time in total did you usually 
spend walking on one of those days? 
 
_____ hours ______ minutes 
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APPENDIX E 
 STANFORD BRIEF ACTIVITY QUESTIONNAIRE 
 
Data Collection Worksheet 
 
 
PhenX Measure: Total Physical Activity-Screener (#150900)  
PhenX Protocol: Total Physical Activity-Screener (#150901)  
 
Date of Interview/Examination (MM/DD/YYYY): _____________________ 
 
Section I: On-The-Job Activity 
Please check the box next to the one statement that best describes the kinds of physical 
activity you usually performed while on the job this last year. If you are not gainfully employed 
outside the home but perform work around the home regularly, indicate that activity in this 
section. 
[ ] A. If you have no job or regular work, check Box A and go on to Section II. 
[ ] B. I spent most of the day sitting or standing. When I was at work I did such things as 
writing, typing, talking on the telephone, assembling small parts or operating a 
machine that takes very little exertion or strength. If I drove a car or truck while 
at work, I did not lift or carry anything for more than a few minutes each day. 
[ ] C. I spent most of the day walking or using my hands and arms in work that required 
moderate exertion. When I was at work I did such things as delivering mail, 
patrolling on guard duty, mechanical work on automobiles or other large 
machines, house painting or operating a machine that requires some moderate 
activity. If I drove a truck or lift, my job required me to lift and carry things 
frequently. 
[ ] D. I spent most of the day lifting or carrying heavy objects or moving most of my 
body in some other way. When I was at work, I did such things as stacking cargo or 
inventory, handling parts or materials, or I did work like that of a carpenter who 
builds structures or a gardener who does most of the work without machines. 
[ ] E. I spent most of the day doing hard physical labor. When I was at work I did such 
things as digging or chopping with heavy tools, or carrying heavy loads (bricks, for 
example) to the place where they are to be used. If I drove a truck or operated 
equipment, my job also required me to do hard physical work most of the day 
with only short breaks. 
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Section II: Leisure-time Activity 
Please check the box next to the one statement which best describes the way you spent your 
leisure-time during most of the last year. 
[ ] F. Most of my leisure time was spent without very much physical activity. I mostly 
did things like watching television, reading or playing cards. If I did anything else, 
it was likely to be light chores around the house or yard, or some easy-going game 
like bowling or catch. Only occasionally, no more than once or twice a month, did 
I do anything more vigorous, like jogging, playing tennis or active gardening.  
[ ] G. Weekdays, when I got home from work, I did few active things. But most weekend 
I was able to get outdoors for some light exercise- going for walks, playing a round 
of golf (without motorized carts), or doing some active chores around the house. 
[ ] H. Three times per week, on the average, I engaged in some moderate activity- such 
as brisk walking or slow jogging, swimming or riding a bike for 15-20 minutes or 
more. Or I spent 45 minutes to an hour or more doing moderately difficult chores- 
such as raking or washing windows, mowing the lawn or vacuuming, or playing 
games such a doubles tennis or basketball. 
[ ] I. During my leisure time over the past year, I engaged in a regular program of 
physical fitness involving some kind of heavy physical activity at least three times 
per week. Examples of heavy physical activity are: jogging, running or riding fast 
on a bicycle for 30 minutes or more; heavy gardening or other chores for an hour 
or more; active games or sports such as handball or tennis for an hour or more; or 
a regular program involving calisthenics and jogging or the equivalent for 30 
minutes or more. 
[ ] J. Over the past year I engaged in a regular program of physical fitness along the 
lines described n the last paragraph (I), but I did it almost daily- five or more 
times per week. 
 
 
Protocol Source: http://phenxtoolkitstage.rti.org/index.php?pageLink=browse.protocoldetails&id=150901  
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APPENDIX F 
 PHYSICAL ACTIVITY AND PERFORMANCE QUESTIONNAIRE 
   Molecular and Cardiovascular Physiology 
Laboratory 
University of Massachusetts 
DEPARTMENT OF KINESIOLOGY,  
TOTMAN BUILDING, 30 EASTMAN LA, AMHERST MA 01003 
(413) 545-6012    (413) 545-2906 FAX 
 
   Physical Activity and Performance 
Questionnaire 
 
 
Physical Activity Information 
 
How many times a week do you exercise? 
_____________________________________________ 
 
How many minutes do you spend exercising per session? 
____________________________ minutes 
 
Do you ever exercise twice a day?  □ No    □ Everyday   □ Occasionally 
_______________________ 
 
Mode(s) of exercise (check all that apply): 
 □ Running   □ Cycling  □ Swimming  □ Other 
_____________________________________ 
 
What is the approximate pace (minutes/mile) for your exercise sessions? 
____________________________ 
 
How many miles do you run/cycle/swim/etc. in an average week? 
 
Running ________  Cycling ________  Swimming ________   Other 
___________________   
 
Have you been exercising continuously since high school or college? □ Yes    □ No 
 
If no, how many years elapsed until you resumed exercising?  
 
_____________________________________ 
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How many years have you been exercising continuously in the last 20 years? 
__________________ 
  
 
 
Please outline a typical week’s work out schedule giving distance covered and times 
registered: 
 
   EXERCISE MODE      MILEAGE COVERED          
DURATION 
      (run/cycle/etc)   
 
SUNDAY   
_________________ _________________    ________________ 
   
MONDAY   
_________________ _________________    ________________ 
TUESDAY   
 
_________________ _________________    ________________ 
   
WEDNESDAY 
_________________ _________________    ________________ 
   
THURSDAY   
_________________ _________________    ________________ 
 
FRIDAY   
_________________ _________________    ________________ 
   
SATURDAY   
_________________ _________________    ________________ 
 
 
 
Please use the space below to provide any additional information regarding your 
exercise/activity history that you feel will be helpful to us. 
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APPENDIX G 
 LOW NITRATE DIET 
Vascular Function Across the Menopausal 
Transition Study 
MOLECULAR AND CARDIOVASCULAR PHYSIOLOGY LAB 
DEPARTMENT OF KINESIOLOGY,  
UNIVERSITY OF MASSACHUSETTS, AMHERST 
 
 
 
Dietary Instructions 
 
Since diet influences your blood pressure, certain dietary restrictions 
(low nitrate diet) apply to this part of the study. We ask that for 3 days you 
minimize from your diet the foods and drinks that are listed on this page.  
 
We will ask you to complete a 3-day diet record (included) for the 3 
days prior to your testing. This will help ensure the accuracy of the results of 
your tests. 
 
 The diet restrictions include those items high in nitrates. Following is 
a list of foods we ask you to avoid for the 3-day period. 
 
• All seafood (shellfish, salt water or fresh water fish)  
• All cured, smoked, preserved, canned or processed meats, e.g., cold cuts, bacon, sausage, ham, 
hotdogs, pepperoni, corned beef, pastrami, salt pork 
• Certain cheeses: cheddar, swiss, blue, american, mozzarella (cottage cheese, cream cheese are 
allowed) 
• All canned meats and fish, including tuna  
• Tofu, soybeans, legumes  
• Vegetarian burgers made with lentils, soybeans or other legumes 
• Nuts, peanut butter  
• Pickles, olives, relish  
• Raw or cooked garlic and onions 
• Tomato-based foods  
• bananas, strawberries, or melons 
• Worcestershire sauce 
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APPENDIX H 
 RISK FACTOR STRATIFICATION 
 Guidelines for Risk Stratification  
Provided by ACSM Guideline’s for Exercise Testing and Prescription (137) 
 
Low Risk Asymptomatic men and women who have 
<1 cardiovascular risk factor 
Moderate Risk Asymptomatic men and women who have 
>2 cardiovascular risk factors 
High Risk Men and women who have >1 sign or 
symptom of cardiovascular disease or 
known cardiovascular, pulmonary, or 
metabolic disease 
*the presence of a positive risk factor allows for the subtraction of one negative risk 
factor when classifying an individual; if the presence or absence of a risk factor is not 
available, that risk factor should be counted as a risk factor, except for prediabetes. If 
prediabetes status is unknown, it should be counted as a risk factor for those > 45 years 
old, especially for those with a body mass index > 25 kg/m2 and those <45 years old with 
a body mass index index > 25 kg/m2 and additional risk factors for prediabetes. 
 
 
 
Negative Risk Factors 
• Age: Men > 45 years old; Women > 55 years old 
• Family History: myocardial infarction, coronary revascularization, or sudden 
death before age 55 for first-degree male relatives (e.g. father) or before age 65 
for first degree females relatives (e.g. mother) 
• Smoking: current use of, or exposure to, cigarettes or use within the last six 
months 
• Sedentary lifestyle: not participating in at least 30 minutes of moderate intensity 
physical activity (40%-<60% oxygen uptake reserve) on at least 3 days per week 
for at least 3 months 
• Obesity: body mass index > 30 kg/m2 or waist girth >102 cm (40 in) for men and 
>88 cm (35 in) for women 
• Hypertension: systolic blood pressure > 140 mmHg and/or diastolic blood 
pressure > 90 mmHg, confirmed by measurements on at least 2 separate 
occasions, or antihypertensive medication 
• Dyslipidemia: low density lipoprotein cholesterol > 130 mg/dL or high density 
lipoprotein cholesterol <40 mg/dL or on lipid lowering medication or total serum 
cholesterol > 200 mg/dL 
• Prediabetes: fasting plasma glucose > 100 mg/dL and < 125 mg/dL or oral 
glucose tolerance test > 140 mg/dL and < 199 mg/dL confirmed by measurements 
on two separate occasion 
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Positive Risk Factor 
• High density lipoprotein cholesterol: > 60 mg/dL 
 
 
Symptoms 
• Pain; discomfort (or other anginal equivalent) in the chest, neck, jaw, arms or 
other areas that may result from ischemia 
• Shortness of breath at rest or with mild exertion 
• Dizziness or syncope (fainting) 
• Orthopnea (shortness of breath while lying down) or paroxysmal nocturnal 
dyspnea (shortness of breath during sleep) 
• Ankle edema (swelling) 
• Palpitations or tachycardia 
• Intermittent claudication 
• Known heart murmur 
• Unusual fatigue or shortness of breath with usual activities 
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APPENDIX I 
12-LEAD ECG PLACEMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Fletcher et al. 2001) 
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APPENDIX J 
 EXERCISE TESTING CONTRAINDICATIONS & VO2MAX DETERMINATION 
 
ACSM Guidelines for Exercise Testing: Absolute/Relative Contraindications 
Provided by ACSM Guideline’s for Exercise Testing and Prescription (137) 
 
 
Pre-test exclusion 
• Recent change in resting ECG 
• Unstable angina 
• Cardiac dysrhythmia (uncontrolled, symptoms or hemodynamic compromise 
present) 
• Severe symptomatic aortic stenosis 
• Symptomatic, uncontrolled heart failure 
• Acute pulmonary embolism or infarction 
• Acute pericarditis or myocarditis 
• Dissecting aneurysm (known or suspected) 
• Acute systemic infection 
• Left main coronary stenosis 
• Moderate stenotic valvular heart disease 
• Electrolyte abnormalities 
• Arterial hypertension (SBP>200 mmHg and/or DBP >110 mmHg) 
• Tachy- or bradydysrhthmia 
• Hypertrophic cardiomyopathy or obstruction of outflow tract 
• Musculoskeletal, neuromotor or rheumatoid disorders made worse with exercise 
• high-degree AV block 
• ventricular aneurysm 
• uncontrolled metabolic disease 
• chronic infectious diseases 
• mental/physical impairment that hinders exercise 
 
Test Termination 
• SBP drop >10 mmHg with increased work load or SBP value below baseline 
measure (in same position) and with symptoms of ischemia 
• Angina score > 3 or increasing chest pain 
• Worsening nervous system symptoms (i.e. ataxia, dizziness, near syncope) 
• Poor perfusion (i.e. cyanosis or pallor) 
• Technical problems with ECG or blood pressure 
• Participant requests test termination 
• Sustained ventricular tachycardia 
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• ST segment elevation > 1 mm in leads without diagnostic Q (excluding V1 or 
AVR) 
• ST segment or QRS changes (i.e. ST segment horizontal or downward depression 
>2 mm) or axis shift 
• Arrhythmias such as multifocal PVCs, supraventricular tachycardia, heart block, 
or bradyrhythmias 
• Fatigue, shortness of breath, wheezing, leg cramps, claudication 
• BBB or intraventricular conduction delay that is indistinguishable from 
ventricular tachycardia 
• SBP >250 mmHg and/or DBP >115 mmHg 
 
Test Validation Criteria 
o RER > 1.1 
o Plateau in oxygen consumption with increasing work 
o Within 15 beats of age-predicted maximal heart rate (220-age) 
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APPENDIX  K 
LINEAR REGRESSION FIGURES 
 
Figure 1. The Relationship Between Total Cholesterol and FSH. 
There was a positive linear relationship between total cholesterol and follicle stimulating 
hormone (FSH). Data are presented as mean±SEM 
 
 
 
 
Figure 2. The Relationship Between LDL-C and FSH. 
There was a positive linear relationship between low-density lipoprotein cholesterol 
(LDL-C) and follicle stimulating hormone (FSH). Data are presented as mean±SEM 
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Figure 3. The Relationship Between HDL-C and FSH. 
There not a linear relationship between high-density lipoprotein cholesterol (HDL-C) and 
follicle stimulating hormone (FSH). However, the relationship between HDL-C and FSH 
appears to vary by FSH level. Data are presented as mean±SEM 
 
 
 
Figure 4. The Relationship Between Triglycerides and FSH. 
There not a linear relationship between triglycerides and follicle stimulating hormone 
(FSH). However, the relationship between triglycerides and FSH appears to vary by FSH 
level. Data are presented as mean±SEM 
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 Figure 5. The Relationship Between Total Cholesterol and FSH by Age. 
There was a linear relationship between FSH and total cholesterol in older, but not 
younger postmenopausal women. However, the beta coefficients were higher in younger 
postmenopausal women, suggesting that FSH has a greater effect on total cholesterol in 
younger women. Data are presented as mean±SEM 
 
 
 
Figure 6. The Relationship Between LDL-C and FSH by Age. 
There was a linear relationship between FSH and low-density lipoprotein cholesterol 
(LDL-C) in older, but not younger postmenopausal women. However, the beta 
coefficients were higher in younger postmenopausal women, suggesting that FSH has a 
greater effect on LDL-C in younger women. Data are presented as mean±SEM 
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Figure 7. The Relationship Between HDL-C and FSH by Age. 
There was not a linear relationship between high-density lipoprotein cholesterol (HDL-C) 
and follicle stimulating hormone (FSH) in younger or older postmenopausal women. 
Data are presented as mean±SEM 
 
 
 
Figure 8. The Relationship Between Triglycerides and FSH by Age. 
There was not a linear relationship between triglycerides and follicle stimulating 
hormone (FSH) in younger or older postmenopausal women. Data are presented as 
mean±SEM 
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